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ABSTRACT 
Catalytic asymmetric synthesis is founded on three pillars: organometallic catalysis, organoca-
talysis and biocatalysis. Over the years, catalysts of these three classes have enabled ground-
breaking chemical transformations. The application of chemocatalysis to the manufacturing of 
chemicals is widespread, and biocatalysis is increasingly being used industrially. To streamline 
chemical syntheses, there has been and continuous to be a push to develop one-pot reactions, 
within which several catalysts from the same or disciplines are combined to catalyze numerous 
chemical steps and yield enantiopure products in high yield and selectivity. While this strategy is 
widespread in the respective fields of chemocatalysis and biocatalysis, examples in which 
chemocatalysts are combined with biocatalysts in one-pot are few and far between, apart from 
the seminal works of Backväll and Kim in which metal racemization complexes combined with 
lipases catalyze dynamic kinetic resolutions. 
  
The work presented in this thesis vows to bridge the gap between chemical catalysts and en-
zymes by engineering one-pot tandem reactions between these two catalytic systems, with a par-
ticular interest on combining cytochrome P450s and enoate reductases with organometallic cata-
lysts. On the one hand, considerable efforts in transition-metal catalysis have culminated in prac-
tical and efficient transformations such as isomerization, olefin metathesis, carbene-mediated 
insertions and others. On the other hand, metalloenzymes and reductases have been investigated 
and engineered to catalyze reactions with organic compounds that are synthetically and industri-
ally important. First, we combined an isomerization of alkenes catalyzed by a ruthenium tri-
phenylphosphine complex with cytochrome P450s variants that catalyze the epoxidation of these 
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alkenes. While the isomerization catalyst and P450 BM3 variants could operate efficiently in a 
biphasic system, mass transfer limitations coupled with low enzyme TTNs greatly limited reac-
tion yields. With a more active P450 BM3, namely the wild type P450, a biphasic reaction com-
bining a cross metathesis reaction catalyzed by a ruthenium catalyst with a regioselective enzy-
matic epoxidation. A 90% yield of a single epoxide could be obtained selectively from the cross 
metathesis of two alkenes, a reaction that would yield a maximum 64% yield if ran sequentially. 
The scope of this tandem reaction was later extended to aromatic substrates, through a combina-
tion of enzyme, substrate and reaction engineering. Lastly, we discovered that an electron defi-
cient iron porphyrin catalyzed diazo coupling reactions in high yields in buffer and at room tem-
perature. Its substrate scope included not diazoacetates, but also diazoketones to form dienones. 
When this catalyst was combined with an enoate reductase which catalyzes the reduction of α, β-
unsaturated alkenes, in one pot, no mutual deactivation of the two catalytic species was ob-
served. Complete reduction of the activated alkenes formed was observed. To form chiral 
diketones and diesters, we further combined the enzymatic reduction with a rhodium-catalyzed 
diazo coupling that forms prochiral alkenes.  
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CHAPTER 1. INTRODUCTION 
 
1.1 Chemoenzymatic strategies for asymmetric synthesis 
1.1.1 Introduction 
Catalytic asymmetric synthesis is built on three pillars: metal catalysis, organocatalysis and bio-
catalysis. Over the years, catalysts of these three classes have enabled groundbreaking chemical 
transformations. The application of chemocatalysis to the manufacturing of chemicals is wide-
spread, and biocatalysis is increasingly being used industrially [1].  However, the conditions un-
der which these catalytic operations are developed are generally fine-tuned for individual reac-
tions, or in the case of enzymes, fermentations. In a multistep synthesis, each reaction typically 
occurs in a separate vessel. After most steps, a purification step is conducted, which results in 
high process costs, incurs yield losses and generates large amounts of waste. Therefore, the need 
to reduce waste and processing costs has turned the attention of chemists towards developing 
tandem processes that combine catalytic transformations within or across the three disciplines of 
asymmetric synthesis [2].   
 
Multistep one-pot processes, so-called tandem processes, have the potential to impact the manu-
facturing of fine chemicals and pharmaceutical intermediates [3-10]. In catalytic asymmetric 
synthesis, they offer an attractive approach to improve the overall efficiency of chemical trans-
formations, starting from simple and readily available achiral substrates to access chiral com-
pounds with high enantio- and regio-selectivity (Figure 1.1). Compared with stepwise synthesis, 
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the combination of multiple catalytic reactions into one synthetic operation reduces the number 
of purification steps, thus contributes to an improved process economy as well as to more sus-
tainable synthetic routes. In addition, multistep one-pot reactions can improve stereochemical 
control and substrate scope, and can suppress side reactions. Lastly, the cooperative effect be-
tween multiple catalysts can enhance reactivity and selectivity by allowing equilibrium reactions 
to proceed to nearly full conversion. 
 
 
Figure 1.1 One-pot tandem catalysis for asymmetric synthesis 
 
Most tandem processes developed to date are based on chemocatalytic multistep reactions [2], 
multi-enzyme reactions and pure biotechnological processes, such as fermentations. One-pot re-
actions involving biocatalysts and chemical catalysts are more challenging due to incompatibility 
stemming mainly from the radically different environments in which catalysts from these two 
disciplines usually operate, as well as mutual inactivation that often occurs when chemical cata-
lysts and enzymes are combined in one vessel.   
 
From synthetic and industrial points of view, the combination of chemical catalysts and biocata-
lysts in one-pot in ways to access highly enantiopure chiral compounds would be valuable. 
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Chemical catalysis and biocatalysis are often considered two complementary fields. In many 
cases, catalysts from these fields effect the same reactions but with different rates, scopes and 
selectivities, but in some cases, they catalyze completely different reactions, of which counter-
parts cannot be found in the other field. In addition, catalysts from each of these fields present 
certain advantages and limitations. For example, organometallic catalysts can react with a wide 
substrate scope and high productivity. However, chiral metal complexes tend to be sensitive to 
species with coordinating ability in the reaction system and generally cannot achieve the very 
high enantio- and regioselectivities required for fine chemical synthesis without the help of di-
recting and protecting groups. Biocatalysts operate in environmentally friendly conditions, and 
offer exquisite regio- and enantioselectivities that may not be achievable by chemical catalysts in 
many cases; but they generally exhibit low stability in organic solvents and high temperatures, as 
well as low to no activity towards many nonnative substrates. Nevertheless, advances in protein 
engineering continues to provide us with options to tailor the performance of a biocatalyst to im-
prove its affinity for unnatural substrates of industrial and/or pharmaceutical relevance, as well 
as to enhance its stability toward organic solvents [11, 12].  
 
Since the pioneering works of Williams [13], Backväll [14], and Kim [15] combining metal cata-
lysts with lipases and serine proteases for the dynamic kinetic resolution of alcohols and amines, 
more effort is now being spent bridging the gap between chemical catalysts and biocatalysts to 
reap the benefits of both catalytic systems in one-pot syntheses. As a result, more and more one-
pot chemoenzymatic reactions are emerging.   
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1.1.2 Dynamic kinetic resolutions 
Dynamic kinetic resolutions (DKRs) catalyzed by metal racemization complexes and lipases or 
proteases are now well-established methods for the preparation of single enantiomers from race-
mates [16-19] (Figure 1.2).  Enzymatic kinetic resolutions are highly selective, but their main 
drawback is that only a maximum yield of 50% can be obtained for the desired enantiomer.  In-
tegration of a racemization catalyst in the system to continuously replenish the depleted enanti-
omer can theoretically drive the resolution up to 100% yield for the enantiomer of interest, there-
by reducing or eliminating further separation steps.  For kinetic resolutions, lipases, specifically 
the immobilized Candida antarctica lipase B (CALB) [19], have been the enzymes of choice 
because of their robustness and activity in organic solvents at temperatures up to 100
o
C. Since 
the native CALB is (R)-selective, to obtain the (S)-enantiomer, Candida antarctica lipase A 
(CALA), an engineered (S)-selective lipase [20-22] or a serine protease such as subtilisin [15, 
23-26]  have all been used.  
 
 
Figure 1.2 General scheme of DKRs 
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For the racemization reaction, most transition metal complexes have found success depending on 
the substrate scope and compatibility with the enzyme, including ruthenium, rhodium, palladium, 
aluminum, and vanadium catalysts [27, 28]. The racemization of amines is more challenging 
and, therefore, less developed. Palladium complexes have been found as the most active for pri-
mary amine racemization [27]. Ruthenium complexes, Raney Ni, and iridium complexes are now 
being integrated into the DKR of amines [29-32]. Excellent reviews of the application of DKRs 
for the production of enantiopure secondary alcohols, diols, as well as primary and secondary 
amines have appeared elsewhere [33-35]. As a further expansion of their applicability, DKRs 
with lipases are now being applied in the synthesis of drugs and pharmaceuticals [29, 36-40] and 
to resolve dynamic combinatorial libraries (DCLs) [41] (Figure 1.3).  
 
 
Figure 1.3 Direct asymmetric lipase-mediated screening of a dynamic nitroaldol library 
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1.1.3 One-pot chemoenzymatic transformations 
1.1.3.1 One-pot sequential reactions 
With the exception of immobilized lipases and serine proteases, a large fraction of biocatalysts 
are incompatible or poorly stable in pure organic solvents, at high temperatures or in the pres-
ence of small molecule catalysts, salts, and catalytic components. As a result, the integration of 
biocatalysts in one-pot reactions with chemical catalysts remains undeveloped. Many chemoen-
zymatic processes reported in the literature occur in separate vessels as distinct steps, and a puri-
fication step is included after each reaction to remove unreacted substrates, side products, and 
catalysts that could be incompatible with the subsequent steps [42-46]. In recent years, one-pot 
cascade chemoenzymatic transformations have been published in which the separation of reac-
tants, catalysts or intermediates prior to the subsequent reaction steps is not required. In certain 
cases, strong evidence of the coexistence of chemical catalysts and enzymes is presented; how-
ever, different reaction conditions required for the catalytic and enzymatic steps, a disparity in 
reaction rates, as well as the enzyme’s substrate selectivity restrict these systems to being se-
quential instead of concurrent. 
 
Schmitzer and Gröger developed a two-step chemo-enzymatic cascade approach for the prepara-
tion of chiral biaryl alcohols by combining a Pd-catalyzed Suzuki cross-coupling reaction with a 
stereospecific enzymatic reduction [47, 48]. In this sequential process, Pd(PPh3)Cl2 catalyzed the 
cross-coupling between phenylboronic acid and aryl ketones at 70
o
C in water in 99% yield. At 
the end of the first reaction, without isolation of the cross-coupling product, conditions were ad-
justed for the stereospecific reduction of the biaryl ketone by an S-specific alcohol dehydrogen-
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ase (ADH) from Rhodoccocus sp. Interestingly, studies of the effects of the Suzuki coupling 
components on ADH activity revealed that the Pd catalyst had no inhibitory effects, even at con-
centrations near the complex’s solubility limit, whereas free phosphane, an additive in the cou-
pling reaction, inhibited ADH at high concentrations. By removing this additive from the system, 
overall yields of 91% were obtained for the preparation of three (S)-biaryl alcohols in >99% ee. 
The substrate scope of this reaction was later expanded by using a two-phase ionic liquid : buffer 
system, where the Suzuki coupling reaction occurred in the ionic liquid phase (Figure 1.4, entry 
1) [48].  
 
Alcohol dehydrogenases also have been successfully combined with proline organocatalysts 
[49] or Zn-catalysts [50]  to obtain enantioenriched 1,3-diols in one-pot (Figure 1.4, entry 2). In 
particular, Aoki and coworkers tested several conditions for the aldol reaction between acetone 
and benzaldehyde using proline or chiral Zn
2+
 complexes of L- and D-phenylalanyl-
pendant[12]aneN4 (L-ZnL3 and D-ZnL3) in aqueous solution to obtain both (R) and (S) aldol ad-
dition products in high ee. In addition, several oxidoreductases were screened for the asymmetric 
reduction of β-hydroxyketones to yield chiral diols. When the two catalysts systems were com-
bined in a cascade one-pot reaction, using the right combination of a chiral organocatalyst or Zn- 
complex with an (S)- or (R)-specific ADH could yield each of the four chiral diol stereoisomers 
in moderate to quantitative yields and > 95 % ee.  
 
Similarly, an olefin metathesis catalyst was combined with a pig liver esterase in a sequential 
one-pot fashion for the synthesis of cyclic malonic acid monoesters, as reported by Groger and 
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coworkers [51]. A ruthenium carbene complex catalyzed the ring closing metathesis of diallyl 
malonate or diethyl 2-allyl-2-(but-3-en-1-yl)malonate on top of buffer. At the end of the catalytic 
reaction, pig liver esterase was added, and after optimization of the co-solvent volume ratio, the 
cyclic malonic monoesters were obtained in 67-95% yields (Figure 1.4, entry 3). Although the 
metathesis catalyst did not have any negative impact on the enzyme and the pig liver esterase 
reacted selectively with the ring closed intermediate over the ring open starting material, this 
process was sequential. Reaction times for the metathesis and hydrolysis were 6 h and >50 h, re-
spectively.  
 
A one-pot reaction for the preparation of chiral secondary alcohols through a direct asymmetric 
transformation of vinylarenes was recently reported by Gröger et al. [52]. In this system, a Pd-
catalyzed Wacker-Tsuji reaction first transformed the vinylarene to a ketone; subsequently, an 
alcohol dehydrogenase catalyzed an asymmetric reduction to afford (R)-secondary alcohols with 
>99% ee (Figure 1.4, entry 4). To obtain a compatible reaction system, ligands such as 2,2-
bipyridine, thiourea, and EDTA were introduced in catalytic amounts to remove Pd species be-
fore the enzymatic reduction since the Pd species were found to interfere with this step. By this 
approach, styrene, p-chlorostyrene and p-methylstyrene were transformed to their respective (R)-
phenylethan-1-ol derivatives with moderate yields and >90% enantioselectivity. Most important-
ly, this approach could be amenable to a concurrent process if a thermotolerant alcohol dehydro-
genase that operates in organic solvents could be introduced.  
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Figure 1.4 Examples of one-pot cascade chemoenzymatic reactions 
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1.1.3.2. One-pot concurrent  
As highlighted in the previous section, one of the major factors that has prevented the successful 
integration of chemical catalysis and biocatalysis in concurrent tandem processes is the distinct 
reaction conditions used for the different classes of catalysts. This includes solvent choice and 
temperature as well as mutual inactivation of the two catalysts, which often occurs. Reports of 
one-pot, concurrent chemoenzymatic reactions have only just started to emerge. So far, these 
processes have been limited to a relatively small number of chemical reactions that can occur at 
mild temperatures, as well as a small number of biocatalysts that are compatible with conditions 
required for the chemical catalyst to operate satisfactorily.   
 
Molinari et al. developed a synthetic method for the one-pot preparation of aldoximes, which 
have wide application in medicine, industry, and analytical and synthetic chemistry [53]. They 
combined the enzymatic oxidation of primary alcohols using different acetic acid bacteria with 
an in situ condensation of the resultant aldehydes with hydroxylamine. In the absence of hydrox-
ylamine, the oxidation of primary alcohols catalyzed by membrane-bound alcohol and aldehyde 
dehydrogenases of acetic acid bacteria generally leads to carboxylic acids through the further 
oxidation of aldehydes. However, since the rate of aldehyde oxidation was slower than the con-
densation reaction between the intermediate aldehydes and hydroxylamine, aldoximes were pref-
erentially formed. Although high concentrations of hydroxylamine were found to inhibit the 
whole cell transformations, several aldoximes were obtained in moderate to high yields (50-
90%) from phenyl-alcohol derivatives (Figure 1.5).  
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Figure 1.5 One-pot chemoenzymatic synthesis of aldoximes from primary alcohols  
 
The copper-catalyzed 1,3-dipolar cycloaddition of azides and alkynes (CuAAC) to form 1,4-
disubstituted triazoles is a common reaction used to form covalent connections between building 
blocks containing various functional groups. As a result, it has seen applications in various areas 
including  drug discovery, polymer chemistry, as well as medicinal and biological sciences [54].  
The bioorthogonality of this reaction is especially suited for one-pot procedures with enzymes. 
Recently, efforts have been directed at engineering one-pot transformations involving CuAAC 
with biocatalysts.  Feringa and coworkers demonstrated that an azidolysis of aromatic epoxides 
by HheC could be combined in one-pot with a subsequent CuCAAC reaction with phenylacety-
lene (Figure 1.6) [55]. To afford the highest yields, the enzyme HheC was added in two portions, 
and the starting substrate concentration was kept below 5 mM to prevent enzyme-substrate inhi-
bition. The substrate scope of this reaction only encompassed styrene and p-nitrostyrene.    
 
  
Figure 1.6 One-pot tandem azidolysis-CuAAC 
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Another area in which combinations of metal catalysts and enzymes have been successful is in 
the chemical and electrochemical regeneration of cofactors used in redox enzymatic reactions. 
The in situ regeneration of expensive cofactors in enzymatic redox reactions is absolutely neces-
sary for preparative scale transformations. Enzymes that regenerate cofactors are abundant in 
nature and have been readily used for large-scale cofactor regeneration. However, the applicabil-
ity of these enzymes may be limited under certain process conditions because of their strict pref-
erence for a specific cofactor (NADPH, NADH or flavin for example) and low stability in organ-
ic solvents and at high temperatures. A few thermostable dehydrogenases have been identified 
[56], while protein engineering has partly addressed problems of stability and cofactor prefer-
ence of a few of these enzymes [57-63].  Although enzymatic cofactor regeneration remains the 
method of choice for preparative-scale redox reactions [64], several cheaper, more versatile me-
diators, mainly organometallic complexes which regenerate cofactors and their analogues, have 
been extensively studied [65-72].  
 
Among the complexes that can catalyze chemical and electrochemical regeneration, pentame-
thylcyclopentadienyl rhodium bipyridine ([Cp*Rh(bpy)(H2O)]
2+
) is particularly attractive be-
cause it is active on several cofactors and their analogues and is stable over very broad tempera-
ture and pH ranges. Therefore, this electro-catalyst represents an alternative to enzymatic regen-
eration systems under certain process conditions [73, 74]. However, the Rh complex was found 
to induce mutual deactivation when present in the same pot as biocatalysts. To prevent direct 
contact between the enzyme and the Rh mediator, a polymer-bound Rh complex was synthe-
sized, and physical separation between the two catalytic centers was implemented. This engi-
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neered system could achieve a yield of 90% of (R)-phenyl-ethanol via ketone reduction by an 
alcohol dehydrogenase. 
 
While mutual inactivation occurs in the presence of the Rh mediator, an Fe(III)-porphyrin was 
found to be fully compatible with enzymes for the regeneration of NADP
+
[75]. After testing sev-
eral water-soluble iron porphyrins, Fe(III) meso-tetrakis(4-sulfonatophenyl)porphyrin was found 
to efficiently oxidize NAD(P)H, while reducing molecular oxygen to water. By combining this 
porphyrin with a glucose dehydrogenase from Bacillus subtilis or an alcohol dehydrogenase, ef-
ficient enzymatic oxidations of monosaccharides and cyclooctanol were achieved, respectively.  
 
1.1.4 Novel ways to combine enzymes and catalysts in one-pot concurrent sys-
tems 
Mutual inactivation has not been investigated in-depth because it occurs on a case-by case basis. 
The interactions between chemical catalysts and enzymes differ depending on the characteristics 
of the two catalysts as well as the reaction being catalyzed. Therefore, a general model or predic-
tion for mutual inactivation is far from being realized. However, new strategies are being devel-
oped to circumvent mutual inactivation between metal catalysts and biocatalysts. These new ap-
proaches hold tremendous promise for future chemo-enzymatic applications, as they describe 
potentially general ways for carrying out classic organic reactions in the presence of biocatalysts.  
One approach to enable cascade or concurrent chemo-enzymatic reactions to occur without mu-
tual inactivation is to compartmentalize the catalytic systems, shielding the catalytic centers from 
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one another.  Ways to achieve such compartmentalization traditionally included biphasic reaction 
conditions, site-isolation, membrane filtration [76], or enzyme immobilization within solid sup-
ports. Alternatively, the use of whole cells could provide a natural protection for biocatalysts. A 
method that combined a non-selective palladium hydrogenation catalyst with an enantioselective 
bio-oxidation system to produce enantiopure cyclic secondary amines was recently reported [77]. 
Aerobic cultures of E. coli, overproducing a recombinant monoamine oxidase possessing high 
enantioselectivity towards chiral amines, were coated with nanoscale Pd(0) precipitated via a bi-
oreduction reaction on the cell membrane [78, 79]. Using this biometallic whole cell catalyst, the 
enzyme oxidizes only the (S)-enantiomer of racemic 1-methyltetrahydroisoquinoline (MTQ) to 
form 1-methyl-3,4-dihydroisoquinoline (MDQ), which is then reduced back to the racemic 
amine by a non-selective Pd/H2 reduction (Figure 1.7). Since hydrogen and air could not be pres-
surized in the reaction vessel at the same time, the deracemization required five cycles of air al-
ternated with five cycles of hydrogen to catalyze the oxidation and reductions steps, respectively, 
and achieve the (R)-MTQ in 96% ee. This work is especially important because few methods are 
reported for the preparation of enantiopure secondary amines, in contrast to primary amines 
which can be obtained through a metal-lipase DKR system.  
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Figure 1.7 Deracemization of a cyclic secondary amine 
 
Another interesting approach to enable chemo-enzymatic reactions in one-pot would be to create 
“hybrid” catalysts bearing two or more orthogonal but complementary catalytic activities. Con-
ceptually, this draws similarities to biometallic whole cell catalysts, but expands the chemical 
scope. Palomo and coworkers recently hinted at such a possibility [80].   They described the syn-
thesis of novel enzyme–metal nanoparticles (NPs) (called nanobiohybrids), where metal nano-
particles were generated in situ from an aqueous noble metal salt solution. These CALB-
metalNPs hybrid catalysts were tested for their respective orthogonal reactions separately and in 
tandem. CALB-PdNPs were capable of catalyzing Heck coupling, Suzuki coupling, nitroarene 
reduction (metal catalysis) reactions, as well as a lipase transesterification (biocatalysis). Inter-
estingly, an amine DKR was also achieved in high yields and >99% ee.  
 
Incorporating metal catalysts inside a protein host has long been an intense area of research for 
the creation of artificial metalloenzymes [81-88].  Artificial metalloenzymes give access to both 
the reactivity and substrate scope of metal complexes, and the regio- and stereoselectivity afford-
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ed by the second coordination sphere of a protein host. Hollmann, Turner, and Ward recently ap-
plied this approach to develop synthetic cascades by combining an artificial transfer hydrogenase 
(ATHase), created by incorporating a biotinylated [Cp*Ir(Biot-p-L)Cl] complex within streptav-
idin (Sav), with several biocatalysts [89].  Whereas mutual inactivation occurred when the free Ir 
complex and the biocatalysts were combined, the encapsulated metal complex enabled one-pot 
concurrent reactions with three different enzymes. First, a double stereoselective amine racemi-
zation was achieved in combination with a monoamine oxidase to form enantiopure cyclic sec-
ondary amines. Second, the formation of L-pipecolic acid from L-lysine was achieved by com-
bining the ATHase with L-amino acid oxidase and a D-amino acid oxidase to enrich the L-
pipecolic acid enantiomer. Third, the regeneration of NADH by the ATHase to promote a 
monooxygenase-catalyzed oxyfunctionalization reaction was also described. These reactions all 
reached 80% to near quantitative yields, which indicated that the Sav-Ir complex was fully com-
patible with the enzymatic reactions.  
 
Similar to the incorporation of transition metal complexes within streptavidin, the use of supra-
molecular host-guest complexes allows synthetic catalysts to work collaboratively with enzymes. 
Firstly, supramolecular assemblies have been shown to stabilize reactive metal species and in-
crease their lifetime [90].  Secondly, water soluble supramolecular host-guest assemblies can pull 
hydrophobic organometallic complexes into an aqueous solution, therefore permitting certain 
reactions traditionally performed in organic solvents to occur in water [90, 91]. Lastly, the su-
pramolecular host-guest assembly prevents diffusion of the transition metal complex in the solu-
tion, thereby averting its direct interaction with proteins [90, 92].   
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Using a supramolecular approach, Bergman, Raymond, Toste and coworkers demonstrated tan-
dem reactions that employed esterases, lipases or alcohol dehydrogenases and Au(I) or Ru(II) 
complexes encapsulated in a Ga4L6 tetrahedral supramolecular cluster [93]. First, lipases and es-
terases were combined with an Au(I)–Ga4L6 host–guest complex for a cascade lipase-hydrolysis 
followed by a hydroalkoxylation of allenes (Figure 1.8). Second, they achieved a Ru(II)-
mediated olefin isomerization of allyl alcohol to give propanal, followed by reduction to propa-
nol via ADH catalysis. The yields obtained from the one-pot reaction were identical to those ob-
tained in the case of sequential reactions. 
 
 
Figure 1.8 Examples for metal catalysts encapsulated within a supramolecular complex in tandem with biocatalysts 
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1.2 Asymmetric transformation of C=C double bonds 
As prochiral substrates, C=C double bonds are very attractive substrate for the preparation of 
several chiral molecules through transformations such as hydrogenation, hydration, hydro-
formylation, halogenation, epoxidation, hydroxylation to produce diols, various electrophilic ad-
ditions, as well as cyclopropanation. In the work presented in this thesis, we are interested in en-
zymatic transformations of double bonds that include the selective addition of oxygen (epoxida-
tion) or hydrogen (reduction). It is important to highlight the catalysts and biocatalysts at our 
disposal to efficiently combine with transformations that form these double bonds such as olefin 
metathesis, isomerization and diazocoupling. Transition metals and transition metal complexes 
are at the heart of most of the transformations that form double bonds 
 
1.2.1 Chemical catalysts for the synthesis of epoxides 
Enantiopure epoxides are very important building blocks for the synthesis of enantiomerically 
pure complex molecules, in particular, of biologically active compounds [94]. Many active natu-
ral products, drugs, pharmaceutical intermediates and metabolites contain epoxides with high 
enantiopurity, which are often required to confer their biological and medicinal properties [95]. 
As a result, discovery of practical methods to prepare enantiopure epoxides by asymmetric epox-
idation of olefins has long been an area of active research. Asymmetric olefin epoxidation meth-
ods fall into four general categories: directed epoxidations, metal-oxo catalyzed epoxidations, 
dioxane-catalyzed epoxidations and nucleophilic epoxidations. Other miscellaneous methods 
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have surfaced in the last ten years as well.  For more in-depth mechanistic, readers are encour-
aged to consult recent reviews [94, 96].  
 
1.2.1.1 Directed epoxidations 
The Sharpless epoxidation is one of the most powerful epoxidation reactions available for the 
preparation of 2.3-epoxyalcohols [97-99]. This well-known reaction comprises the enantioselec-
tive epoxidation of an allyl alcohol using tert-butyl hydroperoxide as oxidant and titanium-
tartrate complex Ti(OiPr)4 as the catalyst. The reactivity and regioselectivity of the epoxidation is 
directed exclusively to the double bond allylic to the alcohol, even in the presence of other dou-
ble or triple bonds. Although this selectivity is remarkable, the Sharpless epoxidation is quiet in-
effective in the absence of the alcohol directing group, in the epoxidation of terminal olefins, and 
does not tolerate functional groups such as carboxylic acids and most aryl groups. Very low reac-
tion temperatures (-40
o
C-0
o
C) also present a limitation in terms of the compatibility of this reac-
tion in tandem.   As a slight modification of the Sharpless method, Yamamoto and coworkers 
recently reported the epoxidation of homoallylic alcohols using a vanadium triisopropoxide ox-
ide to achieve 90% ee and yields up to 78% for simple homoallylic alcohols [100].   
 
1.2.1.2 Metal-oxo catalyzed epoxidations 
As opposed to the Sharpless epoxidation, metal-oxo catalyzed epoxidation does not require 
bonding interactions between the substrate and the catalyst. For this reason, this epoxidation does 
not require an alcohol as a directing group. Various metal-salen catalysts have been reported 
over the last 25 years, including chromium and manganese-salens. The first breakthrough man-
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ganese-salen complex as catalysts for enantioselective epoxidation was reported independently 
by Jacobsen and Katsuki [101, 102]. This epoxidation allowed the enantioselective formation of 
epoxides from various cis-substituted olefins by using a chiral Mn-salen catalyst and a stoichio-
metric oxidant such as bleach or iodomesitylene. Compared to the Sharpless epoxidation, the Ja-
cobsen epoxidation allows a broader substrate scope for the transformation, such as conjugat-
ed cis-olefins (R: Ar, alkenyl, alkynyl; R': Me, alkyl) or alkyl-substituted cis-olefins bearing one 
bulky alkyl group. However, common limitations to the early Mn-salen catalysts developed in-
clude the requirement of an unsaturated conjugated group such as an arene, alkene, or alkyne for 
acceptable reactivity. Terminal epoxidation can be achieved at very low temperatures (-40
o
C) 
with high yields and acceptable enantioselectivity as well (up to 85% ee) [103, 104].  However, 
Mn-salen catalysts often perform badly with trans-alkenes, aliphatic linear alkenes, and create 
trans-epoxides from cis-alkenes: thus, Cr-salen catalysts are preferred for some specific trans-
alkene to trans-epoxide transformations [96]. 
 
1.2.1.3 Metal porphyrins 
In many proteins, porphyrins complete several functions, including O2 storage (myoglobin Mb), 
and transport (hemoglobin), oxidation of inactivated carbon-hydrogen bonds (cytochrome 
P450s), and oxygen reduction (cytochrome c oxidase). Since John T. Groves reported that man-
made porphyrins catalyze enantioselective epoxidation via a highly reactive oxo-metal (M=O) 
intermediate similar to cytochrome P450 in 1979 [105], transition metal porphyrins-catalyzed 
enantioselective epoxidations has been of utmost importance and widely studied. Their rigid 
macrocyclic core and alterable periphery of porphyrins make them attractive templates for build-
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ing asymmetric catalysts. Chiral groups can be attached to porphyrins in various geometries, 
aiming at systems that might give high enantioselectivities and turnover numbers. Most studies 
on metalloporphyrin catalysts are confined to the porphyrin complexes of iron, manganese, ru-
thenium, and molybdenum.  
 
While many iterations of iron-porphyrin catalysts were designed, only a few could achieve very 
high enantioselectivities (>over 80%), led mainly by the seminal works of Eric Rose. In 1999, 
Collman et al. presented a highly efficient catalyst based on a novel chiral iron porphyrin. This 
system gave very high enantioselectivities and turnover numbers for the epoxidation of styrene 
derivatives (83% ee for styrene, 88% ee for pentafluorostyrene, and 82% ee for m-chlorostyrene) 
and some non-conjugated branched terminal alkenes, with ee’s reaching over 90% for trimethyl-
butene [106], exceeding the highest values obtained from any catalytic systems, including Salen-
Mn derivatives. Later in 2004, they synthesized a new chiral binaphthyl-strapped iron porphyrin, 
which exhibited unprecedented catalytic activity toward the enantioselective epoxidation of ter-
minal olefins. For the epoxidation of styrene, typical ee values were measured to be 90-97%, 
whereas the turnover numbers (TON) averaged 16 000 [107].   
 
1.2.1.4 Dioxiranes  
A few organo-catalyzed epoxidations have been published in recent years. These include epoxi-
dations with BINOL systems, dioxiranes [108], chiral ketones [109, 110], chiral aldehydes [111], 
and chiral iminium salts [112, 113]. Many of these systems are efficient for various epoxidations, 
especially for the epoxidation of trans-di- and tri-substituted olefins. Shi and coworkers, who 
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have been leading this effort of synthesizing chiral ketone catalysts, also reported a diooxirane 
catalyst capable of doing terminal epoxidation of styrene derivatives with high ee, comparable 
with the iron porphyrin catalysts developed by Rose, with ee for styrene reaching 90% [114, 
115].  
 
In the last several years, as one can appreciate, many catalysts have been designed for the enanti-
oselective epoxidation of olefins. Nonetheless, man-made catalysts for asymmetric epoxidations 
suffer from several shortcomings. Firstly, the epoxidation of terminal aliphatic alkenes with high 
enantioselectivity still remains a synthetic challenge. A conjugated ring (phenyl) is usually pre-
sent to help increase the activity and enantioselectivity of the reaction. Secondly, asymmetric 
epoxidations, and enatioselective oxidations in general, are not streamlined in tandem reactions, 
as are other important reactions such as metathesis, isomerization, hydroformylation and 
polymerization.  
 
1.2.2 Enzymes for asymmetric epoxidation 
Numerous enzymes are capable of epoxidizing double bonds with high enantio- and regioselec-
tivity, including styrene monooxygenases, ω-hydroxylases, peroxidases, and cytochrome P450s. 
However, many of these enzymes have low activity and total turnovers, are multicomponent, 
have little to no organic solvent tolerance and catalyze only their native biological substrates. 
These obstacles, in many cases, diminish the importance and usage of these enzymes from a syn-
thetic chemistry and industrial biocatalysis point of view. This section will only highlight the en-
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zymes which have been engineered or naturally catalyze the epoxidation of double bonds or the 
oxidation of C-H bonds of synthetically relevant organic compounds with high ee.   
 
1.2.2.1 Styrene monooxygenases 
Of all the monooxygenases that have been investigated and engineered, styrene monooxygenases 
hold the most promise as an industrial biocatalyst for the production of enantiopure styrene oxide 
and styrene oxide derivatives. The two-component system consisting of a styrene monooxygen-
ase (oxygenase StyA) and a NADH-flavin oxidoreductase (StyB) [116, 117]) from Pseudomo-
nas sp. strain VLB120 exhibits a specific activity on styrene of 2.1 U mg
-1 
cell dry weight (cdw), 
the highest activities known for styrene monooxygenases. By expressing the two-component sys-
tem recombinantly in an engineered E. coli, Schmid and coworkers demonstrated the feasibility 
of recombinant whole-cell biotransformations in two-liquid phase systems on a pilot scale [118]. 
They produced 388 g of styrene oxide (>99% ee) from a 30 L fermentation, with an average 
overall volumetric activity was 170 U per liter.   
 
The engineering of styrene monooxygenases has also been reported recently for the epoxidation 
of α- and β-substituents, as well as halogenated styrenes [119]. A newly characterized styrene 
monooxygenase StyAB2 was engineered by site-directed mutagenesis for enhanced activity 
against many styrene derivatives with α-substituents (2-fold improvement for α-ethylstyrene) 
through alanine scanning of four active site residues [120]. In addition, the wild-type StyAB2 
protein showed high activities for β-methylstyrene, butenylbenzene, as well as a few diaryl com-
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pounds with whole-cell biphasic conversions ranging from 35 – 100% [121]. The longer the α-
substituent alkyl chain, the lower the resulting conversion which was obtained.  
 
1.2.2.2 ω-Hydroxylases 
Many bacterial species, such as Mycobacterium sp. and a few marine bacteria, have the ability to 
grow on alkanes as their only carbon source. The first and key step in alkane metabolism is the 
terminal hydroxylation of alkanes to 1-alkanols, a reaction catalyzed by a diverse group of me-
thane, propane, and butane monooxygenases and by some membrane-bound cytochrome P450s. 
Genome mining revealed that cytochrome P450 alkane diiron hydroxylases of the CYP153 fami-
ly are common in alkane-degrading eubacteria lacking integral membrane alkane hydroxylases  
[122, 123]. A few of these alkane hydroxylases have been characterized to different extents. The 
CYP153A6 from Mycobacterium sp. HXN-1500 was shown to hydroxylate medium-chain-
length alkanes (C6 to C11) to 1-alkanols with a maximal turnover number of 70 min
-1
 and has a 
regiospecificity of  over 95% for the terminal carbon atom position [124]. This enzyme was ex-
pressed in Pseudomonas putida as a polycistronic construct of the CYP153A6 P450 enzyme, fer-
redoxin, and ferredoxin reductase from Mycobacterium sp. HXN-1500 [125]. Through fusion 
with the reductase domain from Rhodobacter sp. NCIMW 9784, various CYP153s were recon-
stituted [126]. The CYP153A13a from Alcanivorax burkomensis SK2 was found to catalyze the 
terminal oxidation of alkanes (C6-C10) and produce α-ω-diols [127]. This chimeric enzyme was 
also shown to mono-hydroxylate various aromatics and biaryl compounds with high regioselec-
tivity, although with fairly low activities [128].  
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Alkane hydroylases exhibit a tight carbon length preference, and efforts at expanding their sub-
strate scope is of interest. However, directed evolution of CYP153 oxygenases has not been re-
ported as frequently. Arnold and coworkers used an in vivo selection method to engineer AlkB 
and CYP153A6 for butane oxidation, two enzymes which have C8 carbon chain length prefer-
ence [129]. Pseudomonas cells were transformed with error prone PCR generated libraries of 
AlkB and CYP153A6, respectively. Only cells containing the improved variants were able of 
growing on butane. Although they found a few mutants of each enzyme that could oxidize bu-
tane to produce 1-butanol, the mutation found in the CYP153A6 gene was not responsible for the 
cell growth on butane, which suggested that genome adaptation occurred to afford the improve-
ment.  
 
1.2.2.3 Cytochrome P450s 
Constituting the largest superfamily of heme-containing monooxygenases, cytochrome P450 
monooxygenases are versatile biocatalysts that introduce oxygen into a vast range of molecules 
at allylic positions, across double bonds, and into non-activated C–H bonds in a regio- and ste-
reo- selective manner (Figure 1.9) [130-132]. Besides hydroxylation reactions, P450s are known 
to catalyze several other reactions: aryl–aryl coupling, ring contractions and expansions, S-
dealkylations, N-dealkylations, and O-dealkylations, decarboxylation, oxidative cyclization, al-
cohol and aldehyde oxidation, desaturation, sulfoxidation, nitrogen oxidation, C-C bond scission, 
decarbonylation, and nitration [133].  
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P450 enzymes can be divided into four classes, depending on their redox partners. Class I P450s 
include most bacterial monooxygenases that require a FAD-containing reductase and an iron sul-
fur redoxin (P450cam from Pseudomonas putida). Class II enzymes require only a FAD/FMN-
containing P450 reductase for the transfer of electrons and are found mostly attached to the en-
doplasmatic reticulum. P450 BM3 from Bacillus megaterium and CYP102A2 from Bacillus sub-
tilis belong to this class of enzymes. P450 BM3 from Bacillus megaterium catalyzes the sub-
terminal hydroxylation of long-chain (C12–C20) fatty acids as well as the epoxidation of mono 
and polyunsaturated fatty acids with high regio- and at times enantioselectivity. Due to its high 
activity and catalytic self-sufficiency [130, 131], P450 BM3 represents an excellent engineering 
platform for oxidation. Class III enzymes are self-sufficient and require no electron donor as they 
convert peroxygenated substrates that already contain oxygen. Meanwhile, P450s from class IV 
receive electrons directly from NAD(P)H (P450nor from F. oxysporum). 
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Figure 1.9 Reaction catalyzed by cytochrome P450s 
 
1.2.2.3.1 The P450 catalytic cycle 
The P450 catalytic cycle has been studied in detail (Figure 1.10). In its resting state, the catalytic 
iron is in the ferric (+3) oxidation state. Upon substrate binding, removal of the water molecule 
occurs, and the reduction potential of the heme prosthetic group is increased, which makes it 
possible for an associated reductase to reduce the heme to the ferrous (+2) state via transfer of 
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one electron. The heme subsequently binds molecular oxygen to form ferric superoxide complex 
(step 3). A second electron transfer generates an iron-peroxo intermediate (step 4), which is then 
protonated to give an iron-hydroperoxy intermediate (step 5a). Residue T268A, with the aid of 
water helps to protonate the iron-peroxo and iron-hydroperoxy intermediates, thus promoting O-
O bond scission to generate compound I (step 5b). This hypervalent compound I abstracts hy-
drogen from a substrate C-H bond to yield a substrate radical and the radical compound II (not 
shown) (step 6). The two radicals react with one another very quickly to yield a hydroxylated 
product, with the heme returning to its original ferric (+3) oxidation state. Several P450s can by-
pass the NADPH electron transfer steps and directly be transformed into the iron-hydroperoxy 
intermediate with the use of hydrogen peroxide or organic peroxides such as cumene hydroper-
oxide (step 8). This strategy is used for most peroxidases such as chloroperoxidase. P450s have 
also been evolved to use hydrogen peroxide as an oxidant [134], however, enzyme deactivation 
and low enzyme activities present a sizeable obstacle.  
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Figure 1.10 P450 catalytic cycle (adapted from [135, 136])  
 
1.2.2.3.2 Directed evolution of P450 BM3 
Arnold and coworkers successfully re-specialized the P450 BM3 enzyme, through successive 
rounds of laboratory evolution, to catalyze the selective hydroxylation of short alkanes, including 
propane with native-like activity and coupling efficiency [137], a reaction for which no practical 
catalysts are available [138, 139]. A domain-based protein engineering strategy was used, in 
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which the heme, flavin mononucleotide (FMN), and flavin adenine dinucleotide (FAD) domains 
were evolved separately in the context of the holoenzyme, and beneficial mutations were recom-
bined in a final step. Two mutants, P450PMO R1 and R2, containing mutations in both the re-
ductase and heme domains, could catalyze propane oxidation with high total turnovers (35,600 
and 45,800 for R1 and R2, respectively), while maintaining close to 98% coupling efficiency 
[140]. In P450PMO, little trace of the original P450 BM-3 activity remained (Figure 1.11)  
 
During the course of the evolution, through saturation mutagenesis, the Arnold group altered the 
chemoselectivity of P450 BM3 by engineering of the heme domain to create two mutants, RH-47 
and SH-44, for the selective epoxidation of simple terminal alkenes, versus hydroxylation at the 
allylic position (C-3). The two mutants showed inverted enantioselectivity, with the RH-47 vari-
ant forming the (R)-epoxide, while the (S)-epoxide is formed by the SH-44 variant. Up to 83% 
ee, catalytic turnovers up to 1,370 and high epoxidation selectivities (up to 95%) were obtained. 
However, these two variants suffered from heme alkylation that limited their catalytic turnovers 
[141]. Because the active site of the P450 BM3 can accommodate different sizes and shapes of 
substrates, simple rational design or directed evolution libraries have afforded activities on other 
non-native substrates such as aromatics (α-substituted styrene derivatives, steroids, macromole-
cules, disaccharides) and have been reviewed and reported thoroughly elsewhere [131, 142-148].  
 
31 
 
 
Figure 1.11 Directed evolution of P450 BM3 for activity on small alkanes 
 
Besides P450 BM3, the Auclair group has engineered another P450, namely the CYP3A4 for the 
regioselective oxidation of short alkanes. This is important because, although P450s have an un-
precedented ability to oxidize C-H bonds, it is still challenging to predict and control the regiose-
lectivity in the presence of multiple hydroxylation or epoxidation sites without using some sort 
of enzyme evolution. Regioselectivity in systems in which non-bonding interactions exist be-
tween substrate and catalytic center is also generally difficult to achieve. Strukul and coworkers 
demonstrated with a Pt catalyst, that one could direct double bond epoxidation, even in the pres-
ence of other double bonds [149, 150]. Using the chemical auxiliary theobromine, Auclair and 
coworkers directed the epoxidation and hydroxylation of small chain alkenes and alkanes exclu-
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sively at the C4 carbon [151]. The theobromine cleavage is straightforward and can generate an 
amine or another functional group. Enantiomeric excess varied for each substrate, and could not 
be predicted, but epoxidation of 3,7-dimethyl-1-(pent-4-enyl)-1H-purine-2,6(3H,7H)-dione (1-
pentene attached to theobromine) yielded only the R-epoxide with over 99% ee. More recently, 
Zhi Li and coworkers engineered P450Pyr for the hydroxylation of aliphatic alkanes with high 
regio and enantioselectivity for the production of 2-octanol and phenyl-2-ethanol [152].  
 
1.2.2.4 Hydrolytic kinetic resolution of terminal epoxides 
Although a lot of research has been directed towards the enantioselective epoxidation of olefins, 
it is safe to say that the asymmetric epoxidation of simple linear terminal alkenes remains chal-
lenging to afford with high enantiopurity (>90% ee), with both enzymes and metal catalysts. One 
way enantiopure terminal epoxides can be prepared is through kinetic resolution. In 2002, the 
hydrolytic kinetic resolution of several terminal epoxides was accomplished with a Co(II) salen 
catalyst developed by Jacobsen and coworkers [153, 154].  Using a catalytic amount of water, a 
low loading of this commercially available catalyst, the kinetic hydrolysis of a very wide range 
of terminal epoxides, ranging from aliphatic, halogenated, epoxides bearing ethers, aryl and vi-
nyl, could be resolved, with yields close to the theoretical 50% and over 99% ee. As a biological 
counterpart, epoxide hydrolases from microbial sources, yeast and fungi are very popular for the 
kinetic resolution of terminal and internal epoxides or the preparation of their enantiopure diols 
[155-157].  
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1.3 P450-mediated carbene transfer reactions 
The formation of the hypervalent iron-oxo species (Compound I in Figure 1.10) bears resem-
blance to many metal carbenoid intermediates formed during carbene-mediated insertion chemis-
try (Figure 1.12). The formation of a metal carbenoid complex mediates transfer of groups such 
as oxenes, carbenes and nitrenes to activated and non-activated C-H bonds and C=C bonds to 
create C-O, C-C and C-N bonds respectively. P450-catalyzed oxidations are but one kind of such 
transfers (oxene) into non-activated C-H bonds. In the absence of a nucleophile, coupling of a 
carbene with a carbenoid could occur to form dienones [158]. Based on the mechanistic similari-
ty between P450 catalysis and carbene insertion chemistry, Arnold and coworkers engineered 
P450 BM3 mutants that could catalyze cyclopropanation [159-161], NH insertion [162] and 
amination [163]. This is a breakthrough discovery considering that carbene insertions do not ex-
ist in nature, but are well-documented in organic chemistry [164].   
 
 
Figure 1.12 Carbene-mediated insertions catalyzed by transition metals 
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1.4 Artificial metalloenzymes  
Over the last decades, the design of many metal porphyrin catalysts has been inspired by the ac-
tive site configurations of natural porphyrins. Recently, with the advance of computational tools, 
many artificial enzymes have been designed. In particular, researchers have sought to use en-
zyme scaffolds as natural ligands, and fitted in different catalytic metals and metal complexes. 
Chemical reactions such as Diels-Alder, olefin metathesis [165], reactions which are not per-
formed by any enzyme, as well as C-H activation (hydroxylation) have been achieved using 
streptavidin or biotin scaffolds [166]. Two examples exist as far as artificial metalloenzymes for 
epoxidations. The first one was reported by Kazlauskas, in which they created a manganese-
substituted carbonic anhydrase (CA[Mn]), which showed peroxidase activity with a bicarbonate-
dependent mechanism. In the presence of bicarbonate and hydrogen peroxide, CA[Mn] catalyzed 
the epoxidation of chlorostyrene, styrene, β-methyl styrene with moderate enantioselectivities. A 
maximum conversion of 12.5% was obtained with p-chlorostyrene, a reaction not catalyzed by 
the native zinc enzyme [167]. More recently, Ricoux and coworkers incorporated manganese 
complexes into a xylanase to create new artificial metalloenzymes for enantioselective epoxida-
tion [168].  In particular, they inserted a Mn(III)-meso-tetrakis(p-carboxyphenyl)porphyrin 
[Mn(TpCPP), 1-Mn] into a host protein, xylanase 10A from Streptomyces lividans 
(Xln10A).  The artificial metalloenzyme was able to catalyze the oxidation of p-methoxystyrene 
by KHSO5 with a 16 % yield and the best enantioselectivity (80 % in favor of the R isomer) ever 
reported for an artificial metalloenzyme.  
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1.5 Conclusion 
Strategies that enable one-pot tandem chemoenzymatic reactions are still in their infancy. The 
development of this field has been slow mainly due to the often incompatible conditions required 
for chemo-catalyzed and enzyme-catalyzed transformations. Tandem processes, so far, are gen-
erally comprised of two to three catalytic reactions, even when catalysts from the same category 
are combined. The limited number of steps is in sharp contrast to natural biosynthetic pathways 
in which tens of enzymes work in harmony to achieve very complex transformations. Since the 
metal-lipase DKR, several well-characterized chemical transformations have been combined 
with enzymes, to achieve either sequential or concurrent one-pot processes. However, the variety 
of enzymes that has been integrated, as well as the number of chemical transformations that can 
be coupled in tandem, has been limited.  To expand the synthetic capabilities of one-pot chemo-
enzymatic reactions, contributions from several interdependent research areas are necessary (e.g., 
but not limited to protein engineering, chemical catalyst synthesis, supramolecular assembly, and 
artificial metalloenzymes).   
 
Protein engineering strategies to improve enzyme stability in organic solvents and/or in harsh 
conditions (e.g. high temperatures) is important for the integration of chemical and biological 
transformations in one-pot. Many milestones have been achieved in the engineering of enzymes 
to operate in organic solvents [169, 170] and high temperatures via directed evolution [11, 12, 
171, 172]  and enzyme immobilization techniques [169, 173, 174]. Similarly, in recent years, 
synthetic chemistry has been focusing on developing catalysts that can be effective at mild con-
ditions and in aqueous environments.  Current advances in this area have provided us with many 
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examples of water-soluble metal complexes that catalyze a variety of reactions (e.g. olefin me-
tathesis [175-181], Pd-catalyzed hydrogenation[182], and C-C coupling reactions in aqueous en-
vironments [183]).   
 
Supramolecular approaches are beginning to provide potentially general approaches to create 
synthetic cascades involving transition-metals catalysts and enzymes. One current limitation of 
the supramolecular incorporation of transition metal complexes is that complexes bearing a net 
positive charge are more easily incorporated within the water-soluble supramolecular ligands 
than neutral complexes [90, 92].  Further engineering needs to be performed to increase the 
scope of metal complexes that can be introduced.  In addition, development of supramolecular 
scaffolds that mimic enzyme active sites to mediate substrate recognition via preferential binding 
will be advantageous to maintain reaction selectivity, in cases where several metal catalysts are 
present [184-186].  
 
Artificial metalloenzymes, in particular those based on the biotin-avidin technology, are starting 
to be well-studied for a variety of chemical transformations in water [85, 86], including C-H ac-
tivation, Diels-Alder reactions, hydrogenations and oxidations. Further developments of artificial 
metalloenzymes are needed to improve the productivity and/or stability of the catalyst employed.  
In summary, we envision that with advances in all these research areas in parallel, concurrent 
tandem chemoenzymatic processes can be orchestrated to mimic biosynthetic pathways, in which 
many enzyme-catalyzed processes are able to function simultaneously, resulting in the most 
complex reactions known. 
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1.6 Overview of the projects presented in this thesis 
In the last several decades, considerable efforts in transition-metal catalysis have culminated in 
practical and efficient transformations that form double bonds such as isomerization, olefin me-
tathesis, etc. Conversely, enzymes have been investigated and engineered to catalyze reactions 
which transform double bonds to form enantio-enriched products such as epoxides and other chi-
ral products.  
 
Our projects aimed at combining organometallic catalysts and (metallo)enzymes in tandem for 
these enantio- and regioselective transformations.  In Chapter 2, we present for the first time a 
tandem cross metathesis-oxidation reaction in one-pot. The cross metathesis reaction is catalyzed 
by an air and water-stable ruthenium olefin metathesis catalyst. We show in this case that in a 
biphasic alkane: buffer system, an equilibrium of alkenes can be established by the cross metath-
esis reaction. From this equilibrium mixture of alkenes, P450 BM3 selectively epoxidizes only 
the cross metathesis product with high regioselectivity for epoxidation. The specificity of P450 
BM3 for one member of the mixture drives the reaction forward toward generation of the deplet-
ed alkene via Le Chatelier’s Principle. When this reaction was carefully engineered, yields for 
the final epoxide products could be obtained that are higher than the yield that could be obtained 
if the two steps were run sequentially. This represents the first example of enzymatic epoxidation 
achieved under equilibrium conditions achieved by cross metathesis.  
 
In Chapter 3, we sought to expand the substrate scope of the tandem metathesis-oxidation via a 
combination of substrate, enzyme and reaction engineering. First, we show that P450 BM3 vari-
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ants can be engineered to have high specificity for epoxidation of double bonds placed at differ-
ent positions along a fatty acid chain. In this case, a cross metathesis between two alkenes not 
recognized by P450 BM3 forms a cross metathesis product, which similarly to the examples in 
Chapter 2, become a substrate for the enzyme. By changing the length of the alkene substrates, 
cross metathesis products with a double bond at different positions could be obtained. P450 vari-
ants 87A and 78A-87A were shown to selectively epoxidize tridecenoic acid with the double at 
ω-6 and ω-7, respectively. However, when applied in a biphasic isooctane: buffer system, the 
yields for the tandem reactions were very low, which was due to mass transfer limitations cou-
pled with the low activity of the P450 variants. Furthermore, we applied P450 variant R47L-
Y51F in tandem reactions involving cis-stilbene and symmetrical alkenes such as trans-hexene 
and cis-2-butene. High yields and TTN could be obtained using an improved reaction configura-
tion.  
 
In Chapter 4, P450 BM3 variants known to oxidize small chain alkenes were coupled with an 
isomerization catalyst in a biphasic hexadecane: buffer system, in the hopes of developing a one-
pot reaction in which regioisomers could be resolved. However, we found it very challenging to 
engineer a P450 variant that selectively epoxidizes terminal alkenes in the presence of internal 
alkenes. Other P450s such as terminal alkane hydroxylases (CYP153 family) were found to be 
selective for terminal epoxidation, but catalyzed the terminal hydroxylation of 2-alkenes with 
equal rates in the presence of terminal alkenes.  
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Lastly, in Chapter 5, we sought to extend this tandem approach to new enzymes and new reac-
tions. As a departure from established transition metal catalyzed transformations, we studied the 
coupling of diazo compounds catalyzed by heme containing enzymes, iron porphyrins and rho-
dium complexes. Diazo coupling is poorly studied transition metal-catalyzed reaction, nonethe-
less can yield dienones, which are important precursors for the synthesis of macrocycles and in-
secticides. P450 variants known to catalyze N-H insertion and cyclopropanation reactions also 
exhibit diazo coupling activity, although at low to modest yields. Preliminary results suggest that 
with the right mutations, P450 heme variants can be created with high heme reduction potential 
which may serve as better catalysts for carbene-mediated activities. In parallel, we discovered 
that an electron deficient iron porphyrin catalyzed diazo coupling reactions in high yields in 
buffer and at room temperature. Its substrate scope included not diazoacetates, but also diazo-
ketones. When this catalyst was combined with an enoate reductase which catalyzes the reduc-
tion of α, β-unsaturated alkenes, in one pot, no mutual deactivation of the two catalytic species 
was observed. In fact, complete reduction of the activated alkenes formed was observed. Lastly, 
by combining the enzymatic reduction with a rhodium-catalyzed diazo coupling that forms 
prochiral alkenes, potentially new chiral reduced alkenes were obtained. More work needs to be 
done to improve the conversion and selectivity of the tandem reactions involving rhodium diazo-
coupling and enoate reductases.  
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CHAPTER 2. COOPERATIVE TANDEM METATHESIS-OXIDATION BY 
AN ORGANOMETALLIC COMPLEX AND A METALLOENZYME  
 
2.1 Introduction 
The olefin metathesis reaction, through which pairs of C=C bonds are reorganized, is one of the 
most remarkable and versatile metal-catalyzed reactions in synthetic chemistry (Figure 2.1). This 
is evidenced by the hundreds of research articles and reviews involving olefin metathesis that are 
published every year [1].   Over the last two decades, the emergence and commercialization of 
highly selective ruthenium carbene and molybdenum catalysts have revolutionized synthetic 
methodologies by introducing this elegant way of creating double bonds. These catalysts have 
proven to be stable, easy to handle and modify, in particular the two structurally well-defined 
Grubbs and the Grubbs-Hoveyda catalysts (Figure 2.2). Due to its versatility and ever expanding 
substrate scope, olefin metathesis has found applications in the preparation of scarce molecules 
with highly desirable properties, including in alkane metathesis [2], asymmetric total synthesis 
[3], natural products synthesis (synthesis of diverse polycyclic compounds [4] or enantioselective 
synthesis [5, 6]), and in the synthesis or modification of steroids (reviewed by [1]) and medicinal 
agents [7], among others. Three advantageous features of metathesis catalysts are their wide sol-
vent compatibility [8], functional group tolerance [9] and the ease with which they can be modi-
fied to achieve solubilities in various solvents. Through relatively simple modifications, olefin 
metathesis catalysts with solubility and activity in alkanes [10], ionic liquids [11], emulsions 
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[12], and aqueous solvents [13-15] can be readily prepared as homogeneous or heterogeneous 
systems [16].  
 
Figure 2.1 Typical olefin metathesis reactions 
 
Although still in its infancy, there are several concurrent tandem reactions involving olefin me-
tathesis reported, including both metathesis/metathesis [17, 18] and metathesis/non-metathesis 
tandem catalytic systems. The latter include metathesis/isomerization [19, 20],  metathe-
sis/cyclopropanation [21], and metathesis/Diels Alder cycloaddition [22]. However, these tan-
dem reactions involve either only one metal center performing a single or both reactions, or two 
organometallic catalysts of the same discipline that are very similar (two ruthenium centers, for 
example).  
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In our work, we seek to engineer one-pot reactions for the dynamic regio- and enantioselective 
enzymatic oxidation of olefins prepared by metathesis using metalloenzymes and metathesis cat-
alysts. Namely, this would involve the tandem action of two metal catalysts from very different 
disciplines, working together to accomplish a synthetic goal not accessible by either catalyst 
alone. To this end, we conceived a study to assess whether metalloenzymes and organometallic 
catalysts could work cooperatively to catalyze a multistep process. We define cooperative reac-
tivity in this context as two species catalyzing a reaction that would not occur with either catalyst 
alone and would occur in lower yield if conducted as two sequential reactions.  
 
We chose to assess the potential cooperative reactivity of these catalysts with alkene reactants 
because alkenes are basic feedstocks and are often found as mixtures of cis and trans isomers, 
terminal and internal isomers, and as components of natural fatty acids. Thus, one could envision 
reactions catalyzed by organometallic complexes that lead to an equilibrating mixture of alkenes 
or the production of a mixture of alkenes in tandem with a selective reaction of one member of 
the mixture catalyzed by a metalloenzyme. In the following work, we report this type of dynamic 
process and show that the combination of an olefin metathesis catalyst and a cytochrome P450 
enzyme converts a mixture of alkenes to a single oxidation product. The metathesis catalyst leads 
to an equilibrating mixture of alkenes, and the P450 enzyme converts one member of the mixture 
of alkenes to the corresponding oxidation product.  
 
One reaction with high synthetic value that one can envision would be the regioselective oxida-
tion of medium chain alkenes from a dynamic mixture of shorter alkenes through a tandem me-
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tathesis-oxidation process. Beyond curiosity in science, our motivation also stemmed from the 
fact that there are very few metathesis/oxidations developed even in organic chemistry. Recently, 
three tandem metathesis/oxidation reactions that provide cis-diols or α-hydroxy ketones  [23] 
and  2-quinolones [24] were published. However, these systems suffer from low regioselectivity, 
and no generation of a chiral center was achieved. In addition, the reactions were performed with 
one metal catalyst. Lastly, the ring closing metathesis step cannot establish a dynamic equilibri-
um since the equilibrium strongly favors the ring-closed form.  
 
In order to prove that olefin metathesis catalysts and metalloenzymes could work cooperatively, 
we have to achieve three key steps. First, the metathesis catalyst must be stable in the presence of 
the enzyme, components of the buffer system and oxygen. Second, the enzyme system must be 
stable in the presence of the olefin metathesis catalyst. Third, one should choose reactions and 
enzymes that afford high yields and selectivity for the product(s) of the metathesis, while show-
ing little to no activity for the metathesis substrate(s). In addition, the enzymatic oxidation reac-
tion must exert a driving force on the equilibrium established by the olefin metathesis catalyst, 
thus enable the tandem reaction to achieve a final yield higher or comparable to doing the reac-
tions sequentially. In this chapter, we show our results in establishing said tandem reactions with 
fatty acids and aromatic substrates using commercially available metathesis catalysts and the 
versatile cytochrome P450 BM3.  
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2.2 Results and discussion 
2.2.1 Screening of metathesis catalysts 
The make- or break condition for the tandem metathesis-oxidation to succeed is for the metathe-
sis catalysts to be active in the presence of oxygen and enzymatic entities. The enzyme will use 
molecular oxygen to selectively oxidize C-C and C=C bonds. Generally, metathesis reactions are 
run using Schlenk tube techniques, away from moisture, oxygen and impurities, while using dis-
tilled substrates and solvents.  After surveying the literature, it was found that commercially 
available metathesis catalysts can work in air, using non-distilled solvents and substrates [25-29]. 
For example, Connon and Blechert found that using the Grubbs 2
nd
 generation catalyst (or the 
Hoveyda-Grubbs 2
nd
 generation catalyst with an o-isopropyl group) could afford ring closing 
metathesis and even cross metathesis of challenging substrates with high yields. Another report 
by Lipshutz et al. showed that simply adding the amphiphile polyoxyethanyl α-tocopheryl seba-
cate (PTS) allowed for unsymmetrical olefin cross-metathesis reactions in water, involving wa-
ter-insoluble substrates [30]. This report also pointed out that metathesis reaction could happen 
“on” water, with the reaction occurring while the catalyst and the substrates remained insoluble. 
 
We first tested five catalysts (Figure 2.2A) for their activity in air for the model cross metathesis 
reaction between methyl oleate and trans-3-hexene in dichloromethane. This reaction should 
produce methyl-dodecen-8-oate and 9-dodecene (cis + trans) as the desired cross metathesis 
products (Figure 2.2B). The results are listed in Table 2.1. All five catalysts showed activity in 
air in dichloromethane, although their selectivities were not as high as reactions performed in 
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oxygen free conditions [31]. All reactions were completed within 30 min. To test the reversibility 
of the reactions, the vials were opened to allow trans-3-hexene to evaporate. We observed the 
formation of the methyl oleate starting material approximately 20 minutes after the opening of 
the vial, which suggested that the reactions were reversible. Therefore, a dynamic equilibrium of 
olefins could be maintained by the metathesis catalyst.  
 
 
 
 
Figure 2.2 Hexenolysis of methyl oleate A) Catalysts used in this work B) Cross-metathesis of methyl oleate and 
trans-3-hexene 
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Table 2.1 Cross metathesis of methyl oleate with trans-3-hexene in DCM in air 
Entry Catalyst 
8-dodecenoic acid 
methyl ester  
[%]
[a]
 
9-dodecene 
Conversion 
[%]
[a]
 
Selectivity
[b]
 
Ester product 
(E/Z)
[c]
 
1 C1 42.8 17.9 85.5 60.7 3.1 
2 C2 40.9 18.5 93.2 59.4 5.1 
3 C3 30.1 17.4 87.0 47.4 2.2 
4 C4 35.4 15.3 97.5 50.6 2.4 
5 C5 19 11.0 90.1 30.1 2.7 
[a]
 Estimated by GC-MS from area ratio with control reaction with no metathesis catalyst. Decane was added as in-
ternal standard 
[b]
 Selectivity = [(mmoles 8-dodecenoic acid methyl ester + mmoles 9-dodecene)/mmoles of methyl 
oleate converted] 
[c] 
Estimated by GC-MS. All catalysts are known to be E-selective. E/Z ratio increases steadily    
 
2.2.2 Finding the “right” reactions 
Since the metathesis catalysts in air worked, we sought to find the right substrates for the olefin 
metathesis that would create the right selectivities for the P450 enzyme WT. In addition, we 
sought to find out whether the metathesis catalysts could remain stable under conditions of en-
zymatic oxidation (P450, NADPH, biphasic). We considered that the selectivity of certain P450 
enzymes (for example, P450 BM3) for the oxidation of fatty acids, alkenes and alkanes of certain 
chain lengths could be exploited for the selective reaction of one member of a mixture of al-
kenes. One such general scheme can be seen in Figure 2.3.  
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Figure 2.3 General scheme of proof-concept for tandem metathesis-oxidation reactions 
 
The wild-type P450 BM3 enzyme hydroxylates C12-C20 fatty acids selectively [32, 33]. We envi-
sioned reactions in which a cross metathesis reaction between a shorter unsaturated fatty acid and 
a symmetrical alkene would elongate the acid chain to create a substrate for P450 BM3. The 
P450 BM3 enzyme would oxidize the resulting longer-chain fatty acid (>C12). For example, we 
found that P450 BM3 shows 100% selectivity for dodecanoic acid hydroxylation at ω-1, ω-2 and 
ω-3 over hydroxylation of 5-hexenoic acid. In addition, the enzyme reacts with a more than 5-
fold preference for oxidation of a C13 chain over a C11 chain with 82% selectivity for hydroxyla-
tion of the ω-2 and ω-3 carbons of tridecanoic acid (Table 2.2). With this system, we hypothe-
sized that fatty acids of C13 length with an alkene at the ω-2 position would undergo selective 
epoxidation. Alternatively, if the alkene is not at ω-2, hydroxylation would occur at this position 
of the longer cross metathesis product. Based on the P450 WT selectivity, we therefore sought to 
design tandem reactions as shown in Figure 2.4.  
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Table 2.2 Kinetics and selectivity of P450 BM3 against 10-undecenoic acid and tridecanoic acid 
 
 
 
Figure 2.4 Tandem metathesis-oxidation reaction schemes 
 
In the first example reaction, the cross metathesis between 5-hexenoic acid and 7-tetradecene 
would yield 5-dodecenoic acids as the main cross metathesis product, while the P450 enzyme 
selectively hydroxylates the C12 cross metathesis product. Since the oxidation happens at carbons 
2, 3 and 4, the double bond remains unreacted and can undergo further cross metathesis. An ad-
ditional equilibrium could be established between the final product and the other metathesis 
components of the reaction. In reaction 2, the cross metathesis between 10-undecenoic acid and 
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trans-3-hexene would create a dynamic equilibrium mixture in which the cross metathesis prod-
uct 10-tridecenoic acids would be selectively epoxidized by the wild type P450 BM3 enzyme. In 
both reactions, the self-metathesis of the starting acid will occur. A reduction of the self-
metathesis of the starting acid can be used as an indication of the reaction being driven forward 
towards replacing the cross metathesis C12 intermediate.  
 
2.2.3 Tandem metathesis-oxidation (5-hexenoic acid + 7-tetradecene) 
In our first example reaction, the cross-metathesis of 5-hexenoic acid and trans-7-tetradecene to 
afford 5-dodecenoic acids. This cross-metathesis reaction also yields the self-metathesis of the 
respective starting materials. Since one of the alkenes is symmetrical, its self-metathesis yields 
only cis- and trans- alkenes. We first attempted biphasic reaction systems. In this strategy, we 
hypothesize that the catalysts need to be stable only to the conditions under which its partner re-
acts. For the oxidation reaction, the WT P450 BM3 purified enzyme and an NADP
+
 alcohol de-
hydrogenase regeneration system were used. Catalase was added at 600 U/mL to disperse any 
formed hydrogen peroxide produced from the decoupling of NADPH from the oxidation of the 
fatty acid. The results for this reaction are presented in Table 2.3. 
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Table 2.3 Tandem metathesis-oxidation involving 5-hexenoic acid and trans-7-tetradecene 
 
 
Two biphasic configurations were chosen for the tandem reaction. First, we attempted an isooc-
tane: buffer biphasic reaction system. Isooctane has been shown to be compatible with metathe-
sis catalysts [8, 29] and has been used as a biocompatible solvent in biphasic biocatalysis involv-
ing P450 enzymes [34]. In this system, the metathesis catalyst is predissolved in dichloro-
methane, since commercially available catalysts have very low solubility in this solvent. We find 
that the cross metathesis of 5-hexenoic acid with 1 eq. of 7-tetradecene using 3-10 mol% of C3 
yields 33% of the 5-dodecenoic acids (2) at equilibrium in a 1:2 v/v of isooctane: buffer with an 
E/Z of 6:1. A 25% yield of the self-metathesis of 5-hexenoic acid (3) was also isolated (Table 
2.3, entry 1). A concurrent reaction with cell lysate of P450 BM3 gives an overall yield of 25% 
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for the hydroxylated products (4) (sum of ω-1, ω-2 and ω-4 products) after 48h, while 3% of 2 
remained, along with 12% yield of 3 (entry 2). We also attempted a neat: buffer reaction (entry 
3-6). In this case, 5 eq. of trans-7-tetradecene was used, and this alkene served as the organic 
phase as well, while the metathesis catalyst C3 was added as an insoluble powder on top. After 5 
hours, we found that the equilibrium metathesis produced 60% of 2 and 5% of 3 (entry 3). Un-
fortunately, although the CM yields were significantly higher, yields of 4 remained around 25% 
(entry 4) in the tandem reaction. We noticed that the yields of 4 increased to 25%, which is the 
equilibrium achieved when 1 eq. of tetradecene was used.  This suggested that either secondary 
metathesis between the final hydroxylated products 4 and 2 continued to occur, or that the me-
tathesis reaction itself was being driven towards making the self-metathesis product in the pres-
ence of enzyme components. When the enzymatic reaction was performed with the equilibrium 
concentration achieved in the metathesis reaction alone (entry 5), a yield of 20% of 4 was ob-
tained.  
 
In conclusion, for this reaction, we found that doing the two reactions in tandem did not signifi-
cantly increase the yields of the final oxidation product compared to doing the two reactions se-
quentially, but only by a small margin. We further found that the self-metathesis of 7-tetradecene 
was accompanied by isomerization. Many ruthenium olefin metathesis complexes are known to 
isomerize long chain alkenes, and self-metathesis of 7-tetradecene has been shown to produce a 
semi-symmetrical distribution of olefins C9-C21 [35], which could represent up to 70% of the 
starting tetradecene. In our system, after metathesis, we observed many new olefin peaks on GC-
MS (Figure 2.5).  
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Figure 2.5 GC-MS trace of the tandem reaction of 5-hexenoic acid with trans-7-tetradecene. The GC-MS signal 
was turned off between 8 and 9.5 min to hide trans-7-tetradecene.  
 
Since we did not observe any additional cross metathesis product starting from the final product 
(polyols from C12-5-OH (4)), we assumed that the olefin metathesis catalyst C3 was not stable 
enough in the reaction. When we started the cross metathesis reaction with 4 and 7-tetradecene, 
we observed many diols, which corroborated our point of C3 being unstable. More importantly, 
because the double bond does not react, the driving force relies only on the solubility of the hy-
droxylated product compared to the starting materials and to the self-metathesis diacid. In effect, 
due to the higher solubility of the 3, a driving force cannot be implemented. At least when using 
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olefinic fatty acids, we realized that reacting out the double bond is the only way to drive the re-
action forward.  
 
2.2.4 Tandem metathesis-oxidation (10-undecenoic acid + trans-3-hexene) 
For this reaction, several components were optimized. First, we re-tested the catalysts stability in 
an isooctane: buffer biphasic reaction in the presence of enzymatic components (P450, NADPH). 
Second, we chose phosphite dehydrogenase as the NADPH regenerating enzyme, taking sodium 
phosphite to sodium phosphate, with concomitant oxidation of NADP
+
 to NADPH. Having this 
enzyme avoided the need to purchase the expensive NADP
+
-dependent T. brockii alcohol dehy-
drogenase. This enzyme has been previously engineered in our laboratory [36-38].  
 
We investigated the reactivity of the five ruthenium carbene catalysts for the cross metathesis 
between 10-undecenoic acid and trans-3-hexene in this biphasic setting in the presence of P450 
and NADP
+
. This reaction produces a dynamic equilibrium of the desired cross metathesis prod-
ucts cis and trans-10-undecenoic acids, as well as the self-metathesis product of 10-undecenoic 
acid. Complexes C4 and C5 did not catalyze the metathesis reaction under these conditions. The 
Hoveyda-Grubbs
II
 C3 did convert 50% of the starting material after addition of the unsaturated 
fatty acid in two batches. In contrast, catalysts C1 and C2 continued to convert the unsaturated 
fatty acid even after addition of a third batch of acid (Figure 2.6).  The subsequent experiments 
were conducted with catalyst C1. 
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Figure 2.6 Catalyst stability test in isooctane: buffer (buffer contained 5 µM P450 BM3 lysate, 0.2 mM NADP
+
) 
 
2.2.4.1 Time course of 10-undecenoic acid and trans-3-hexene tandem reaction 
Using catalyst 1, time course experiments were designed (Figure 2.7A). Since type I olefins such 
as terminal olefinic acids and esters have a high rate of homodimerization [39], the suppression 
of the self-metathesis of 10-undecenoic acid can be monitored as an indication that the enzyme 
reaction is exerting a driving force on the metathesis reaction. At a low equivalence of the alkene 
partner (1.5 eq.), the self-metathesis of 1 was formed preferentially. When no P450 BM3 was 
present, a 95% conversion of the starting material was obtained, with only 18% yield of the cross 
metathesis product. A fed-batch tandem reaction time course showed a continuous production of 
10,11-epoxytridecanoic acids over the 39h-reaction. The P450 BM3 WT reacted with the cross 
66 
 
metathesis intermediate with 100% selectivity,  while the intermediate was continuously replaced 
by the olefin cross metathesis, proving that indeed the epoxidation of the double bond of the 
cross metathesis product drove the cross metathesis reaction forward (Figure 2.8). 
1
H NMR and 
13
C NMR and TMCES derivatization of the final products confirmed that both the cis- and trans-
10-tridecenoic acids were epoxidized with >95% selectivity compared to respective hydroxyla-
tions at ω-1 or ω-4 (Figure 2.9). Concurrently, the concentration of self-metathesis was dimin-
ished by up to 50% over course of the reaction compared to the metathesis reaction alone (Figure 
2.7B). Lastly, at every time point sampled, the concentration of starting material in the tandem 
reaction was always lower than in the metathesis alone (20 to 40%) as further evidence that more 
starting material was being funneled towards forming the cross metathesis products as a result of 
enzyme epoxidation (Figure 2.7C). A final yield of 27% of 10,11-epoxytridecanoic acids was 
obtained, which corresponds to a 1.5-fold improvement over doing both reactions sequentially, 
assuming that a 100% recovery can be achieved from the metathesis reaction, and a 100% yield 
can be obtained from the biotransformation.  
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Figure 2.7 Fed-batch tandem cross-metathesis-epoxidation. A) Reaction scheme. B) Suppression of self-metathesis 
of 10-undecenoic acid by P450 BM3 in tandem with metathesis catalyst. C) Ratio of 10-undecenoic acid starting 
material present in the tandem compared to the metathesis alone. 
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Figure 2.8 Time course of fed-batch olefin metathesis-epoxidation 
 
 
 
 
 
 
 
 
 
69 
 
 
 
Figure 2.9 TMCES derivatization of 10,11-epoxytridecanoic acids. Peaks at 10.28 and 10.32 min represent the cis isomers, while the ones at 10.6 
and 10.68 min are the trans isomers.  
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2.2.4.2 One-pot tandem reactions with 10-undecenoic acid and trans-3-hexene 
One-pot batch reactions were set up and optimized by adjusting the NADPH regeneration rate, 
substrate loading and cross partner equivalence. Table 2.4 shows the yields of 4 from a series of 
reactions conducted with the two catalysts together and varied ratios of trans-3-hexene and 10-
undecenoic acid. These data allow comparison of the yields of 4 from the tandem process to the 
highest possible yields that could be obtained if the two reactions were run sequentially. De-
creasing the concentration of 1 resulted in an increase in the yield of 4 from 35% (50 mM, entry 
2a) to 70% (12.5 mM, entry 4a). As shown in entry 4b, only a 26% theoretical yield of 4 could 
be obtained if the two reactions were run sequentially.  
 
The concentration of cross metathesis product remaining in entries 1a-2a was significantly lower 
than that of diacid 3; compound 3 progressively precipitated as the reaction proceeded, thus be-
coming less available to regenerate the cross-metathesis product. Only 10-15% of 3 was dis-
solved in the two layers after 39 h, as determined by centrifugation of aliquots of the two layers, 
extraction with ethyl acetate, and GC analysis. As a result, further addition of catalyst C1 did not 
significantly increase the yield of 4 from the reactions in entries 1a-2a.  
 
By increasing the ratio of trans-3-hexene to 1 from 3:1 to 10:1, the accumulation of the self-
metathesis product was suppressed. Under these conditions, yields up to 90% of epoxide 4 were 
obtained within 12 h (entries 5a, 6a and 7a, Figure S8). An assessment of the stability of the 
P450 enzyme under the tandem reaction conditions suggested that it is inactive by the end of this 
particular reaction. With a fixed regeneration rate of 4 nmol/min, decreasing the substrate load-
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ing from 50 mM to 12.5 mM increased the yield of 4 from 35 to 70% (Table 3.4, entries 1a, 2a 
and 3a), which represents a respective 1.8, 2.0 and 3.1 fold improvement over doing the reac-
tions sequentially (entries 1b, 2b and 3b). Being pseudo-first order with respect to substrate con-
centration, the lower starting acid concentration slowed down the metathesis reaction, allowing 
the enzyme more time to react a larger proportion of formed cross metathesis product. It is worth 
noticing that the cross metathesis product remaining in entries 1a, 2a and 3a was significantly 
lower than their equilibrium metathesis counterparts, while a large concentration of self-
metathesis remained. While the metathesis catalyst remained active through that period, the self-
metathesis product progressively precipitated out of solution, thus becoming less available for 
further metathesis to replenish the cross metathesis pool. In the case of entries 1a and 2a, addi-
tion of catalyst 1 did not significantly improve the yields. Using 3 to 10 eq. of trans-3-hexene, 
the self-metathesis thermodynamic sink was almost completely avoided, as yields of up to 90% 
were obtained within 12h of reaction (entries 4a, 5a and 6a and Figure 2.10).  Enzyme stability 
studies suggested that the enzyme was deactivated at the end of the reaction. However, we ob-
served that in the presence of the pre-catalyst in PTS: buffer, the enzyme remained active. The 
enzyme deactivation may be caused by a toxic intermediate resulting from the olefin metathesis 
catalyst decomposition. 
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Figure 2.10 Representative GC-MS traces of tandem reactions in comparison with the metathesis alone and with 
starting substrate control. Retention times: 10-undecenoic acid 1 (7.1 min), 10-tridecenoic acids 2 (8.4 min), C13-
epoxides 4 trans (9.35 min), cis (9.45 min), eicosane internal standard (10.35 min) dimers of 10-undecenoic acids 3 
(12.85 and 13.01 min). 
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Table 2.4 Results of tandem metathesis-oxidation of 10-undecenoic acid and trans-3-hexene 
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2.2.5 Tandem metathesis-epoxidation (4-butenyloxybenzoic acid + trans-3-
hexene) 
To assess whether the cooperative effect of the two catalysts extends beyond 10-undecenoic acid 
and trans-3-hexene, we sought to identify a second combination of alkenes that would react in a 
similar fashion (Table 2.5). Studies on the reactions of unsaturated alkylbenzoic acid derivatives 
showed that the P450 BM3 enzyme epoxidized 4-hexenyloxybenzoic acid (6), an unnatural sub-
strate, with a rate (judged by the consumption of NADPH) of 65 nmol NADPH/nmol P450 BM3
-
1
/min
-1
. This rate is 2.5-fold higher than that for reaction of 4-butenyloxybenzoic acid (5). Com-
pound 6 formed in 58% yield from the cross-metathesis of 5 with 1.4 equivalents of trans-3-
hexene in a dioctyl phthalate: buffer biphasic system, with little formation of the product from 
self-metathesis of 5 (Table 2.5, entry 2). Moreover, P450 BM3 catalyzed the reaction of com-
pound 6 to form epoxide 8 as a single product, as shown by NMR spectroscopy. Although the 
specific NADPH depletion rates of the enzyme for the epoxidation of 6 over 5 is only 2.5 and the 
rate of metathesis of 5 is slow, a final yield of 8 of 75% was obtained. A yield of 7 of 20% is also 
obtained. This yield is higher than the 58% yield for two reactions occurring sequentially in per-
fect yield (entry 1 and Figure 2.11). This example shows that the process can be conducted with 
several alkenes, including those that are unnatural classes of substrates for epoxidation by P450 
BM3.  
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Table 2.5 Tandem olefin cross metathesis-epoxidation of 4-butenyloxybenzoic acid with trans-3-hexene 
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Figure 2.11. Representative HPLC traces of the tandem reaction involving 4-butenyloxybenzoic acid and trans-3-
hexene (red), substrate control (black) and metathesis alone (blue). Compounds were detected at 254 nm. 
 
2.3 Conclusions and outlook 
In summary, we have shown for the first time that an organometallic catalyst and a metalloen-
zyme can work in tandem for a highly selective and high yielding tandem cross-metathesis- 
epoxidation. The first reaction takes advantage of the remarkable selectivity of the P450 BM3 
wild-type enzyme for >C12 fatty acid carbon chain lengths, while the second reaction takes ad-
vantage of the enzyme’s slightly higher selectivity for the cross metathesis product 4-
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hexenyloxybenzoic acid. The two reactions work very efficiently, although it is known that ex-
posed carboxylic acids are known to deactivate ruthenium metathesis catalysts [40]. In addition, 
the final product obtained represents an unnatural epoxy-fatty acid that could not be obtained 
through one catalytic reaction. So far, we notice that reaction of the double bond of the target 
substrate created by cross metathesis is vital to exert a driving force towards the final epoxida-
tion product. Considering the shear immensity of substrate scope and versatility of both the ole-
fin metathesis catalysts and P450 BM3, a platform of metathesis-oxidation tandem reactions 
could be, theoretically, a plug and play exercise, as long as the right selectivities and activities 
are satisfied. Moreover, since the P450 BM3 enzyme mutants obtained through directed evolu-
tion often show strict carbon chain length-dependent reactivity, these selective tandem metathe-
sis-oxidations can be designed which could not be achievable using chemical catalysts alone. 
Tandem reactions of particular interest to us include the selective epoxidation of regio- and ste-
reoisomers of simple linear olefins, or the oxidation of longer chain olefins generated from the 
metathesis of shorter olefins, two examples with potential resounding impact in the selective C-H 
bond functionalization for fine chemicals. 
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2.4 Experimental procedures  
2.4.1 Materials 
All chemicals, solvents and catalysts were purchased from Sigma-Aldrich (St. Louis, MO) unless 
otherwise noted and used without further purification.  The Zannan catalyst was purchased from 
Strem Chemicals (Newburyport, MA).  E. coli DH5α cells were purchased from the Cell Media 
Facility at the University of Illinois at Urbana-Champaign (Urbana, IL).  Oligonucleotides for 
cloning were purchased from Integrated DNA Technologies (Coralville, IO.).  Restriction en-
zymes were purchased from New England Biolabs (Ipswich, MA).  NADPH was purchased from 
Enzo Life Sciences (Farmingdale, NY).  NADP
+
 was purchased from Roche Diagnostics (Indi-
anapolis, IN).  5-Aminolevulinic acid hydrochloride was purchased from Sigma-Aldrich (St. 
Louis, MO).  Isopropyl-β-D-thiogalactoside (IPTG) was purchased from GoldBio (St. Louis, 
MO).   
 
2.4.2 Cloning, expression and purification of P450 BM3 
The full gene encoding the wild-type P450 BM3 was amplified from the genomic DNA of Bacil-
lus megaterium using primers BamHI-for 
(ATACCGGGATCCATGACAATTAAAGAAATGCCTCAGCCAAAAACG) and EcoRI-rev 
(ACGTGCGAATTCTTACCCAGCCCACACGTCTTTTGCGTATC).  Restriction sites are un-
derlined.  The gene was cloned into the vector pCWori
+
 digested with the same enzymes and 
transformed into E. coli DH5α.  Expression and purification of P450 BM3 was done as follows.  
Briefly, 500 mL Terrific Broth (TB) medium supplemented with 100 mg/mL ampicillin, was in-
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oculated with an overnight culture (5 mL) in a 2.8 L flask and incubated at 30
o
C and 250 rpm 
shaking.  After 12 h of incubation, 5-aminolevulinic acid hydrochloride (ALA; 0.5 mM) was 
added, expression was induced by addition of 1 mM IPTG; and the shaking speed was reduced to 
180 rpm.  Cells were harvested by centrifugation for 24 h after induction.  The cell pellets were 
resuspended in 20 mL 100 mM potassium phosphate buffer, pH 8.1 and lysed by sonication.  
The enzyme was purified by FPLC using a DEAE-anion exchange column following published 
procedures [41, 42].  Enzyme concentration was measured in triplicates by the CO binding 
method [43]. 
 
2.4.3 Expression and purification of phosphite dehydrogenase (PTDH) 
A thermostable phosphite dehydrogenase, previously engineered in Zhao laboratory, was puri-
fied according a previous protocol [38].  The buffers used for protein purification included start 
buffer A (SBA) (0.5 M NaCl, 20% glycerol, and 20 mM Tris-HCl, pH 7.6), start buffer B (SBB) 
(same as start buffer A but with 10 mM imidazole), and elution buffer (EB) (0.5 M imidazole, 
0.5 M NaCl, 20% glycerol, and 20 mM Tris-HCl, pH 7.6).  Transformants with pET15b-derived 
vectors were grown in Terrific Broth medium containing 100 μg/mL ampicillin at 37 °C with 
good aeration (shaking at 250 rpm).  When the log phase was reached (OD600 ~0.6), cells were 
induced with IPTG (final concentration 0.3 mM) and incubated at 25 °C with shaking at 250 rpm 
for 8 h.  Cells were harvested by centrifugation at 5000g, 4 °C, for 15 min, then resuspended in 3 
mL/(g of cell pellet) start buffer A containing 0.6 mg/g of lysozyme, and stored at −80 °C.  The 
frozen cell suspension was thawed at room temperature and lysed by sonication.  Cells were cen-
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trifuged at 18000g at 4 °C for 30 min, and the supernatant containing the crude extract was fil-
tered through a 0.22 μm filter to remove any particles.  Purification was done by affinity chroma-
tography using FPLC.  The targeted protein eluted at 100 mM of imidazole was buffer ex-
changed against 50 mM Tris-HCl, pH 7.4 and concentrated using an Amicon-Ultra (10 kDa cut-
off).  The purified protein was stored in 15% glycerol, aliquoted and stored at -80 °C.  
 
2.4.4 General protocol for tandem reactions of 10-undecenoic acid 
All reactions were set up and performed in air without prior purification of the solvents in 10-mL 
headspace crimp cap vials (Agilent Technologies).  The aqueous phase (2 mL total volume), con-
tained: 9 µM P450 BM3, 0.4-2 U/mL PTDH, 600 U/mL catalase, 0.2 mM NADP
+
, and 100 mM 
sodium phosphite, 50 mM Tris-HCl, pH 7.4.  The metathesis catalyst was prepared as a 30 
mg/mL stock in dichloromethane.  The isooctane organic phase (500 µL total volume) contained 
12.5 mM-100 mM 10-undecenoic acid, the appropriate equivalence of trans-3-hexene, and 20 
mM eicosane as internal standard.  The olefin metathesis catalyst was added to 2.5 mol% to start 
the reaction.  Reactions were sealed to prevent the evaporation of trans-3-hexene and shaken at 
180 rpm on a plate shaker (Tallboys, Thorofare, NJ).  At the end of the reactions, the aqueous 
phase was acidified with 1N HCl, the metathesis catalyst was deactivated using 100-fold ethyl 
vinyl ether and extracted with 6 mL ethyl acetate.  The organic phase was dried over magnesium 
sulfate and dried under vacuum.  The residue was resuspended in 300 µL ethyl acetate.  Finally, 
100 µL of the mixture was derivatized with the addition of 50 µL methanol and 50 µL TMS-
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diazomethane and ran on GC-MS.  The GC-MS program was as follows: 80 °C for 2 min, 
20 °C/min to 310 °C, hold for 2 min.    
 
2.4.5 Derivatization of 9-(3-ethyloxiran-2-yl) nonanoic acid methyl ester with 
BSTFA + 1% TMCS 
The extracted tandem reaction previously derivatized with TMS-diazomethane was dried once 
more to evaporate hexane and methanol.  To the residue was added 100 µL of BSTFA (N,O-
bis(trimethylsilyl) trifluoroacetamide) containing 1% TMCS (trimethylchlorosilane), followed by 
incubation at 80 °C for 30 minutes.  
 
2.4.6 Preparation of (E)-tridec-10-enoic acid 
To a 10 mL glass vial: 184 mg (1.0 mmol) 10-undecenoic acid, 841 mg (10.0 mmol) trans-3-
hexene, 18 mg Hoveyda-Grubbs
II
 (3.0 mol %) were mixed in 4 mL dichloromethane.  The solu-
tion was stirred at room temperature for 2 h, then the mixture was applied to silica gel column 
chromatography for separation directly with an eluent 4:1 hexane: ethyl acetate. The yield was 
90%.
 1
H NMR:
 
5.41-5.30 (m, 2H), 2.36-2.20 (t, 2H), 2.05-1.89 (m, 4H), 1.63-1.50 (m, 2H), 1.40-
1.23 (m, 10H), 1.00-0.81 (t, 3H); 
13
C NMR: 205.9, 132.2, 129.7, 33.8, 32.8, 30.0, 29.9, 29.8, 
29.0, 28.8, 25.8, 25.2, 14.0.  
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2.4.7 Preparation of 9-(3-ethyloxiran-2-yl) nonanoic acid 
10 mL Tris-HCl buffer (50 mM, pH=7.5) containing 700 U/mL catalase, 3 µM P450 BM3 and 8 
mg (0.038 mmole) (E)-tridec-10-enoic acid was added into a 10 mL glass vial, then 31 mg 
(0.038 mmole) NADPH was added into the mixture to initiate the reaction.  After shaking at 200 
rpm at room temperature for 12 h, the reaction was quenched by addition of 5 mL of 0.2N HCl 
aqueous solution.  The mixture was extracted with ethyl acetate three times, and the combined 
organic phase was dried under anhydrous Na2SO4. The solvent was evaporated from the resulting 
solution under vacuum.  The crude oil was purified by silica gel column chromatography, eluting 
with hexane: ethyl acetate 4:1.  The yield was 23%. 
1
H NMR: 3.97-3.74 (m, 1H), 3.65-3.48 (m, 
1H), 2.34-2.22 (t, 2H), 2.11-1.85 (m, 2H), 1.78-1.51 (m, 4H), 1.50-1.20 (m, 10H), 1.08-0.87 (m, 
3H); 
13
C NMR: 205.9, 68.4, 58.5, 33.8, 32.0, 30.1, 29.8, 29.5, 29.3, 29.1, 26.9, 25.3, 11.1.  
 
2.4.8 General protocol for tandem reactions of 4-butenyloxybenzoic acid (5) 
All reactions were set up and performed in air without prior purification of the solvents in 10-mL 
headspace crimp cap vials (Agilent Technologies).  The aqueous phase (2 mL total volume), con-
tained: 9 µM P450 BM3, 2 U/mL PTDH, 600 U/mL catalase, 0.2 mM NADP
+
, and 100 mM so-
dium phosphite, 50 mM Tris-HCl, pH 7.4.  The metathesis catalyst was prepared as a 30 mg/mL 
stock in dichloromethane.  4-butenyloxybenzoic acid was dissolved in dioctyl phthalate with 
mild heating to 30 mM. In a separate vial, a 42 mM stock of trans-3-hexene was prepared in di-
octyl phthalate. Equal volume of each stock solution was mixed to obtain 15 mM of 5 and 1.4 eq. 
of trans-3-hexene to a final volume of 500 µL. The olefin metathesis catalyst was added to 5 
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mol% to start the reaction.  Reactions were sealed to prevent the evaporation of trans-3-hexene 
and shaken at 180 rpm on a plate shaker (Tallboys, Thorofare, NJ).  At the end of the reactions, 
the aqueous phase was acidified with 1N HCl, the metathesis catalyst was deactivated using 100-
fold ethyl vinyl ether and extracted with 6 mL ethyl acetate.  The organic phase was dried over 
magnesium sulfate and dried under vacuum.  The residue was resuspended in 300 µL ethyl ace-
tate.  Finally, 100 µL of the mixture was derivatized with the addition of 50 µL methanol and 50 
µL TMS-diazomethane. Prior to running on HPLC, the mixture was dissolved 10 fold in acetoni-
trile. A Zorbax C-18 column was used to run the samples. The HPLC program was as follows: 
40% acetonitrile (3 min), 40-100% acetonitrile (15 min), 100% acetonitrile (5 min), 40% ace-
tonitrile (4 min).   
 
2.4.9 Preparation of 4-hexenyloxybenzoic acid methyl ester 
To a 10 mL glass vial: 100 mg (0.5 mmol) 4-(pent-4-enyloxyl) benzoic acid, 125 mg (1.5 mmol) 
trans-3-hexene, 6.6 mg Hoveyda-Grubbs
II
 (2.0 mol %) were mixed in 3 mL dichloromethane.  
The solution was stirred at room temperature for 4 h, then 1 mL of the mixture (the extra 2ml 
was used directly for the next step) was quenched by adding 100 µL MeOH and 600 µL (Trime-
thylsilyl) diazomethane (2N in hexane), After standing at room temperature for an hour, the mix-
ture was evaporated and applied to silica gel column chromatography for separation directly with 
an eluent 6:1 hexane: ethyl acetate. The yield was 72%.
 1
H NMR:
 
7.96 (d, 2H,), 6.89 (d, 2H), 
5.63-5.56 (m, 1H), 5.48-5.41 (m, H),4.00 (t, 2H), 3.86 (s, 3H), 2.49-2.44 (m,2H), 2.03-1.99 (m, 
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2H), 0.98 (t, 3H); 
13
C NMR:167.18, 162.97,135.41, 131.71, 124.24, 122.59,114.31, 68.18,52.02, 
32.56, 25.87, 13.96. 
 
2.4.10 Preparation of 4-(3-(3-methyloxiran-2-yl) propoxyl) benzoic acid methyl 
ester (8) 
2 mL of the reaction mixture prepared above was evaporated and re-suspended into 200 µL iso-
propanol for the enzyme reaction. To a 20 mL glass vial, 10 mL Tris-HCl buffer (50 mM, 
pH=7.5) containing 700 U/mL catalase, 3 µM P450 BM3 and 16 mg (0.075 mmole) 4-
hexenyloxybenzoic acid was added, then 62  mg (0.076 mmole) NADPH was added into the 
mixture to initiate the reaction.  After shaking at 200 rpm at room temperature for 12 h, the reac-
tion was quenched by addition of 5 mL of 0.2N HCl aqueous solution.  The mixture was extract-
ed with ethyl acetate three times, and the combined organic phase was dried under anhydrous 
Na2SO4. The solvent was evaporated from the resulting solution under vacuum.  The crude oil 
was methylated by six equivalent of (trimethylsilyl) diazomethane in the presence of MeOH for 
an hour at room temperature, then the mixture was evaporated and purified by silica gel column 
chromatography, eluting with hexane: ethyl acetate 4:1.  The yield was 16%. 
1
H NMR: 7.99 (d, 
2H), 7.25(d, 2H), 4.15-4.12 (m, 2H), 3.87 (s, 1H), 2.91-2.88 (m, 1H), 2.76-2.74 (m, 1H), 2.16-
2.08(m,1H),1.96-1.91 (m, 1H), 1.60-1.54(m, 2H), 1.00-0.84 (m, 3H); 
13
C NMR: 166.7, 162.4, 
131.5, 122.6, 114.0, 64.8, 60.0, 55.4, 51.8, 31.9, 25.0, 9.8 
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CHAPTER 3. EXPANDING THE SUBSTRATE SCOPE OF THE TANDEM 
METATHESIS-OXIDATION BY SUBSTRATE, ENZYME AND 
REACTION ENGINEERING 
 
3.1 Introduction 
In this work, our goal was to further expand the substrate scope of the tandem metathesis-
oxidation reaction introduced in Chapter 2. The tandem reactions presented in Chapter 2 encom-
passed two substrates, both containing a carboxylic acid moiety. Although the carboxylic acid 
group increased their aqueous solubility, they presented several limitations. First, exposed car-
boxylic acid groups are known to deactivate metathesis catalysts, although metathesis catalysts 
with O-isopropoxy groups are more tolerant to acids and alcohols than ones containing a PCy3 
group [1]. Second, upon dimerization of the unsaturated carboxylic acid substrate, the diacid 
formed is no longer soluble in either a non-polar organic solvent or in an aqueous buffer; thus, in 
a biphasic reaction system, the diacid product crashes out of the reaction and is effectively re-
moved from contention in further metathesis reactions. Third, although carboxylic acids can be 
used as precursors for the synthesis of amino acids, the epoxides of carboxylic acids are not as 
important, especially the enantioselectivity of the formed epoxides is not very high, as exempli-
fied in Chapter 2.   
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We wanted to combine a substrate and enzyme engineering approach to expand the substrate 
scope of the tandem metathesis-oxidation. First, we hypothesized that one could engineer P450s 
that would epoxidize an acid chain with the double bond at a different position along the aliphat-
ic acid chain, epoxidize shorter acids (Figure 3.1 entry 1), esters (entry 2) and aromatic substrates 
(entry 3) with high regioselectivity, stereoselectivity and substrate specificity.  Second, we 
sought to use different oxidation enzymes, such as styrene monooxygenase (entry 3) or a cis-
selective enzyme such as CPO (entry 4) to engineer a cis- selective tandem metathesis-
epoxidation. In this Chapter, we detail our efforts at engineering reactions in entries 1 and 3. 
 
 
Figure 3.1 Examples of reaction that expand the substrate scope of the tandem metathesis-oxidation 
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3.2 Results and discussion  
3.2.1 Change of regioselectivity of P450 BM3 by rational engineering 
One important requirement for a selective tandem metathesis-oxidation is to have a highly regi-
oselective and active enzyme. As highlighted in Figure 3.1, one would need to engineer a P450 
enzyme that could specifically oxidize the double bond, while not hydroxylating the other ali-
phatic carbons. The wild-type P450 shows selectivity for oxidation mainly at the ω-1, ω-2 and ω 
-3 positions of C12-C22 fatty acid chains. In order to switch the selectivity to other positions (ω-
5, ω-6 and ω-7), we targeted two of the main residues known to influence regioselectivity in 
P450-BM3 oxidation, mainly residues 78 and 87 [2-6]. As observed by others, changes in resi-
dues that affect regioselectivity and stereoselectivity in P450 BM3 are often accompanied with a 
decrease in substrate binding affinity and NADPH coupling, i.e. specific activity [4]. The two 
residues we picked to mutate, 78 and 87, retained low activity compared to the wild-type enzyme 
(15-20% of wild-type product formation rate), but their regioselectivity towards α- and ɣ- car-
bons of lauric acid was the most pronounced (Table 3.1).  
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Table 3.1 Regioselectivity of the hydroxylation of lauric acid by P450 BM-3 wild-type and mutants (adapted from 
[4]). 
Mutant ω-9 ω-8 ω-7 ω-6 ω-5 ω-4 ω-3 ω-2 ω -1 Product formation rate1 
WT      <1 38 28 36 500 
F87A     21 19 46 9 5 102 
V78A-F87A 3 - 1 4 42 14 24 7 5 63 
            1
NADPH depletion rate x NADPH coupling efficiency 
 
We created variants F87G, F87A, F87V and V78A-F87A of the full-length P450 BM3 and tested 
their regioselectivity on tridecanoic acid and lauric acid oxidation. The variants F87G and F87V 
typically showed a very scrambled pattern of regioselectivity, while variants F87A and the dou-
ble mutant V78A-F87A showed a more controlled regioselectivity.  
 
The results of the regioselectivity of these two P450 variants on lauric acid and tridecanoic acid 
are shown in Table 3.2. With both mutants, the regioselectivity of oxidation is spread over ω-2 to 
ω-7; however, variant V78A-F87A shows a higher regioselectivity for oxidation at the ω-7 car-
bon (52%). With this variant, we hypothesized that a double bond located across the ω-6 and ω-7 
carbons could undergo selective epoxidation.  Variant F87A shows a high regioselectivity for 
oxidation at the ω-5 carbon (57%).  With this variant, we hypothesized that a double bond locat-
ed across the ω-5 and ω-6 carbons could undergo selective epoxidation. Unfortunately, as we 
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expected, the NADPH depletion rate towards tridecanoic acid were as low as 5-fold compared to 
the wild-type on the same substrate.   
 
Table 3.2 Regioselectivity of P450 BM3 variants on tridecanoic acid hydroxylation 
Mutant ω-8 ω-7 ω-6 ω-5 ω-4 ω-3 ω-2 ω -1 NADPH depletion1 NADPH coupling (%)2 
V78A-F87A - 52 12 24 3 6 4 - 254 20 
F87A - 8 15 57 9 4 4 <1 200 ~15 
1
nmol NADPH.min
-1
.nmol P450
-1
. 
2
nmol substrate converted as judged by GC-MS/nmol NADPH fed. Duplicate 
experiments. 
 
Based on these two results, we envisioned to expand the substrate scope of the tandem reaction 
to two additional examples (Figure 3.2). In the first example, the cross-metathesis between 6-
heptenoic acid and trans-7-tetradecene would produce cis- and trans- tridecenoic acids with a 
double bond across the ω-7 and ω-8 carbons. P450 variant V78A-F87A in turn would selectively 
epoxidize the cross-metathesis product. In the second example, the cross-metathesis between 8-
nonenoic acid and trans-5-decene would produce cis- and trans- tridecenoic acids with a double 
bond across the ω-5 and ω-6 carbons. P450 variant F87A in turn would selectively epoxidize the 
cross-metathesis product. To test the selectivity of the V78A-F87A variant for epoxidation, we 
mixed the P450 variant with purified 3 and 1 equiv. of NADPH.  This reaction produced one ma-
jor product (>80% of total product) as observed by GC-MS analysis of the extracted reaction 
products derivatized with trimethylsylil diazomethane. All products formed were monooxidation 
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products (m/z of 243 corresponding to the addition of one molecule of oxygen to the starting ma-
terial). Further derivatization with N,O-Bis(trimethylsilyl)trifluoroacetamide (BSTFA), an agent 
which adds a trimethysilyl group specifically at hydroxyl groups, did not affect either the reten-
tion time or the mass of the main peak of m/z of 273, which suggested that this product was in-
deed an epoxide.  
 
Figure 3.2 Example tandem reactions based on the epoxidation of tridecenoic acids with the double bond at differ-
ent positions catalyzed by a metathesis reaction. For simplicity purposes, the dimers of 1, 5 and 9 are not shown. 
Possible hydroxylation side products are not shown either. 
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3.2.2 Tandem reaction results  
 
Figure 3.3 Metathesis catalysts used in this study 
 
Tandem reactions as shown in Figure 3.2 were set up in a two-phase isooctane: buffer system. 
Catalyst C1, introduced in Chapter 2, catalyzed the metathesis reaction. A phosphite dehydro-
genase (PTDH) regeneration system, also described previously, was used to regenerate NADPH.  
When 1 was combined with 2, C1 and the enzymatic reaction, a very low yield of 4 was ob-
served (<10% as judged by GC-MS), even though 3 was formed in decent yields (>30%). Com-
pound 2 has a high propensity for isomerization with C1 and this has been observed previously 
[7]. The addition of benzoquinone and other additives have been shown to eliminate undesirable 
isomerization [8], but was not attempted by us because of the high aqueous solubility of the addi-
tives. Similarly, low yields were obtained for 8 and 11 in their respective tandem reaction, alt-
hough the cross metathesis reactions themselves were not hampered. The low yields obtained for 
the enzymatic reaction were not caused by the presence of the metathesis reaction, rather by the 
low activity of the P450 variants (high Km for the acid substrates), coupled with mass transfer 
limitations. Yields for 4, 8 and 11 were similar when the enzymatic reaction was run starting 
with 3, 7 and 10.  In an attempt to overcome mass transfer limitations, addition of 1% docusate 
sodium salt (AOT) was attempted [9]; however, AOT was found to denature P450 BM3. Addi-
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tion of other surfactants such as methyl-β-cyclodextrin did not increase the yields significantly 
[10].  
 
3.2.3 Expansion of the substrate scope of the tandem reaction to aromatic com-
pounds 
We hoped to extend the substrate scope of the metathesis-oxidation reaction to encompass aro-
matic substrates. As a proof of concept, we hypothesized that a cross metathesis between cis-
stilbene (12) and a symmetrical alkene such as trans-3-hexene (13) would form trans-
butenylbenzene (14). A P450 variant could be found that selectively epoxidizes 14 to form 16 
(Figure 3.4). P450 variants with high activity against styrene derivatives have been reported pre-
viously [11].  Competition assays between 12, 13 and 14 revealed that one P450 variant, P450-
R47L-Y51F (P450-RLYF), was found to specifically oxidize 14 under limiting NADPH condi-
tions. This is because the NADPH depletion rates of P450-RLYF in the presence of 12, 13 and 
14 were 60, 15 and 200 nmol. nmol P450
-1
.min
-1
, respectively. We did not calculate the NADPH 
coupling on these substrates, but assumed that the higher the NADPH depletion rate, the higher 
the NADPH coupling.  
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Figure 3.4 Tandem metathesis-oxidation for the synthesis of aryl epoxides 
 
We tested the metathesis reaction between 12 and 13 in a biphasic isooctane: buffer system using 
C1.  Using 1 eq. of 13 led to a yield of 14 of 32.8%, while increasing the eq. of 13 to 2 and 3 in-
creased the yield of 14 to 52% and 60% respectively (Table 3.3). When the metathesis reaction 
was combined with the enzymatic oxidation reaction in one-pot, a yield of ~2% was obtained for 
16. Very low yields are also obtained when the oxidation of 14 was attempted in a similar bipha-
sic setting.  
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Table 3.3 Yield and selectivity for cross metathesis of 12 with 13 in isooctane: buffer catalyzed by C2 (Hoveyda-
Grubbs 2
nd
 generation) 
12 13 (eq.) Yield of 14 (%)
a
 Z/E
b
 Selectivity for 14 (%)
c
 
50 mM 1 32.8 ~30-40:1 23 
50 mM 2 52.6 ~30-40:1 43 
50 mM 3 60.1 ~30-40:1 50 
Reaction conditions: 1:2 v/v isooctane: buffer (100 mM phosphate buffer, pH 8.1) 2.5 mol%  
C1 (added at 3% v/v of aqueous phase from 30 mg/ml stock in dichloromethane).  
a
 Determined by GC. 
b
 Estimated by GC-MS. 
c
 Yield of 14/conversion of 12.  
 
3.2.4 Optimization of the enzyme reaction with the substrate on top of buffer 
In light of the low yields obtained in the isooctane: buffer biphasic setting mostly because of 
mass transfer limitations, we opted to engineer the reaction in order to obtain higher yields for 
the enzymatic oxidation. Many reactions have been reported in which no organic solvent is used, 
rather the substrate is layered on top of the buffer solution containing the enzyme(s) [12-16]. 
Typically, a co-solvent is added to the buffer solution (dimethyl sulfoxide, isopropanol). This 
strategy has been particularly effective for chloroperoxidase and esterases [17]. To test this strat-
egy for our system, we performed the epoxidation of cis-β-methylstyrene (18) layered on top of 
buffer using P450-RLYF. Concurrently, we compared two regeneration systems, one driven by 
phosphite dehydrogenase previously described and the other driven by an NAD(P)H-dependent 
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glucose dehydrogenase cloned from the Bacillus megaterium genome [18]. These reactions con-
tained 44 mM cis-β-methylstyrene on top of buffer, 10 µM P450-RLYF lysate, 3 U/mL glucose 
dehydrogenase (GDH) (PTDH), 100 mM glucose (sodium phosphite), 600 U/mL catalase, 0.2 
mM NADP
+
 and 2.5 % DMSO in 3 mL of 100 mM phosphate buffer, pH 8.1. With the glucose 
dehydrogenase cofactor regeneration system, a yield of cis-β-methyl-styrene oxide of ~70% 
could be reached within 12 h, compared with just ~50% with the PTDH regeneration system. In 
addition, the protein yield for GDH could reach over 200 mg/L, compared to 50 mg/L for PTDH. 
Therefore, we chose the GDH cofactor regeneration to continue our studies.   
 
The glucose dehydrogenase reaction produces gluconic acid from glucose dehydrogenation with 
concomitant reduction of NADP
+
; this process decreases the pH of the solution as more gluconic 
acid is produced. At the end of the reactions described above, the pH of the reaction dropped 
from 8.1 to 6.2, which precipitated various components from the reaction mixture. To counter 
this pH change, the volume of the reaction was steadily increased, while keeping the amount of 
enzyme and substrate constant (Table 3.4). To test the selectivity of the P450-RLYF in this con-
text, as well as to take into account the effect of cis-stilbene on the partitioning of cis-β-methyl-
styrene, 0.5 eq. of 12 was added to the reaction. Yields of the epoxide increased with respect to 
the increase in reaction volume. When 3 mL of buffer was used, the yield of epoxide reached 
69% (entry 3), while 77% yield of the epoxide and 97% conversion of cis-β-methylstyrene were 
obtained with 5 mL of buffer (entry 4). In entries 3 and 4, no precipitation was observed at the 
end of the reactions. Interestingly, production of 17 was never observed. Alternatively, the ionic 
strength of the buffer can be increased to 300 mM instead of 100 mM, and similar results could 
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be obtained. However, we feared the negative impact of phosphate salts on the metathesis cata-
lyst.  
 
Table 3.4 Optimization of the enzyme reaction:  reaction volume optimization  
 
Entry
a
 P450 Volume Conversion (%)
b
 Yield of epoxide (%)
b
 TTN
c
 
1 5 µM 1 mL 52 56 6160 
2 2.5 µM 2 mL 84 60 6600 
3 1.7 µM 3 mL 86 69 7590 
4 1 µM 5 mL 97 77 8470 
a
0.055 mmol cis-β-methylsytrene, 0.027 mmol cis-stilbene on top of 100 mM KPi buffer.  
b
Determined by GC using authentic standards.  
c 
mol product·mol P450-1.  
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The epoxidation of cis-β-methylstyrene was followed overtime (Figure 3.5). Within 4 h, a 45% 
yield of the epoxide could be obtained, corresponding to 1220 nmol product·nmol P450
-1
·min
-1
. 
In this reaction system, substrate availability was still limiting. Decreasing the concentration of 
enzyme from 2 µM or 1 µM to 0.5 µM gave the same yields of 19 after 1 h.  It is noteworthy to 
point out that surface area is very important to achieve the highest yields. These reactions were 
run in 20 mL vials with a diameter of 28 mm; simply switching to 10 mL vials with a diameter of 
14 mm decreases the epoxidation yields significantly 
 
Figure 3.5 Time course of the epoxidation of cis-β-methylstyrene by P450-RLYF. 3 mL reaction, 5 µM P450, 1 
U/mL GDH, 100 mM glucose, 0.2 mM NADP
+
, 2.5 % DMSO, 5 mg cis-stilbene, 8 mg cis-β-methyl styrene,  100 
mM KPi buffer, pH 8.1.  
 
To eliminate doubts that the metathesis reaction could have an impact on the enzymes (P450, 
GDH, catalase), we performed the oxidation of ethylbenzene on top of buffer in the presence of 
0
10
20
30
40
50
60
70
80
90
100
0 2 4 6 8 10 12 14
Time (h)
Y
ie
ld
 (
%
)
0
10
20
30
40
50
60
70
80
90
100
S
u
b
s
tr
a
te
 r
e
m
a
in
in
g
 (
%
)
yield
substrate remaining
101 
 
active C2. In these reactions, we added C2 and cis-stilbene, which made C2 active. However, the 
variant RLYF exhibits higher activity towards ethylbenzene oxidation versus cis-stilbene. In the 
presence or absence of active C2, the yields of phenyl-2-ethanol were unchanged.  
   
3.2.5 Optimization of the metathesis reaction 
Having found a reaction system which gave high yields for the epoxidation of cis-β-
methylstyrene, we sought to engineer a metathesis reaction on top of buffer. Metathesis reactions 
in air and protic solvents have begun to be reported [19-22]. More recently, a ring closing me-
tathesis reaction catalyzed by a Grubbs second generation catalyst was combined with an ester-
ase in a sequential manner for the preparation of cyclic malonic acid monoesters [17]. Inspired 
by these works, we attempted optimization of the cross metathesis between cis-stilbene (12) and 
trans-3-hexene (13) for ease of analysis, we did not use cis-2-butene to optimize the metathesis 
reaction, since the use of trans-3-hexene as a cross metathesis partner does not require a closed 
system (Figure 3.6).  
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Figure 3.6 Cross metathesis of cis-stilbene and trans-3-hexene 
 
To achieve an optimized system, we chose to balance several parameters, while keeping in mind 
the optimized parameters of the enzymatic oxidation. Since the metathesis occurs on top of buff-
er, the metathesis catalyst will either be dissolved in the substrates or remain as an insoluble 
powder on top of the buffer solution. We found that a viscous buffer solution (achieved by addi-
tion of either glycerol or lysate), caused severe aggregation of the metathesis catalyst becomes, 
which negatively impacted the metathesis yields. Therefore, we decided that the amount of lysate 
of P450-RLYF should be minimized (less than 15% of the total reaction volume).  Typically, a 
yield of 2.4 µmol/L of active P450-RLYF (calculated from CO binding assay) is obtained from 
overexpression of RLYF in TB medium. Re-suspending the cell pellet in ~28 mL of 100 mM 
KPi buffer pH 8.1 results in a lysate containing 40 µM of P450-RLYF.  Addition of lysate to a 
final concentration of 5 µM would result in 12.5% of lysate in the total reaction volume.  
 
We performed some rough calculations to get started. First, since the enzyme can reach only as 
high as 9,000 TTN on cis-β-methyl-styrene, in order to minimize the amount of cell lysate used 
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in the reaction (maximum of 5 µM in 5 mL from a 40 µM stock of lysate) while maximizing the 
epoxidation yield, the amount of cis-stilbene used to start the reaction should not exceed 100 
µmol (18 mg). If we assume a 50% conversion of this substrate to form butenylbenzene (as is 
roughly achieved using 3 eq. of trans-3-hexene), then the amount of enzyme used would be suf-
ficient to react more than twice the amount of product formed, although we do not expect the 
RLYF variant to achieve the same TTN on butenylbenzene as cis-β-methylstyrene. Under the 
assumption that the metathesis catalyst is stable and the remaining cis-stilbene can undergo fur-
ther metathesis, it would be possible to design a system in which the yield of the epoxide product 
could be higher in the concurrent tandem reaction than if the metathesis and oxidation reactions 
were run sequentially. Since trans-stilbene is a solid and crashes out of solution when formed in 
high concentrations, it would be preferable to have a metathesis catalyst which is not active for 
cis-stilbene dimerization. 
 
With this in mind, we tested three catalysts  for the cross metathesis of 12 and 13 on top of KPi 
buffer starting with 55 µmol of 12 and 3 eq. of 13. After 8 h, all three catalysts produced 14 to 
roughly the same yield (35-50%); however, C2 and C3 catalyzed the dimerization of the remain-
ing 12 nearly completely to form 14, while only 10-15% yield of 14 could be observed with C1. 
Therefore, we chose C1 for further analysis.  
 
First, we optimized both the cis-stilbene loading and trans-3-hexene equivalence. These results 
are shown in Table 3.5. The volume of buffer added was found to have no impact on the metath-
esis yields. However, the higher substrate loading of 12 resulted in a higher yield of 14. When 
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2.5 mg of 12 was used, the metathesis reaction yields were very low (<10% yield for 14). In all 
cases, the yield of 15 was kept low.  
 
Table 3.5 Effect of substrate loading and aqueous phase volume on metathesis   
 
Entry 12 
(mg) 
Volume of aq. 
phase (mL) 
Yield of 
14 (%) 
Conversion of 
12 (%) 
Yield of 
15 (%) 
1 5 1 37 50.8 7.8 
2 5 2 39 50.9 8.7 
3 5 3 35 47.7 10.0 
4 10 1 50 56.0 6.0 
5 10 2 46 62.0 5.0 
6 10 3 52 58.0 5.0 
 
Next we analyzed the impact of organic co-solvents on the metathesis reactions; in particular 
DMSO is known to coordinate the metal complex. However, we found that co-solvents had no 
effect on the metathesis reaction (Table 3.6). Lastly, in the presence of all the components of the 
enzymatic reactions (except for NADP
+
), the metathesis reaction was unaffected. On the contra-
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ry, the yield for the metathesis seemed to increase (Table 3.7).  Interestingly, in the presence of 
PTDH and sodium phosphite, a high yield of homodimerization of 12 was observed with C1; this 
phenomenon was not observed with GDH and glucose. 
 
Table 3.6 Effect of co-solvents on the metathesis reaction 
Entry
a
 Co-solvent 4h CM GC yield (%) 8h CM GC yield (%) 
 
1 None 27 33 
2 2.5% DMSO 22 33 
3 2.5% isopropanol 23 36 
4 2.5% EtOH 27 37 
a
0.055 mmol (10 mg cis-stilbene), 3 eq. trans-3-hexene, on top of 1 ml phosphate buffer, 
 ~3 mol% C1, RT. 
 
Table 3.7 Cross metathesis on top of buffer in the presence of enzymatic components 
Entry
a
 Enzyme 8h CM GC yield (%) 
1 GDH 41 
2 PTDH 46 
                  a
0.055 mmol (10 mg cis-stilbene), 3 eq. trans-3-hexene 
           on top of 1 ml phosphate buffer, ~3 mol% C1, RT. 
           Buffer contains 10 µM P450 RLYF lysate, 
           3 U/mL GDH/PTDH, 600 U/mL catalase, 
           150 mM glucose/sodium phosphite, 2.5 % DMSO. 
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3.2.6 Tandem reaction results for the production of trans-butenylbenzene oxide 
Having found optimized and compatible conditions for the metathesis and enzymatic reactions, 
the two reactions were combined in one-pot. The results are shown in Table 3.8. When 12 and 13 
were combined with C1 and the enzymatic reaction, 16 was formed in 21.5% yield, while 17 was 
produced in 6.7% yield. Unexpectedly, contrary to the optimization trials, 15 was formed in high 
yields as well (21%) (entry 1). The reason for the high dimerization of 12 to form 15 under tan-
dem reaction conditions as opposed to when the enzymatic reaction is not active is currently un-
known to us.  As one can see, in the absence of enzyme, the metathesis reaction alone produces 
35% of 14 and only 10% of 15 (entry 2). It is interesting that in the presence of the enzymatic 
reaction, the conversion of 12 is higher. While one could argue that the enzymatic oxidation is 
driving the metathesis reaction forward, the low yields of 14 obtained in these cases are incon-
clusive. Similarly, a yield of 18% is obtained for the oxidation of 14 under the conditions tested, 
which is indicative that the enzymatic reaction is limiting in this case (entry 3). In entries 1 and 
2, the metathesis catalyst was carefully added as an insoluble powder on top of the buffer. We 
wanted to see whether having the catalyst predissolved in acetone, subsequently added to the re-
action to form a truly one-phase reaction would be as efficient. In these reactions, 12 and 13 
were predissolved in acetone as 2 M stock solutions and added to the reaction buffer to 25 mM 
and 75 mM, respectively. Screening C1, C2 and C3 as predissolved solutions in acetone re-
vealed that C2 was the most reactive and stable under these conditions and yielded 42% for 14 
and 13% for 15 (entry 4). The truly one-phase tandem reaction, however, lost selectivity for 16, 
as close to 10% of 17 was also formed (entry 3).     
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Table 3.8 Tandem metathesis-oxidation results for the production of 16 
 
Entry
a
  Co-solvent Catalyst Reaction  Aq. Vol. Conv. 12 14 15 16 17 
1 DMSO C1 Tandem 3 mL 80 26 21 21.5 6.7 
2 DMSO C1 Metathesis 3 mL 47 35 10   
3
c
 DMSO - Enzyme reaction only 3 mL    18  
4
b
 Acetone C2 Tandem 1 mL 85 24 10 18 9.7 
5
b
 Acetone C2 Metathesis 1 mL 60 42 13   
a 
Yields and conversions are in %. Yields determined by GC using a calibration curve for each compound. Average 
of duplicate experiments. 16 h at room temperature. 
b 
Catalyst was predissolved in acetone. 
c
 Enzyme reaction start-
ed with 0.040 mmol 14. 
 
3.2.7 Tandem reaction results for the production of β-methylstyrene oxide 
From the example above, it was clear that the enzymatic reaction was limiting. To overcome this 
limitation, we investigated the butenolysis of cis-stilbene. This reaction produces 19 in high 
trans-selectivity (40:1). In addition, homodimerization of 12 only occurs in less than 10% yield. 
In a 10 mL crimp cap vial containing 3 mL of buffer, we determined the yield of 19 as a function 
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of cis-2-butene pressure (Table 3.9). The cross metathesis reaction occurs in very low yields at 2 
psig of cis-2-butene (entry 1), but this yield is gradually increased with increasing butene pres-
sure. Under 8 psig of butene pressure, a yield of 69% of 19 can be obtained.   
  
Table 3.9 Yield of 19 as a function of butene pressure 
 
Entry cis-2-butene pressure (psig) GC yield of 19 
1 2 3 
2 4 26 
3 8 69 
 
Subsequently, we combined the two reactions in one-pot. In the tandem reaction, trans-β-
methylstyrene oxide was produced in 53% yield (Table 3.10). This yield is lower than the 69% 
yield produced from the metathesis reaction alone. Unfortunately, in the tandem reaction, most 
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of the remaining starting material is converted to 15; as hypothesized, 15 can no longer partici-
pate in cross metathesis since it is a solid which crashes out of solution and most likely would 
require high temperatures to undergo further cross metathesis. Interestingly, the oxidation of 12 
was never observed, which suggests that this tandem reaction is 100% selective for the cross me-
tathesis product. We tried to increase the yields via some troubleshooting steps. We thought that 
the high pressure of cis-2-butene would affect the activity of RLYF, by depriving the enzyme 
with oxygen; however such was not the case. The yield of 19 was the same in the presence or 
absence of cis-2-butene. To our surprise, we found that the diameter of the vial (i.e. the surface 
area) had a significant impact on the epoxidation reaction yields. The yields were significantly 
higher (full conversion compared to 60% conversion in some cases) when a 28 mm diameter 
(20-mL vial) was used versus when a 22 mm (10-mL vial) was used. Unfortunately, in a 28 mm 
diameter 20-mL vial, the metathesis reaction was not reproducible due to the difficulty in sealing 
the vial. Further reaction engineering is needed to solve this technical problem.  
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Table 3.10 Tandem metathesis-epoxidation for the synthesis of β-methylstyrene oxide 
 
 
Entry  Catalyst Reaction  Aqueous vol. 19 20 
1 C1 Tandem 3 mL  53 
2 C1 Metathesis 3 mL 69  
 
3.3 Conclusions and future prospects 
In this work, we attempted to expand the substrate scope of the metathesis-oxidation reaction. To 
achieve this, first we showed that by rational engineering, P450 variants can be engineered to 
selectivity epoxidize the double bond of the fatty acid chain located at different positions along 
the chain. Namely, we showed that the F87A P450 variant had selectivity towards the ω-5 and ω-
6 carbons while the double mutant V78A-F87A P450 had selectivity for the ω-6 and ω-7 carbons 
of tridecanoic acid. Tridecenoic acids with a double bond across the ω-5 and ω-6 carbons, or the 
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ω-6 and ω-7 carbons were selectively epoxidized by variant F87A and V78A-F87A, respective-
ly. However, tandem metathesis-oxidation reactions in which this selectivity could be taken ad-
vantage of were low yielding for the final epoxidation product(s). We believe that mass transfer 
limitation, as well as the low activity (and stability) of these two variants could be the source of 
the low yields. It is possible to shift the regioselectivity of P450 BM3 through other residues 
such as 82, 263 and 328 [23, 24].   
 
We were able to extend the tandem reaction substrate scope via a combination of substrate, en-
zyme and reaction engineering. In the case of the butenolysis of cis-stilbene followed by oxida-
tion, this reaction exhibited 100% substrate selectivity and 100% selectivity for epoxidation. 
Yields of 53% and 18% for β-methylstyrene oxide and trans-butenylbenzene oxide were ob-
tained respectively in the tandem reaction. Unfortunately, we did not observe a “dynamic effect,” 
i.e. the yields obtained for the one-pot reactions were not higher than the ones that would be ob-
tained if the two reactions were run sequentially. In the case of trans-butenylbenzene oxide pro-
duction, the enzymatic reaction was limiting, therefore similar yields where obtained from the 
sequential reactions as compared with the one-pot concurrent. In the case of β-methylstyrene ox-
ide production, the yields obtained from the tandem one-pot reaction were slightly lower (53% 
for β-methylstyrene oxide in the tandem one-pot reaction versus 69% for β-methylstyrene in the 
metathesis reaction alone). However, for this case, further reaction engineering may be needed to 
optimize the yields further.  
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This tandem metathesis-oxidation is limited by the fact that it is difficult to engineer a reaction in 
which high enzyme selectivity can be achieved. Moreover, although the use of symmetrical start-
ing materials simplifies the system by decreasing the number of cross metathesis products that 
can be formed, this limits the reaction substrate scope. One can imagine that such confine may 
ultimately not be needed. Parameters such as the stability and recyclability of the metathesis cat-
alyst remain to be investigated in greater detail.  
 
Looking ahead, the use of styrene monooxygenases [25, 26] instead of P450s for the epoxidation 
of aryl alkenes in tandem with metathesis catalysts may be more advantageous. First, there is 
ample evidence of the use of whole cells expressing styAB in biphasic alkane: buffer mixtures. In 
addition, although we did not calculate the enantioselectivity of the P450-catalyzed epoxidations 
in this work, they are known to be at most moderate on styrene derivatives, except for one exam-
ple [27]. Enantioselectivities obtained with styrene monooxygenases are usually >99% ee. Re-
cently, we have been investigating completely new tandem reactions, for example involving a 
ring closing metathesis followed by epoxidation and epoxide hydrolysis to synthesize chiral pyr-
rolidines and piperidines (Figure 3.7). Along with the work presented in Chapter 5, these new 
directions will introduce more diversity to our tandem catalysis approach.  
 
Figure  3.7 Tandem ring closing metathesis-epoxidation-hydrolysis.  
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3.4 Materials and methods 
3.4.1 Materials 
All chemicals, reagents and catalysts were purchased from Sigma-Aldrich, unless noted other-
wise. E. coli DH5α cells were purchased from the Cell Media Facility at the University of Illi-
nois at Urbana-Champaign (Urbana, IL).  Escherichia coli BL21 (DE3) and plasmid pET28a
+
 
were purchased from Novagen (Madison, WI). Oligonucleotides for cloning were purchased 
from Integrated DNA Technologies (IDT DNA) (Coralville, IO).  Ten-mL headspace crimp cap 
vials, crimp caps and septa were purchased from Agilent Technologies (Santa Clara, CA). Re-
striction enzymes were purchased from New England Biolabs (Ipswich, MA).  NADPH was pur-
chased from Enzo Life Sciences (Farmingdale, NY).  NADP
+
 was purchased from Roche Diag-
nostics (Indianapolis, IN).  Isopropyl-β-D-thiogalactoside (IPTG) was purchased from GoldBio 
(St. Louis, MO).  The strain Bacillus megaterium (B14308) was obtained from the NRRL culture 
collection (Peoria, IL).  
 
3.4.2 Cloning, expression and purification of GDH from Bacillus megaterium  
Bacillus megaterium B14308 was inoculated in 5 mL TGY medium and grown at 30ºC for 18 h. 
Genomic DNA was isolated using the Wizard
®
 Genomic DNA purification kit from Promega 
according to the manufacturer’s protocol. The gene encoding the gdh was amplified from the ge-
nome of B. megaterium using primers gdh-NdeI-for and gdh-HindIII-rev. Restriction sites are 
underlined. The gene was ligated into pET28a
+
 and transformed in E. coli DH5α. 
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The plasmid pET28a-gdh was transformed into E. coli BL21. For expression of GDH, a BL21 
colony harboring pET28a-gdh was inoculated in 5 mL LB containing 50 µg/mL kanamycin and 
grown overnight at 37ºC. This overnight culture was used to inoculate 500 mL of TB medium 
containing 50 µg/ml kanamycin, which was grown at 37ºC until an OD of ~0.7 was reached, and 
subsequently induced with the addition of 0.3 mM IPTG. The induced culture was placed at 25ºC 
for 16 h for protein production.  
 
Following expression, BL21 cells were recovered by centrifugation (6000 x g for 15 min), lysed 
by sonication and clarified by centrifugation (18 000 x g for 30 min). The protein was subse-
quently purified by affinity chromatography using a HisTrap column fitted to an AKTA FPLC 
system (GE Lifesciences, Pittsburgh, PA). The purified protein was buffer exchanged against 
100 mM PKi buffer, pH 8.1 using an Amicon Ultra concentration tube (10 kDa cut-off) before 
being stored in 15% glycerol and stored in 100 µL aliquots at -80ºC 
 
3.4.3 Construction of a full length P450 BM3 gene with a silent mutation intro-
ducing a SacI cut site in the heme domain 
The primer heme-SacI-rev (CGTTAAAGTTTCTTTAATATCGAGCTCGTAGTTTGT 
ATGATCTT: restriction site underlined) was used to introduce a silent mutation which created a 
SacI restriction site in the heme of the wild-type P450-BM3 gene (nucleotide position 1292). The 
P450 BM3 gene was amplified using primers hom-pC-heme-for and heme-SacI-rev. The plasmid 
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pCWori-rh47, which encodes for a full length P450 BM3 variant in which the heme already con-
tained a SacI restriction site (Chapter 4), was digested with BamHI and SacI, and served as the 
receiver plasmid for the wild-type heme fragment digested with the same enzymes. Upon liga-
tion and transformation in E. coli DH5α, the full length wild-type P450 BM3 with a SacI re-
striction site within the heme was obtained, named pCWori-P450BM3FL-SacI.  
3.4.4 Construction of the P450-R47L-Y51, F87A and V78A-F87A variants  
The template pCWori-P450BM3FL-SacI was used to construct this plasmid.  The RLYF variant 
was created by overlap-extension PCR using primers RLYF-for and RLYF-rev as the mutagene-
sis primers and hom-pC-heme-for and heme-SacI-rev as the gene amplification primers, and sub-
sequently ligated in pCWori-P450BM3FL-SacI digested with BamHI and SacI. The two muta-
tions were encoded on a single primer because of their close proximity. A similar strategy was 
used to construct the variants F87A and V78A-F87A, the latter using one primer which encoded 
both mutations. 
 
3.4.5 Expression and purification of P450 variants 
The cytochrome P450 BM3 variants were expressed as follows. Overnight cultures of DH5α-
pCWori+-bm3 variant were inoculated in 500 mL TB medium supplemented with 100 µg/mL 
ampicillin. After 12 h of growth at 30
o
C and 250 rpm, protein expression was induced with 0.5 
mM ALA (provide full name) and 1 mM IPTG and allowed to grow for a further 24 h at 30ºC 
and 180 rpm, after which the cells were harvested by centrifugation (6000 rpm, 4
o
C, 10 min). 
The cell pellets were resuspended in 27-30 mL of 0.1 M phosphate buffer (pH 8.1) and 1 mg/mL 
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of lysozyme was added. After a freeze-thaw cycle at -80
o
C, the cells were disrupted by soni-
cation (5s on, 5 off, 40% amplitude) for 5 minutes, and the lysate was clarified multiple times by 
centrifugation (20,000 rpm, 4
o
C, 15 min). The clarified lysate was filtered through a 0.22 µM 
Amicon filter. The P450 concentration was measured by the carbon monoxide binding assay 
[28]. Typical concentrations of 40 µM P450 were readily obtained. This lysate was used as is in 
tandem reactions.  
 
For purification of the P450 BM3 variants, the cell lysate was purified as follows. The lysate was 
loaded onto a column packed with DEAE 650-M resin (Toyopearl, Los Angeles, CA) coupled to 
a fast-performance liquid chromatography. A wash step with 15% NaCl in 25 mM phosphate 
buffer, pH 8.1 was applied. The protein eluted at 25% NaCl in the phosphate buffer. Purity of the 
protein was assessed at around 70%. At this purity, the protein was judged to be pure enough for 
biocatalysis.    
 
3.4.6 Kinetic assays using P450 variants 
Purified or cell lysates of P450 BM3 variants were used to calculate NADPH depletion rates and 
coupling efficiencies. For NADPH depletion rate calculations, a typical reaction contained 0.2 
µM P450, 0.5 – 1 mM substrate from 100x stock in DMSO. Reactions were started with the ad-
dition of 0.15 mM NADPH. The depletion of NADPH at 340 nm was followed using a Cary UV 
spectrophotometer blanked with the reaction mixture prior to addition of NADPH.  
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To calculate the coupling efficiencies, a 0.5 mL reaction volume contained 0.2 µM P450 and 1 
mM of the desired substrate (added from 100x stock in DMSO), followed by incubation at 5 min 
at room temperature. One mM of NADPH was added to start the reaction. The reaction was 
shaken gently at room temperature for at least 4 h to allow all the NADPH to react followed by 
extraction with ethyl acetate containing 0.1 mM eicosane as an internal standard. A blank reac-
tion without the addition of enzyme was used as a reference to calculate the depletion of sub-
strate and was extracted in the same way as the enzymatic reactions. Reactions with β-
methylstyrene were directly injected onto GC-MS. In the case of the fatty acid substrates, the 
extracted reactions (and blanks) were dried under nitrogen, resuspended in 200 µL of N,O-
Bis(trimethylsilyl)trifluoroacetamide (BSTFA) followed by incubation at 80ºC for 1 h for deri-
vatization prior to injection on GC-MS. GC-MS analysis was performed on an HP5-MS column 
(60 m x 2.5 µm x 3.2 µm) (vendor, city, state) with the following program: 80ºC for 5 min, 
30ºC/min to 315ºC, hold 315ºC for 5 min.  
 
3.4.7 General protocol for the tandem reaction of fatty acids and symmetrical al-
kenes  
All reactions were set up and performed in air without prior purification of the solvents in 10-mL 
headspace crimp cap vials (Agilent Technologies).  The aqueous phase (2 mL total volume), con-
tained: 9 µM P450 BM3, 0.4-2 U/mL PTDH, 600 U/mL catalase, 0.2 mM NADP
+
, and 100 mM 
sodium phosphite, 100 mM phosphate buffer, pH 8.1.  The metathesis catalyst was prepared as a 
30 mg/mL stock in dichloromethane.  The isooctane organic phase (500 µL total volume) con-
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tained 50 mM 10-undecenoic acid, the appropriate equivalence of symmetrical alkene, and 20 
mM eicosane as internal standard.  The olefin metathesis catalyst was added to 2.5 mol% to start 
the reaction.  Reactions were shaken at 180 rpm on a plate shaker (Tallboys, Thorofare, NJ).  At 
the end of the reactions, the aqueous phase was acidified with 1N HCl, the metathesis catalyst 
was deactivated using 100-fold ethyl vinyl ether and extracted with 6 mL ethyl acetate.  The or-
ganic phase was dried over magnesium sulfate and dried under vacuum.  The residue was resus-
pended in 300 µL ethyl acetate.  Finally, 100 µL of the mixture was derivatized with the addition 
of 50 µL methanol and 50 µL TMS-diazomethane and ran on GC-MS.  The GC-MS program 
was as follows: 80 °C for 5 min, 30 °C/min to 315 °C, hold for 5 min.    
 
3.4.8 General protocol for the tandem reaction on top of buffer using cis-stilbene 
and trans-3-hexene or cis-2-butene 
All reactions were set up and performed in air without prior purification of the solvents in 10-mL 
headspace crimp cap vials (Agilent Technologies).  The enzyme reaction contained: 1-5 µM 
P450 RLYF lysate, 1-3 U/mL PTDH or GDH, 100 mM sodium phosphite or glucose, 600 U/mL 
catalase, 0.2 mM NADP
+
, and 2.5% v/v DMSO in 100 mM phosphate buffer pH 8.1. On top of 
the buffer were carefully added, in order cis-stilbene, trans-3-hexene, and 1 mg of C1 before 
sealing the vial with a crimp cap. When cis-2-butene was used, the vial was sealed after the suc-
cessive additions of cis-stilbene and C1. The vial was then pressurized with the appropriate pres-
sure of cis-2-butene.  
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3.4.9 Synthesis of trans-butenylbenzene  
Trans-butenylbenzene was synthesized following a published protocol [29]. In a 50 mL flask 
with a magnetic stirrer were placed trans-β-nitrostyrene (1 mmol) and triethylborane (3 mmol, 
1.0 M in THF solution) in 8 mL of THF, and the solution was bubbled with the air that filled in 
the balloon. After 5-10 min, the solvent was evaporated and the oily residue was purified by 
flash column chromatography by using hexane to obtain 20% trans-butenylbenzene. The 
1
HNMR spectrum of trans-butenylbenzene is shown below (Figure 3.8) 
 
Figure 3.8 
1
H NMR spectrum of trans-butenylbenzene 
 
BUTENYLBENZENE 
 
BUTENYLBENZENE OXIDE 
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3.4.10 Preparation of trans-butenylbenzene oxide by m-chloro-parabenzoic acid  
0.18 mmol trans-butenylbenzene was dissolved in 3 mL dichloromethane and cooled on an ice-
water bath. 0.55 mmol NaHCO3 and 0.36 mmol m-chloro-parabenzoic acid (mCPBA) (70 wt%) 
was added and the solution was stirred intensely while slowly reaching room temperature. A lot 
of white precipitates were formed, which occasionally blocked the stirring. After 5 h, the reac-
tion was quenched by stirring intensely with3 mL Na2SO4 until the two phases became clear. The 
two phases were separated and the aqueous phase was extracted with 3×2 mL dichloromethane. 
The combined organic phases were washed with 3×3 mL saturated NaHCO3 (aq), dried over 
Na2SO4, filtered and carefully evaporated on a rotavap to approximately 0.5 mL. The crude 
product was chromatographed on silica eluting with hexane: ethyl acetate (4:1).  
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Figure 3.9 
1
H NMR spectrum of trans-butenylbenzene oxide 
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CHAPTER 4. TANDEM ISOMERIZATION-EPOXIDATION OF ALKENES 
INVOLVING RUTHENIUM TRIPHENYLPHOSPHINE CATALYSTS AND 
P450 BM3 MUTANTS 
 
4.1 Introduction 
The recent initiative for green and sustainable chemistry has increased the interest of chemists in 
improving synthetic efficiency of chemical transformations. Synthetic chemists thrive to develop 
novel catalysts that work in mild conditions, require less separation costs, to achieve transfor-
mations with high purity, selectivity, and yield through minimal synthetic steps. To that effect, 
concurrent tandem catalytic processes, aptly named multicatalyst promoted asymmetric tandem 
reactions have emerged as a powerful strategy to improve said synthetic efficiency. Although the 
complexity of engineering these reactions still remain a synthetic challenge in terms of fine-
tuning substrate and product selectivities, as well as reaction condition compatibility, there are 
several successful examples of concurrent asymmetric tandem reactions in the literature involv-
ing two or more catalysts from the same or different disciplines of chemistry [1, 2].  
 
Tandem reactions involving multiple catalysts have found success in synthetic chemistry, how-
ever only a few reports of a tandem catalytic system incorporating both enzyme and organome-
tallic catalysts have previously been published [3, 4].  These have used an organometallic cata-
lyst that reversibly and dynamically racemize a mixture of enantiomers (secondary alcohols and 
amines) and a lipase enzyme that selectively esterifies only one of the isomers into a product, 
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specifically enriching the desired isomer to a yield higher than 50%. Similarly, one can envision 
a dynamic kinetic resolution where regioisomers are resolved instead of stereoisomers. An inter-
esting example of such a dynamic kinetic resolution would be the tandem isomerization and 
epoxidation to produce terminal olefins. Taking a page out of the tandem metathesis-epoxidation 
in Chapters 2 and 3, we envisioned that a tandem system could be created that combined an 
isomerization of alkenes catalyzed by an organometallic complex with a regioselective and enan-
tioselective bio-oxidation. This process would allow for a mixture of aliphatic olefins (terminal, 
internal cis- and trans- as obtained from alkane dehydrogenation for example) which usually are 
quite difficult to separate, to be reacted only to yield a single epoxide regio-isomer, in the hardest 
case the terminal olefin (Figure 4.1). Ideally, the yields for the terminal epoxide obtained for 
such a tandem reaction would be higher than if the reactions were run sequentially, given that the 
oxidation step showed high selectivity for terminal epoxidation, versus epoxidation of internal 
alkenes and unactivated C-H bonds.  
 
 
Figure 4.1 Schematic representation of a tandem isomerization-epoxidation for the epoxidation of terminal olefins 
 
 
 
 
Scheme 2.1. Representation of a tandem isomerization-epoxidation for the regio- and 
enantioselective epoxidation of terminal olefins 
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The enantio- and regioselective epoxidation of olefins is of great synthetic value. Enantiopure 
epoxides, as well as their corresponding vicinal diols, are valuable intermediates in fine organic 
synthesis, in particular for the preparation of biologically active compounds [5]. Effectively, the 
very reactive oxirane ring can be attacked by a wide variety of nucleophiles to produce chiral 
intermediates (Figure 4.2). In recent years, the preparation of enantiopure epoxides has been pur-
sued using both pure chemical and enzymatic approaches [6].  The first methodologies of Katsu-
ki and Sharpless using titanium-tartrate complexes allowed for the epoxidation allylic alcohols 
[7]. Since then, many more catalysts allowing for the epoxidation of non-functionalized olefins 
have been developed, leading to high stereoselectivities when applied to the epoxidation of cis-
alkenes [8, 9]. However, these complexes preferably oxidize the internal double bond over the 
terminal double bond. In addition, the selectivity of these complexes suffers with trans- olefins 
and terminal olefins [10]. On the other hand, as mentioned in Chapter 1, several enzymes can 
catalyze the epoxidation of olefins with high enantioselectivity, naturally or through enzyme en-
gineering [11-14]. 
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Figure 4.2 Reaction of nucleophiles with epoxides. Adapted from [15]. 
 
Using an enantioselective enzyme would make it possible, from a mixture of various pro-chiral 
olefins, to synthesize enantiomerically and regio-isomerically pure terminal epoxides. However, 
one can appreciate how difficult this tandem reaction would be to monitor, considering that only 
5% terminal olefin is formed from the thermodynamically uphill isomerization from internal to 
terminal olefins. Firstly, the thermodynamic barrier for the isomerization of internal olefins to 
terminal olefins would make it difficult to follow the progress of isomerization reaction. The 
success of the epoxidation reaction would also be difficult to establish at low concentrations of 
the terminal epoxide. To make it easier to set up the proof of concept, one could start from the 
terminal olefin and isomerize to the internal olefin mixture. The enzyme would in turn selective-
ly epoxidize one of the internal olefins (Figure 4.3). This approach alleviates the thermodynamic 
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problem while addressing cis- trans- selectivity issues and opens up new directions for develop-
ment of tandem catalysis. 
 
 
Figure 4.3 An alternative approach to study and engineer the tandem reaction. The reaction would start from ther-
modynamically downhill terminal-internal isomerization, followed by the selective epoxidation of one internal iso-
mer 
 
The first two necessary parts of this tandem system are the two catalysts: an organometallic cata-
lyst that efficiently isomerizes olefins and a regio- and stereo- selective epoxidation enzyme. 
Secondly, suitable reaction conditions must be engineered to house both reactions and have them 
operate compatibly. The success of this tandem reaction relies on several additional requirements 
as listed in Table 4.1. In this chapter, we present our work on engineering a reaction for the tan-
dem isomerization and epoxidation of short olefins.  
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Table 4.1 List of requirements for metal catalyst and enzyme in tandem reaction 
 
Requirements for metal catalyst Requirements for enzyme 
Reactivity at or below biological conditions Compatible with metal catalyst 
Air- and water-stable Selectivity for one isomer 
Solubility and reactivity in less polar solvents such as 
hydrocarbons 
High yields for the selective epoxidation 
 
4.2 Results and discussion 
4.2.1 Choice of enzyme, selectivity and activity 
4.2.1.1 T4MO versus P450 BM3 
As pointed out previously, there are several enzymes that are capable of doing epoxidation of 
aliphatic olefins. However, not many of them are capable of selectively oxidizing linear aliphatic 
olefins. After surveying the literature, two enzymes were selected for the epoxidation of short 
alkenes: a toluene-4-monooxygenase (T4MO) [16] and two cytochrome P450 BM3 mutants ob-
tained from the Arnold lab [11]. The variant T4MO I100G was previously shown to increase the 
wild-type activity for epoxidation [17]. Regioselectivity and activity experiments on hexenes 
were conducted (Table 4.2).  P450 BM3 mutants was 30-fold higher selective for the terminal 
alkene in a 1:1 mixture of terminal and trans-2-hexene, while no regioselectivity was observed in 
the case of T4MO and T4MO I100G. In addition, the P450 mutants exhibited higher turnovers 
than T4MO. It is noteworthy that although the RH47 and SH44 mutants react with trans-2-
hexene when supplied as the only substrate, terminal selectivity predominates in a 1:1 mixture of 
terminal and trans-2- olefins. This may be due to the faster binding of the terminal olefin in the 
enzyme active site of the enzyme through having a more exposed double bond than the trans-
internal alkenes.  
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Table 4.2 Regioselectivity of T4MO and P450 BM3 towards 1- and trans-2-hexene. 
a
10 g/L whole-cells, 37 
o
C, 50 
mM Tris-HNO3 buffer at pH=7.4 
b
0.2µM cell lysate, 0.75 mM NADPH in 100 mM phosphate buffer pH 8.1. Epox-
ide concentrations are in µM.  Each substrate was added at a final concentration of 4 mM in ethanol (1% v/v).  At 
least two independent experiments were performed. Errors are at most 15%. See experimental procedures for details. 
 
Enzyme/substrate 1-hexene trans-2-hexene 1:1 mixture 
T4MO
a
 52
c
 46 33:33 
T4MO (I100G)
a
 79 22 25:17 
RH47
b
 233 100 140:4  
SH44
b
 70 30 141:5 
 
4.2.1.2 P450 BM3 RH47 and SH44 alkene regioselectivity and activity on branched and straight 
chain short alkenes  
The isomerization of terminal olefin produces a thermodynamic mixture of terminal, cis- and 
trans- internal olefins, with the thermodynamic ratio favoring the trans- isomers. When testing 
the regioselectivity of P450 BM3 mutants in mixtures of terminal and cis-alkenes, we found that 
the selectivity drops dramatically. In the case of 1-hexene and cis-2-hexene for example, the re-
gioselectivity dropped to 1.3-1.6 fold for the RH47. For the SH44 mutant, the enzyme preferred 
the cis- alkenes in most cases. The activity of the P450 RH47 and SH44 was further tested 
against C5-C7 aliphatic straight or branched alkenes, as well as the enzyme regioselectivity in 
mixtures of these alkene isomers, as shown in Table 4.3 in accordance with the envisioned sub-
strate scope of the tandem reaction.  The SH44 mutant does not show any terminal selectivity 
except slightly in the case of pentene isomers. However, one can observe terminal selectivity for 
RH47, especially with 4-methyl-pentenes and t-butyl-propenes, affording 8.3 and 4.2-fold termi-
nal selectivity, respectively. This terminal selectivity of RH47 can be explained by the presence 
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of a phenylalanine at residue 87, contrary to SH44 which has a valine at this position. Residue 87 
in P450 BM3 has been studied in depth in several works and has been shown to be one of the 
main residues that determine regioselectivity in hydroxylation [18-20]. In addition, the bulky res-
idue 87 provides increased protection to the heme, alleviating the devastating effects of heme 
alkylating agents such as aldehydes [21], acetylenic substrates and terminal double bonds [22].   
 
Table 4.3 Terminal regioselectivity of RH47 and SH44 in alkene mixtures. Experiments were set up as in 
b
 in Table 
4.2 
 
Substrates RH47 SH44 
1-octene/cis-2-octene 0.82  ± 0.02 0.79 ± 0.04 
1-hexene/cis-2-hexene 1.20  ± 0.01 0.56 ± 0.01 
4-methyl-1-pentene/4-methyl-cis-2-pentene 8.30  ± 0.64 0.62 ± 0.10 
t-butyl-1-propene/t-butyl-cis-2-propene 4.20  ± 0.29 0.60 ± 0.03 
1-pentene/cis-2-pentene 1.90 ± 0.21 1.40 ± 0.2 
 
 
P450 BM3 RH47 and SH44 were able to react with all the olefin substrates fed with reasonable 
activity (TTN of 200-1000).  Lower TTNs (~200) were observed for the branched alkenes, espe-
cially the 4-methyl-pentenes. When NADPH depletion was monitored for this substrate, it was 
observed that rapid enzyme deactivation occurred, caused most likely by heme alkylation. 
 
4.2.2 Enzyme reaction optimization 
4.2.2.1 Screening of organic solvents 
While enzymes are naturally active in aqueous buffers, aqueous environments (air, water, room 
temperature) are generally not suitable for chemically-catalyzed synthetic transformations. First-
ly, the large isoelectric constant of water is not favorable for many chemical catalysts; secondly, 
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many organic compounds of commercial interest afford minute water solubility.  Therefore, it is 
not surprising that various organometallic catalysts were not synthesized to be soluble in aqueous 
solutions. In our tandem reaction, it became quickly evident that a biphasic aqueous/nonpolar 
two phase reaction system should be employed, similar to the strategy employed in Chapter 2.  
Separation of the two catalysts by having them in different phases would minimize cross-talk and 
potentially afford higher catalyst compatibility. For example, the aqueous buffer phase would 
include the biocatalyst (cells, lysate or purified enzyme), and the organic solvent as a second 
phase would contain the soluble organometallic catalyst, serve as a substrate reservoir and prod-
uct extraction pool, exhibiting high product recovery capacity and biocompatibility [23]. The ad-
vantages of this aqueous/nonpolar medium two-phase systems would include not only the pro-
duction of sparingly water-soluble compounds (aliphatic olefins), but also in situ product recov-
ery, which reduces end-product inhibition and favors the bioconversion by shifting the thermo-
dynamic equilibrium (Table 4.4) [24].  
 
Table 4.4 Desirable solvent characteristics 
Low emulsion-forming tendency Favorable properties for product recovery 
Chemical and thermal stability Nonbiodegradability 
Biocompatibility Nonhazardous 
Favorable distribution coefficient  Inexpensive 
High selectivity Available in bulk quantities 
Low aqueous solubility NADPH uncoupling of P450 
 
While the other criteria are relative, biocompatibility and NADPH uncoupling remain very re-
strictive criteria. Biocompatibility of an organic solvent is closely related to the log of its oc-
tanol/water partition coefficient (logP), which is a measure of its hydrophobicity [25]. In general, 
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organic solvents with a logP of 4 or higher are regarded as being biocompatible with both cells 
and enzymes [24]. One of our reaction designs would use E. coli whole-cells as the epoxidation 
catalyst. Since P450 BM3 substrate oxidation is accompanied by the reduction of stoichiometric 
amount of the expensive cofactor NADPH, we hypothesized that using the E. coli cell metabo-
lism to regenerate NADPH would be economical. In addition, a regeneration enzyme, such as 
glucose dehydrogenase, could be expressed in the cells simultaneously to compensate the natural 
regeneration [26]. The biocompatibility of many organic solvents with respect to cell growth was 
screened. Expectedly, we found that the growth of E. coli cells harboring the plasmids P450-
bm3-RH47 was not significantly affected (no organic solvent) under up to 50% v/v decane, do-
decane, and hexadecane which have logPs of 5.6, 6.8 and 8.8, respectively (Figure 4.4). On the 
other hand, when pure olefins were chosen as the organic solvents markedly high toxicities were 
observed (not shown).  Even at a concentration of 1 M 1-hexene in decane or dodecane, cell 
growth was significantly impaired. In addition, hexadecane proved to be the solvent that gave the 
highest yield of 1,2-epoxyhexane after 4h (Figure 4.5).  
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Figure 4.4 Growth of E. coli cells harboring pET28a-bm3_RH47 under decane and dodecane containing increasing 
concentrations of 1-hexene. 
 
We further optimized the substrate concentrations in hexadecane to be 1.0 M, as well as the or-
ganic phase: buffer ratio to be 40% v/v. At this concentration of substrate in hexadecane, E. coli 
cells did not show adverse growth effects and the epoxidation rate was the highest reached (Fig-
ure 4.6). Whole cells concentration was adjusted to 20 g/L in phosphate buffer supplemented 
with 2% glucose, based on a calculated E. coli glucose consumption rate of 0.63 g glucose g 
cdw
-1
 h
-1
.  
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Figure 4.5 Whole-cell biocatalysis in biphasic reaction. E. coli BL21 cells harboring pET28a-bm3_RH47 in phos-
phate buffer (0.1 M), OD = 20, ~ 4.8 g cell dry weight/L, 2% glucose, 1 M 1-hexene dissolved in organic solvent, 
30
o
C, 40% v/v organic phase volume ratio. 
 
In addition, we studied the effect of these solvents on their NADPH uncoupling properties. As 
pointed out by Schrader and others [27], an organic solvent may uncouple NADPH from sub-
strate oxidation, albeit not being oxidized itself, thus driving NADPH away from the reaction. 
Studying the NADPH uncoupling effects of several solvents suggested that in fact, dodecane 
caused NADPH uncoupling of P450 BM3 RH47. This solvent has been used in previous reports 
as an organic phase, but with a different P450 mutant [28].  Hexadecane and diisononyl phthalate 
caused little NAPDH uncoupling of the P450 BM3 mutants compared to the negative control 
(1% DMSO) (Figure 4.6). Keeping in mind that the isomerization catalyst was being fitted to 
achieve solubility in higher alkanes, hexadecane was chosen as the organic solvent for the tan-
dem reactions in our further experiments. 
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Figure 4.6 P450 BM3 specific NADPH uncoupling/consumption rate in the presence of various solvents 
 
4.2.2.2 In vitro epoxidation with cofactor regeneration 
In parallel, we also studied the epoxidation reaction in vitro with cofactor regeneration. Several 
reasons prompted this investigation. First, the whole cell biocatalysis gave a low yield of epox-
ides. Secondly, the epoxide products would at times be further metabolized and not be recovered 
in the extraction. To efficiently regenerate NADPH, we used the alcohol dehydrogenase from 
Thermoanaerobium brockii. The NADP
+
 alcohol dehydrogenase from T.  brockii has been 
shown previously to efficiently regenerate NADPH in previous reports and has high organic sol-
vent resistance [11, 29, 30]. There are several commercially available NAD
+
 dependent enzymes 
used for regeneration, but the same cannot be said for NADP
+
 counterparts. A mutant of formate 
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dehydrogenase from Pseudomonas sp. capable of using NADP
+
 has been reported, however, the 
specific mutations to obtain this mutant were not revealed. NADP
+
 glucose dehydrogenases and 
isocitrate dehydogenases have also been reported; however, the organic solvent resistance of 
many of these enzymes has not been well studied, nor has their specific activity outcompeted the 
T. brockii ADH. Lastly, a thermostable NADP
+
-dependent phosphite dehydrogenase, engineered 
in our laboratory, could have been used for regeneration [31]. However, in our initial studies, we 
found that the activity of PTDH may not be high enough in phosphate buffer, the buffer of 
choice for P450 activity. In the future, switching to a different buffer for the P450 will enable us 
to use this enzyme.  
 
Using the NADP
+
-dependent T. brockii, we found that a minimum of 1 U/ml had to be used for 
the regeneration reaction when 10 µM P450 BM3 RH47 reacted with 1-hexene. As a rule of 
thumb, 1 U/ml of ADH was used in the subsequent tandem reactions.  
 
4.2.3 Isomerization catalyst optimization (with Martin Jarenmark) 
4.2.3.1 Achieving solubility in higher alkanes 
As mentioned before, the first and foremost requirement for the isomerization catalyst is to be 
functional and stable at room temperature, in air, and in the presence of enzymatic entities (e.g. 
cells, buffer, enzymes). The second requirement is that it should be soluble and active in a bio-
compatible solvent, in our case higher alkanes such as hexadecane. While the commercially 
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available RuHCl(CO)(P(Ph3))3 and RhHCO(Ph3P)3 catalysts were found to be stable in air and at 
biological conditions, they afforded no solubility or activity in alkanes (Table 4.5).  
 
Table 4.5 Activity of ruthenium catalyst in polar organic solvents 
 
 
To increase solubility in alkanes, alkyl chains were incorporated into the para-position of the 
phenyl groups of the triaryl phosphine ligands. Incorporation of t-butyl groups increased the sol-
ubility and activity in pentane for the ruthenium complexes, however, in hexadecane, the solubil-
ity was still low (<1 mg/ml estimated). Therefore, in hexadecane: buffer, the conversion was on-
ly 50% after 24h (Table 4.6). At last, simply switching from t-butyl groups to n-butyl groups af-
forded solubility in hexadecane.  In the presence of 20 mol% catalyst, the isomerization rate of 1-
hexene could reach 60% in 6 hours at room temperature.  
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Table 4.6 RuCl(CO)(PPh3-tbutyl)3 activity in organic solvents  
 
4.2.3.2 Optimizing activity in hexadecane (sulfur activation) and activation at biological condi-
tions 
The isomerization of olefins by metal-hydride catalysts generally requires coordination of the 
olefin to the metal center. Therefore, one of the ligands needs to dissociate for the substrate to 
bind to the metal center. It was found that activation of the Ru(n-butyl) complex with 1.5 eq. el-
emental sulfur (after optimization) increased the rate 7-fold (from 10% at 30 min to 68% with 
sulfur activation) (Figure 4.7). The activation time was also optimized (See experimental proce-
dures for details) to 5 minutes for optimal activity. Longer activation times deactivated the ru-
thenium catalyst by possibly withdrawing additional ligands from the metal center. Although ac-
tivation on sulfur made the catalyst much faster, the trade-off was that it steadily decreased the 
catalyst lifetime. With 20 mol% catalyst, after about 6h, the catalyst activity had dramatically 
decreased to about 5-10%. Finally, we also found that the isomerization was as effective in hex-
.  
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adecane: buffer (with lysate containing no P450) as in hexadecane alone (Figure 4.8). In hexade-
cane, we noted that there was very minimal formation of 3-hexenes.  
 
 
Figure 4.7 Formation of internal alkene by isomerization of 1-hexene catalyzed by RuHCl(CO)(P(PhnBu)3)3 acti-
vated by sulfur or  dibenzothiophenes (DBTS) in hexadecane. Conditions: 0.1 M 1-hexene, 20 mol% catalyst, 0 or 1 
eq sulfur reagent, room temperature. 
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Figure 4.8 Formation of internal hexene isomers through isomerization of 1-hexene catalyzed by 
RuHCl(CO)(P(PhnBu)3) pre-activated by 1.5 eq elemental sulfur in the absence and presence of aqueous buffer and 
cell lysate without P450 (empty vector plasmid). 
 
4.2.3.3 Isomerization of various alkenes in hexadecane: buffer  
With these optimized isomerization conditions, isomerization of various alkenes were attempted. 
The results are summarized in Figure 4.9. Interestingly, when starting from cis-2 isomers, the 
amount of terminal isomer formed in the isomerization increased with the degree of substitution 
of the olefin (b, e and h). This is due to the decreased stability of the cis-2 isomer caused by the 
larger steric interaction between the 1, 2- substituents of the ethylene moiety. While the cis-2 
isomers seem to work decently in the isomerization reaction, the trans-2 isomers are generally 
poor substrates, due to the thermodynamic stability of the trans- double bond compared to the 
cis- bond (c, f and i).  
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Figure 4.9 Isomerization of various alkenes with RuHCl(CO)(P(PhnBu)3)3, activated with 1.5 eq. elemental sulfur. 
Reactions were run in hexadecane: buffer 2:5 v/v.  
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4.2.4 Tandem isomerization-epoxidation in hexadecane: buffer biphasic systems 
4.2.4.1 Whole-cell tandem reactions 
In our quest to achieve solubility in hexadecane, we made several pit stops. In one of them, we 
used an isomerization catalyst with t-butyl groups at the para- position of the phenyl ring.  Alt-
hough this catalyst has very low solubility in hexadecane, it could be dissolved to up to 1 mol% 
in pure 1-hexene (used as substrate and organic phase). In the tandem reaction, we observed for 
the first time the formation of the internal cis-2,3-epoxyhexane. The overall yield of the reaction 
was 150 µM of total products, with 1.6 fold higher terminal epoxide.  
 
In the previous sections, we optimized the catalyst loading and activity in hexadecane, the sub-
strate concentration in the organic phase, as well as the cell density. Tandem reactions were set 
up with hexadecane as the organic phase in which 0.1 M 1-hexene and 20 mol% Ru-n-butyl cata-
lyst were dissolved. The aqueous phase contained 4.8 g/L BL21 cells harboring pET28a-rh47 in 
phosphate buffer, pH 7.5.  Catalyst activation on sulfur prior to the tandem reaction fastened the 
isomerization, therefore increasing the amount of cis-2-hexene in the tandem reaction at early 
times. Without sulfur activation, the yield of internal epoxide was only 15 µmol/g cdw, com-
pared to 33 µmol/g cdw, when activated sulfur was used. In this system, however, the reaction 
yields were very low and stopped after 5h, and as mentioned previously, the epoxides were fur-
ther metabolized or reacted by the cells (Figure 4.10 A and B).  
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Figure 4.10 Tandem isomerization-epoxidation with whole cells of P450 RH47. (A) with sulfur activation of 
RuHCl(CO)(Ph3P-n-butyl)3. (B) no sulfur activation  
 
4.2.4.2 Tandem isomerization-epoxidation using cell lysate of P450 and regeneration system 
Using cell lysate or purified P450 BM3 RH47 or SH44, we set up several tandem reactions with 
the optimized conditions (Ru-n-butyl catalyst, P450 cell lysate plus ADH regeneration system). 
Starting with 1-hexene for the isomerization, we observed the formation of cis-2,3-epoxyhexane 
at 2.5-fold higher concentration than the internal epoxide. Interestingly, starting with trans-2-
hexene, the terminal epoxide was also observed, although at a much lower concentration of 6-
  
 
Figure 2.2.4.1. Tandem isomerization-epoxidation with whole cells of P450 RH47 A) with 
sulfur activation of RuHCl(CO)(Ph3P-n-butyl)3 B) no sulfur activation 
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fold less than both the internal epoxides (cis- and trans-). We found earlier that in a mixture of 
terminal and trans- internal alkenes, we observed very little activity against the trans-alkenes. 
With a high starting concentration of trans-2-hexene, and very slow isomerization, at most 5% of 
terminal hexene formed, it was interesting to observe that the terminal epoxide was formed in the 
tandem reaction using the RH47 mutant. Using the SH44 mutant, the terminal epoxide could not 
be observed (Figure 4.11).  
 
 
Figure 4.11 Cell lysate tandem reaction. A) Representation of reaction scheme. B) Time course of tandem reactions 
starting with 1-hexene and trans-2-hexene, respectively. Reactions were run in duplicates. Errors were within 10%.  
 
RH47 
A 
B 
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The tandem reaction was expanded to a few straight and branched aliphatic alkenes (Table 4.7). 
As a general observation, in most of the reactions starting with the terminal alkenes, the cis- in-
ternal epoxides are formed with higher yields than the starting terminal alkene product (entries 1, 
2, 5, 6). One particular exception (entries 3 and 7) involves 4-methyl-1-pentene. As far as the 
RH47 mutant, the terminal selectivity of the RH47 in mixtures of 4-methyl-pentenes explains 
why the tandem reaction does show formation of the epoxides with particular preference. Con-
versely, entries 10 and 11 represented our best results in terms of selectivity for terminal epoxi-
dation. Starting with either the trans- or cis- 4-methyl-2-pentenes, all three epoxides were 
formed in equimolar concentrations with the RH47 mutant. In entries 4, 8, 9 and 12, the enzymes 
showed not high enough terminal selectivity, therefore, low amounts of the terminal epoxide was 
formed. A theme of these reactions is the low overall epoxide conversion. With such low conver-
sions, we did not expect the epoxidation reaction to have any impact on the isomerization reac-
tion, i.e., to exert a selective and “dynamic” pull of the substrates from the organic phase. In or-
der to double check entries 10 and 11, control reactions were run starting with 4-methyl-2-
pentenes without the addition of isomerization catalyst. The 4-methyl-1,2-epoxypentane peak did 
not appear unless the isomerization catalyst was added.  
 
This peak was also confirmed with spiking with authentic standard, prepared chemically. Alt-
hough the isomerization only produces 5% terminal alkene at most, we could observe a 1:1:1 
mixture of epoxides in the tandem reaction. To further understand this, we performed a mutual 
solubility test. While in the organic phase, the ratio of internal to terminal alkenes could be 10:1, 
in the aqueous phase, the ratio was determined to be about 4:1. This is due to the cis-2-hexene 
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going beyond the threshold for solubility-dependent partition, highlighting that the ratio of iso-
mers obtained in the organic phase may not be the same seen by the P450 enzyme in the aqueous 
phase.  
 
Table 4.7 Tandem Isomerization-Epoxidation of various alkenes 
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4.2.5 Attempts at increasing the yield of the P450 biphasic reaction 
In all the above tandem reactions, rather low yields are obtained (1-2 %). In order to increase the 
epoxidation yields, many strategies were employed. First, the P450 enzyme concentration was 
increased from 1-10 µM to 33 µM. Second, the highly soluble phase transfer catalyst (>200 g/L) 
methyl-β-cyclodextrin (Figure 4.13B) was added at different concentrations. The ability of cy-
clodextrins to form complexes with hydrophobic molecules has led to their usage in increasing 
the solubility of organic compounds in aqueous solutions and has been shown to increase bipha-
sic reaction yields [32]. In addition, methyl-β-cyclodextrin was shown to increase the rate of sty-
rene epoxidation by the styrene monooxygenase StyAB [33].  
 
Hexene partitions were calculated as a function of methyl-β-cyclodextrin added. The results are 
shown in Figure 4.12. As expected, increasing the concentration of both phase transfer agent and 
hexene concentration in the organic phase increased the concentration in the aqueous phase. A 
concentration of 1 mM was eventually reached in the aqueous phase. Strangely, we did not reach 
the concentration-independent partition of 1-hexene. Increasing the partition of 1-hexene in the 
aqueous phase was accompanied by an increase in epoxidation yields, which suggests that the 
reaction is partly mass transfer limited (Figures 4.13C). Our best result of 7% yield was obtained 
when 40 µM of P450 was used with 30% methyl-β-cyclodextrin. Unfortunately, at these low 
yields, the tandem reaction would not show a dynamic pull as expected.  
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Figure 4.12 Influence of percentage of methyl-β-cyclodextrin on the partition of 1-hexene. 
 
 
 
 
 
 
Figure 4.13 Enhancement of epoxidation yields with the addition of methyl-β-cyclodextrin. A) Schematic represen-
tation of reaction with conditions. B) Core structure of methyl-β-cyclodextrin. C) Increase in epoxidation yields as a 
function of methyl-β-cyclodextrin concentration. 
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4.2.6 Tandem isomerization-epoxidation of terminal carboxylic acid methyl es-
ters 
Following our target to increase the epoxidation yields, we switched to olefinic methyl esters as 
substrates with higher solubility in the aqueous phase. These substrates should in principle give 
higher epoxidation yields. Using P450 RH47, we screened olefinic acid methyl esters of lengths 
C4 to C8 (butanoic to octanoic) and determined the regioselectivity of oxidation. We found that 
while 7-octenoic acid methyl ester only resulted in the allylic oxidation product when combined 
with P450 RH47, 5-hexenoic acid methyl ester yielded the terminal epoxide selectively. In addi-
tion, P450 BM3 RH47 and SH44 mutants showed good turnovers on these substrates. A nitro-
benzyl pyridine assay [34] was performed with these substrates and the TTNs were estimated to 
be 500 and 700 for the RH47 and SH44 mutants, respectively. Although P450 BM3 has been en-
gineered to catalyze the oxidation of short chain acids [35], it had not yet been shown to epox-
idize short alkene methyl esters. We studied the epoxidation of 5-hexenoic acid methyl ester at 
37
o
C in biphasic hexadecane: buffer. When the substrate concentration in the organic phase was 
adjusted 5 mM (1 µmol), we observed 48% conversion of the starting material to the terminal 
epoxide product after 24h. A time course suggested that the reaction did finish in 6 to 7 hours.  
Reasons why the reaction did not reach completion are unknown, since addition of P450 did not 
result in increased yields.  
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4.2.6.1 Optimization and characterization of isomerization of carboxylic acid methyl esters in 
hexadecane 
At room temperature, the isomerization 5-hexenoic acid methyl was significantly slower than 
with the alkenes (Figure 4.14). In the tandem reaction, we wanted to avoid catalyst activation 
(for easier handling and reproducibility). Therefore, in order to increase the isomerization rate, 
the concentration of 5-hexenoic acid methyl ester was optimized to 200 mM at 37
o
C. Optimiza-
tions of the volume of hexadecane used as the organic phase compared to buffer and catalyst 
loading were also performed as to increase the isomerization rate, while keeping the hexadecane 
organic phase volume low. Entry 2 in Figure 4.15 gave us the best result, and thus was used in 
the subsequent tandem reactions. It is worth noting that since we could not separate the cis- and 
trans- isomers at a respective position, we could not discern the E/Z ratio formed for each regioi-
somer. As a result, we report the mixture of cis- and trans- isomers in Figure 4.15 for each regi-
oisomer.  
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Figure 4.14 Isomerization of various concentrations of 5-hexenoic acid methyl ester at 37
o
C with 20 mol% 
RuHCl(CO)(PPh3-nbutyl)3  in hexadecane: buffer (1:1 v/v). 
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Entry Substrate concen-
tration (M) 
RuHCl(CO)(PPh3-nbutyl)3 
loading (mol%) 
Volume hexade-
cane (µL) 
Volume 
buffer (µL) 
1 0.25 40 20 500 
2 0.25 40 50 500 
3 0.25 40 100 500 
4 0.25 20 20 500 
5 0.25 20 300 0 
6 0.25 40 300 0 
7 0.25 80 20 500 
8 0.50 20 300 0 
9 0.50 40 300 0 
 
Figure 4.15 Optimization of isomerization reaction. All reactions were run at 37
o
C. Reactions were extracted at 6h 
with 2 volumes of ethyl acetate and ran on GC-MS. Dodecane was used as the internal standard. The ratios of peak 
area of each isomer with the internal standard peak were used to quantify each isomer. A control with no isomeriza-
tion catalyst was used as a negative control to correct for control area differences. 
 
Proton NMR was used to quantify the cis-trans isomeric ratio in the isomerization of 5-hexenoic 
acid methyl ester. 
1
HNMR of the isomerization of 5-hexenoic acid methyl ester in hexadecane 
proved to be impractical because of too many protons in the solvent. In addition, the isomeriza-
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tion of 5-hexenoic acid methyl ester in THF yielded mostly the conjugated α-trans- olefin, of 
which we observed very little amount when the isomerization was run in hexadecane. Therefore, 
the cis -trans- isomeric ratio of the isomerization of methyl-2,2-dimethylhex-5-enoate (Figure 
4.16), which only forms the cis- and trans-4 product, was studied in THF at room temperature 
and was found to be 60:40 trans: cis ratio by 
1
H NMR. We assumed a similar ratio of cis- and 
trans- products would be formed in the case of 5-hexenoic acid methyl ester isomerization.  
 
 
Figure 4.16 Isomerization of methyl-2,2-dimethylhex-5-enoate 
 
 
4.2.6.2 Tandem isomerization-epoxidation of terminal carboxylic acid methyl esters 
Tandem reactions were set up under several optimized conditions as determined in Figure 4.15 
(Figure 4.17). Entries 7 and 8 in Table 4.8 represent our best results for this tandem reaction. For 
entries 7 and 8, yields of 36% and 32.2% were obtained, respectively, which were the highest 
were obtained with any of our previous tandem reactions with the alkenes. Unfortunately, in all 
our examples, the enzyme still preferred the terminal alkene as a substrate, compared with the 
internal alkenes formed by isomerization. 
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Figure 4.17 Tandem reaction of 5-hexenoic acid methyl ester. A. isomerization catalyst B. epoxidation enzyme 
 
The cis- versions of the internal olefin methyl esters are either not commercially available or 
very expensive.  They are even harder to synthesize. Therefore, we could not figure out 1) 
whether the P450 showed selectivity for the cis-alkene versus the trans-alkenes, 2) whether the 
cis- and trans- epoxides from these internal alkenes had different retention times than the cis-
epoxides. We knew previously that peak #6 represented the 5,6-(terminal) epoxide, and we were 
positive that the terminal epoxide is the only product obtained from epoxidation of 5-hexenoic 
acid methyl ester by either variant RH47 or SH44. Based on their mass spectrum fragmentations, 
the internal epoxide products formed at carbons 3,4 and 4,5 were identified as peaks #4 and #5, 
respectively (Figure 4.19 trace C). In order to gather more insights into the tandem reaction such 
as the enzyme selectivity, we performed reactions with only trans- internal alkene methyl esters 
in biphasic conditions similar to those of the tandem reactions. Surprisingly, we observed that 
there was no reaction when either trans-3-pentenoic acid methyl ester, trans-2-hexenoic acid me-
thyl ester or trans-2-pentenoic acid methyl ester were used (Figure 4.18 traces A and B). Inter-
estingly, 4-pentenoic acid methyl ester yielded the terminal epoxide, although the yields were 
lower than with 5-hexenoic acid methyl ester. This suggested that the P450 RH47 may either 
show some cis-selectivity with these substrates or that these substrates are borderline long 
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enough to be recognized by the P450, which could explain that the more reactive cis- double 
bonds would react preferentially compared with the trans- double bonds formed during isomeri-
zation (Figure 4.18). The selectivity of this tandem reaction was not further pursued.  
In addition, we have tried substrate B in the tandem reaction. This substrate, as highlighted pre-
viously, only migrates the double bond by 1 position to form the cis- and trans-4 alkenes.   
 
Table 4.8 Tandem isomerization-epoxidation of 5-hexenoic acid methyl ester in different configurations 
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Figure 4.18 Determination of cis-selectivity of the tandem reaction. Black trace: Isomerization in hexadecane: buff-
er with no P450 present. Teal trace Trans-3-pentenoic acid methyl ester reaction. Blue trace:  Trans-2-hexenoic acid 
methyl ester reaction. Red trace: Tandem reaction with all components added.   
 
With this hypothesized cis-selectivity, we would expect the tandem reaction to selectively pull 
the cis-olefins through their epoxidation. However, the trans-cis isomerization is way too slow to 
replenish the cis- olefin depleted.  Therefore, we did not observe a dynamic effect. Trans-cis 
isomerization was attempted for various substrates in hexadecane, but all failed. The only suc-
cessful trans-cis- isomerization occurred in THF with the more active RuHCl(CO)(PPh3-tbutyl)3. 
 
4.3 Conclusions and outlook 
In this chapter, we have explored the possibility of combining a ruthenium catalyst with a metal-
loenzyme for the tandem isomerization-epoxidation of linear and branched olefins. P450 BM3 
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mutants RH47 and SH44 were found to be suitable biocatalysts for the epoxidation of alkenes 
and alkenoic methyl esters. Ruthenium catalysts were synthesized to achieve activity and solubil-
ity in hexadecane, and were active at biological conditions. We showed that two catalysts from 
very different disciplines, namely an organometallic catalyst and a metalloenzymes, could work 
in tandem in one-pot to achieve a transformation not accessible by a single catalyst alone. Using 
a biphasic reaction system (hexadecane: buffer), we showed that starting with the terminal al-
kene, the isomerization produced the internal olefin, which was subsequently epoxidized by the 
P450 BM3 mutants with at best 2-fold higher yields than the terminal olefin. We also tackled the 
thermodynamically challenging transformation starting with trans-2-hexene as the isomerization 
substrate. In our best case, starting with trans-4-methyl-pentene, one could observe the formation 
of the terminal 4-methyl-1,2-epoxypentane, at an equimolar concentration with the two internal 
epoxides. Meanwhile, there are several limitations to our tandem process. Firstly, the selectivity 
of the P450 mutants for terminal epoxidation over internal epoxidation is not high enough to tru-
ly drive the reaction.  Secondly, the epoxidation yields were too low in the case of the alkenes to 
disturb the equilibrium of olefins established by the isomerization. Thirdly, the enzyme activity 
towards the alkene substrates is not high enough to overcome the mass transfer limitation im-
posed by the hexadecane: buffer system. In order to address the terminal selectivity, directed 
evolution was used to increase the selectivity of the P450 BM3 for epoxidation of terminal al-
kenes. A GC-MS based screening method was used to assess whether mutations at 10 active-site 
residues via saturation mutagenesis would improve regioselectivity. Our most selective mutant, 
87H9, reacted with only a 1.3-fold increase in selectivity for epoxidation of terminal over inter-
nal alkenes. Additional directed evolution was not conducted because the margin of increase was 
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found to be small, and the screening method was too time-consuming. Difficulties faced when 
transforming the P450BM3 into a terminal hydroxylase has been described in the literature [36]. 
The most effective method proved to be the addition of the phase transfer catalyst methyl-β-
cyclodextrin. Addition of 15% of the phase transfer catalyst effectively increases the partition of 
1-hexene up to 0.01 and the epoxidation conversion up to 7%.  Choosing more soluble sub-
strates, such as unsaturated methyl esters, further increased the yield to 35% after reaction opti-
mization. The epoxidation was found to be selective for the terminal alkene and cis-alkene (no 
trans-methyl ester tested reacted). However, we did not observe trans- to cis- isomerization of 
these olefinic methyl esters. Trans- to cis- isomerization was only achieved in non-compatible 
solvents such as THF.  
 
An additional key component of the tandem reaction that has not been tampered with is the co-
factor regeneration system. Although it has been shown to be effective, the alcohol dehydrogen-
ase from T. brockii is not readily used in biocatalytic transformations. Inhibition of the activity of 
the ADH by acetone may be limiting the regeneration efficiency [37]. In addition, ADH is inhib-
ited by DMSO, one of the best co-solvents usually involved in biphasic reactions [38]. We will 
surely change the regeneration system in the future and explore new options [39].   
 
One may continue to expand the reaction substrate scope by investigating olefins containing ke-
tone groups and unsaturated carboxylic acids. P450 BM3 mutants have been shown to react these 
substrates with high activities [14]. We hypothesize that finding substrates exhibiting both high 
isomerization and epoxidation rates may unlock a system that undergoes dynamic isomerization-
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epoxidation. One promising substrate is shown in Figure 4.19. This substrate would likely un-
dergo isomerization to form a high percentage of the terminal alkene, similar to the trisubstituted 
alkene shown in Figure 4.9 h, because of steric hindrance of the internal alkenes. In addition, a 
P450 enzyme can be engineered to react the terminal alkene selectivity and in high yields, based 
on our observation that the 4,4-dimethyl-1-pentene is a substrate for the P450.  
 
Figure 4.19 (Z)-4-methoxy-4-methylpent-2-ene 
 
Other methods to engineer a dynamic isomerization-epoxidation would be to use a metathesis 
catalyst in combination with a cis-selective enzyme. For example, butenolysis or self-metathesis 
of trans-2-alkenes would form an equilibrium mixture of cis-2, trans-2- and dimer of the trans-
2-alkene starting material. If this mixture, along with a metathesis catalyst, was to be incubated 
with a cis-selective enzyme, such as chloroperoxidase [40], the cis-epoxide would be formed se-
lectively.  
 
4.4 Experimental procedures 
4.4.1 Materials 
The Escherichia coli cloning strain DH5α, expression strain BL21(DE3) and the expression vec-
tor pET28a were obtained from EMD Biosciences (San Diego, CA). Antibiotics and isopropyl-β-
D-thiogalactopyranoside (IPTG) were purchased from Gold Biotechnology (St. Louis, MO). The 
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plasmids pCWori
+
-bm3_rh47 and pCWori
+
-bm3_sh44 encoding P450 BM3 RH47 and SH44 
respectively, were obtained from the Frances Arnold laboratory (Caltech, Pasadena, USA). The 
T4MO plasmid was constructed by Haige Lu, a former postdoc in our laboratory. All chemicals 
were obtained from Sigma-Aldrich (St. Louis) unless otherwise noted. NADPH tetrasodium salt 
was from Enzo Life Sciences (Ann Arbor, MI).  NADP
+
 was purchased from Roche Diagnostics 
(Indianapolis, IN).  4-Methyl-cis-2-pentene was purchased from TCI America Fine Chemicals 
(Portland, OR). t-butyl-trans-2-propene was from BOC Biosciences (Shirley, NJ). All PCR rea-
gents and restriction enzymes were purchased from New England Biolabs (Ipswich, MA), and 
DNA Miniprep and Gel Purification Kits were purchased from Qiagen (Valencia, CA). 
 
4.4.2 DNA manipulations 
P450 BM3 mutants were subcloned into the BamHI and EcoRI sites of pET28a for expression in 
BL21 and whole cells preparation. Primers used were BamHI-for-BM3 
(GCGGATCCATGACAATTAAAGAAATGCCTCAGC) and EcoRI-rev-BM3 
(GCGAATTCTTACCCAGCCCACACGTCTTTTGCG). Restriction sites are underlined.   
 
4.4.3 Protein expression and purification 
The cytochrome P450 BM3 RH47 and SH44 were expressed as described elsewhere [11]. Brief-
ly, overnight cultures of DH5α-pCWori+ bm3 mutants were inoculated in 500 mL TB supple-
mented with 100 µg/mL ampicillin. After 24h of growth at 30
o
C and 180 rpm, protein expression 
was induced with 0.5 mM aminolevulinic acid and 1 mM IPTG and allowed to grow for a further 
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24h at the same condition, after which the cells were harvested by centrifugation (6000 rpm, 4
o
C, 
10 min). The cell pellets were resuspended in 20 ml of 0.1 M phosphate buffer (pH 8.1) and 1 
mg/mL of lysozyme was added. After a freeze-thaw cycle at -80
o
C, the cells were disrupted by 
sonication (5s on, 5 off, 40% amplitude) for 5 minutes, and the lysate was clarified multiple 
times by centrifugation (20,000 rpm, 4
o
C, 15 min). The clarified lysate was filtered through a 
0.22 µM Amicon filter. The P450 concentration was measured by the carbon monoxide binding 
assay [41]. Typical concentrations of 10-20 µM of P450 BM3 mutants were readily obtained. 
This lysate was used as is in some tandem reactions.  
 
For purification of the P450 BM3 mutants, the cell lysate was purified as described previously 
[42]. The lysate was loaded onto a column packed with DEAE 650-M resin (Toyopearl, Los An-
geles, CA) coupled to a fast-performance liquid chromatography. A wash step with 15% NaCl in 
25 mM phosphate buffer, pH 8.1 was applied. The protein eluted at 25% NaCl in phosphate 
buffer. Purity of the protein was assessed at around 70%. At this purity, the protein was judged to 
be pure enough for biocatalysis.    
 
4.4.4 Preparation of whole cells of P450 BM3  
Typically, a single colony carrying the target gene cloned in pET28a was inoculated in 5 mL LB 
+ 50 µg/ml kanamycin and grown overnight (16h). This seed culture was used to inoculate 500 
mL of TB media supplemented with 50 µg/mL kanamycin. The culture was grown at 37
o
C, 250 
rpm until the OD had reached 0.8-1, upon which protein expression was induced with 0.5 mM 5-
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aminolevulinic and 0.5 mM IPTG. The shaking speed and temperature were decreased to 160 
rpm and 30
o
C, and the cells were left to grow for 20h. The cells were harvested by centrifugation 
and resuspended in 0.1 M potassium phosphate buffer, pH 7.5 containing 15% glycerol to a cell 
dry weight of 12 g/L.   
 
4.4.5 General procedure for isomerization of alkenes by sulfur activated 
RuHCl(CO)((4-nBu-Ph)3)3 in hexadecane 
 A vial was prepared with 280 μL hexadecane, 40 μL 1.0 M alkene solution in hexadecane and in 
relevant cases 500 μL 0.1 M phosphate buffer. In a second vial, 37.7 mg sulfur on Celite (10 
wt% sulfur) was weighed out and to this was added 784 μL 0.1 M RuHCl(CO)((4-nBu-Ph)3)3 in 
hexadecane and the mixture was stirred at room temperature for 5 min. Then the mixture was 
filtered through Kleenex paper in a Pasteur pipette and 40.0 μL of the filtrate was transferred to 
the reaction vial that was then stirred at room temperature. Isomerization progress was followed 
by GC after taking a 40.0 μL sample and diluting it in 360 μL toluene containing nonane in tolu-
ene as the internal standard (final conc. of nonane was 5.0 mM).  
 
Notes  
- In general at least 1.4 times the desired volume of activated catalyst needs to be treated 
with sulfur due to loss in transfer and filtration of the suspension. For low volumes (≤ 
100 μL), larger volume excess is necessary.  
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- The activation can also be done in an Eppendorf or centrifuge tube, which avoids filtra-
tion by spinning down the Celite. Magnetic stirring is then difficult and the tube needs to 
be shaken frequently to keep the sulfur on Celite in suspension. It is best done on a vortex 
shaker.  
- When running pentanes contaminations by volatile solvents (acetone, diethyl ether etc.) 
often mess up the analysis. Check which solvents are used in the washing container. 
Make sure to run one or more blanks before the samples to remove solvents in needle 
from previous samples.  
- The stock of sulfur on Celite was prepared by thoroughly grinding 10 wt% of sulfur with 
Celite in a mortar to ensure high homogeneity.  
 
4.4.6 Synthesis of epoxide standards 
1.28 g (18.2 mmol) cis-2-pentene was dissolved in 180 mL dichloromethane and cooled on an 
ice-water bath. 4.62 g (55.0 mmol) NaHCO3 and 9.02 g (36.6 mmol) m-chloro-parabenzoic acid 
(mCPBA) (70 wt%) was added and the solution was stirred intensely while slowly reaching 
room temperature. A lot of white precipitates were formed, which occasionally blocked the stir-
ring. After 5h the reaction was completed according to a sample from GC (1 mL sample shaken 
thoroughly with 1 mL Na2S2O3(aq) and 100 μL of the organic phase is diluted in 1.8 mL diethyl 
ether and 100 μL 0.1 M nonane in diethyl ether is added. The reaction was quenched by stirring 
intensely with 50 mL Na2SO4 until the two phases became clear. The two phases were separated 
and the aqueous phase was extracted with 3×20 mL dichloromethane. The combined organic 
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phases were washed with 3×30 mL saturated NaHCO3 (aq), dried over Na2SO4, filtered and care-
fully evaporated at 300 Torr and 15-20°C on rotavap to approximately 5 mL. The crude product 
was chromatographed on silica eluting with first Pentane:dichloromethane 9:1 to remove chloro-
benzene formed and then 7:3 to elute the product. The fractions containing the product according 
to TLC (SiO2, Pentane:DCM 9:1, visualize with anisaldehyde) was evaporated to 5 mL and this 
crude was distilled on Kugel rohr at 80°C 500 Torr after discarding fractions at 40, 50 and 60°C 
yielding 300 mg of cis-2,3-epoxypentane. Product is 77 wt% pure by 
1
H-NMR and the only sig-
nificant contamination is dichloromethane.  
 
An alternative work-up method is to avoid quenching with Na2S2O3 (aq) which forms significant 
amounts of chlorobenzene. Instead the reaction mixture can be treated with water and concen-
trated NaOH until pH>12 and all non-reacted m-chloroperoxybenzoic acid is deprotonated and 
dissolved. The organic phase is then washed with water (pH>12) and dried and evaporated as 
usual. This yields less chlorobenzene and chromatography before distillation is not necessary, 
although chlorobenzene can still be detected but at very low concentrations. 
 
4.4.7 Typical tandem isomerization-epoxidation of alkenes with cell lysate + 
ADH regeneration 
A vial was prepared with 31.0 mg sulfur on Celite (10wt% S). Another vial was prepared with 
310 μL 0.1 M potassium phosphate buffer pH 7.6, 10 μL alcohol dehydrogenase (1-2 U/mL), 5.0 
μL 2-propanol (1% v/v), 100 μL lysate with 23.8 μM P450 BM3 RH47. The Ru-catalyst was 
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then activated by addition of 644 μL 0.1 M RuHCl(CO)((4-nBu-Ph)3)3 stock solution in hexade-
cane to the vial with sulfur on Celite. While this mixture was stirring at room temperature, 75.0 
μL 4.0 mM NADP+ in 0.1 M KPi buffer was added to the vials with the enzyme. After stirring 
the Ru-catalyst with sulfur for 5 min, the suspension was filtered through KimWipe paper in a 
Pasteur pipette and from the filtrate was taken 460 μL and diluted in 1.61 mL hexadecane to 
make a 0.0222 M pre-mixed solution. From this was transferred 180 μL to the vials containing 
the enzyme and to start the reaction, 20.0 μL 1.0 M 1-pentene in hexadecane was added. Reac-
tions are stirred at room temperature and worked up by extraction with 300 μL hexanes and cen-
trifugation to separate the phases. 198 μL of the organic phase is transferred to a GC vial inset 
together with 2.0 μL 25 mM nonane in ethanol. Samples analyzed by GC/MS at the Metabolom-
ics Centre at the University of Illinois at Urbana-Champaign. A typical oven program was as fol-
lows: 50
o
C for 5 min, 10
o
C/min to 120
o
C, 35
o
C to 310
o
C, hold at 310
o
C for 5 min. The program 
was slightly modified to accommodate various (this sentence is in complete) 
 
4.4.8 Typical tandem isomerization-epoxidation of alkenes with whole cells over-
expressing P450 
The procedure was similar to 2.4.6, except that instead of the cell lysate plus ADH regeneration, 
20 g/L of whole cells harboring P450 enzymes were used.  
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4.4.9 Typical tandem isomerization-epoxidation of alkenoic methyl esters with 
cell lysate + ADH regeneration 
The aqueous phase contained: 20-40 µM P450, 2 U/mL ADH, 600 U/mL catalase, 0.4 mM 
NADP
+
, 1 % 2-propanol, in phosphate buffer at a total volume of 500 µL. The ruthenium cata-
lyst was added as 20 mol% in hexadecane. The reaction was started with the addition of substrate 
in the organic phase (0.25 M to 0.5 M). The volume ratios of hexadecane to buffer were varied in 
accordance to which experiment was ran. At the end of the reactions, dodecane internal standard 
was added, and the reaction was extracted with 300 µL ethyl acetate. The extraction was centri-
fuged to separate the two phases, and 200 µL of the organic phase was transferred to a GC vial 
for analysis. A typical oven program was as follows: 50°C for 5 min, 10°C/min to 200°C, 35°C 
to 310°C, hold 310°C for 5 min at a flow of 1 mL/min. A calibration curve built with the authen-
tic terminal alkenoic acid methyl ester oxide was used to quantify the tandem reaction products.  
 
4.4.10 Partition coefficient determination 
The partition of organic substrates dissolved in organic solvent in aqueous buffers was deter-
mined as follows. In a 1:1 mixture of hexadecane: buffer was added various concentrations of 
alkene substrates. The mixture was vortexed for 10 seconds and let sit for 1 min. This process 
was repeated 5 times. The mixture was then centrifuged. With a Hamilton syringe, a 50 µL ali-
quot was carefully taken from the aqueous phase and extracted with 200 µL volumes toluene 
containing cyclohexane as the internal standard. One hundred µL of the top phase was trans-
ferred to a GC vial for analysis. A 60m HP-5-MS column (Agilent, CA) was used in these exper-
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iments. A typical GC program was as follows: 35°C for 5 min, 5°C/min to 80°C, 35°C/min to 
310°C, hold 310°C for 5 minutes.  
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CHAPTER 5.  TANDEM ALKENE FORMATION/ALKENE REDUCTION 
CATALYZED BY THE COMBINATION OF A METAL CATALYZED 
DIAZOCOUPLING WITH AN ENOATE REDUCTASE 
 
5.1 Introduction 
The asymmetric reduction of C=C double bonds is of synthetic importance because it can gener-
ate up to two new stereocenters; thus it is one of the most widely employed strategies for the 
production of chiral materials. In organic chemistry, cis-hydrogenation using organometallic 
complexes is now a mature field [1-4]. However, the complementary trans-hydrogenation is still 
being developed [5].  The biocatalytic counterpart to alkene reduction in organic chemistry is 
performed by enoate reductases, members of the “old yellow enzyme” superfamily [6]. Enoate 
reductases catalyze the selective reduction of α,β unsaturated carbonyl compounds (ketones, al-
dehydes, acids, esters) and nitroesters  at the expense of NAD(P)H (Figure 5.1). These ubiqui-
tous flavin-dependent enzymes are widely distributed in microorganisms — particularly in bacte-
ria and lower fungi — and in plants.  
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Figure 5.1 Asymmetric bioreduction of activated C=C bonds using enoate reductases at the expense of NAD(P)H 
yields the corresponding alkane in non-racemic form. The asterisks (*) indicate chiral centers. X denotes an activat-
ing (electron-withdrawing) group, such as ketone, aldehyde, carboxylic acid, ester, anhydride, lactone, imide, and 
nitro. 
 
 
The mechanism of enoate reductases has been studied in detail [7]. It has been shown that a hy-
dride (derived from FMNH2) is stereoselectively transferred to Cβ, whereas a Tyr residue adds a 
proton (which is ultimately derived from the solvent) to Cα from the opposite side (Figure 
5.2).  As a consequence of the stereochemistry of this mechanism, the overall addition of [H2] 
proceeds in a trans-fashion with absolute stereospecificity, which complements cis-
hydrogenation by organometallic catalysts quite well. Due to the requirement for an electron 
withdrawing group to activate the C=C double bond, non-activated double bonds are completely 
unreactive. This high regio- and stereoselectivity of alkene reduction has been exploited for bio-
catalytic purposes, both using whole cells and isolated proteins in combination with cofactor re-
cycling systems. The most prominent industrial application of enoate reductase is the asymmetric 
bioreduction of ketoisophorone to produce (R)-levodione by baker's yeast on a scale of 13 kg [8]. 
In addition, purified enoate reductases are used on a large scale to produce protected versions of 
the industrially used building block “Roche ester”[9]. 
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Figure 5.2 The catalytic mechanism of enoate reductases proceeds in a trans-specific fashion. The hydride being 
transferred from the flavin cofactor is indicated in red.  
 
In our efforts to bridge the gap between chemical catalysis and biocatalysis, we envisioned that 
we could combine the biocatalytic reduction of activated alkenes with organometallic transfor-
mations that form α,β unsaturated carbonyls in one-pot to produce highly chiral compounds. 
Such organometal catalyzed reactions that can form α,β unsaturated carbonyls include cross-
metathesis, ring-closing metathesis, isomerization and diazocoupling (Figure 5.3). All three reac-
tions can be used to form tri-substituted alkenes for example, which would serve as substrates for 
the enoate reductase. In this Chapter, we detail our efforts at engineering a one-pot tandem reac-
tion in which a diazocoupling reaction (catalyzed by iron porphyrins, heme containing proteins 
or rhodium salts) is combined with an enzymatic alkene reduction (catalyzed by an isolated eno-
ate reductase coupled to a cofactor regeneration system).   
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Figure 5.3 Tandem one-pot reaction combining organometallic complexes that form alkenes with bioreduction of 
these alkenes by enoate reductases. 
 
5.2 Results and discussion 
5.2.1 Metal-catalyzed alkene formation by carbene-carbene coupling reaction 
Our initial interest into the metal-catalyzed alkene formation by diazo coupling stemmed from 
the discovery that carbene insertion into N-H and C=C bonds could be accomplished using heme 
variants of P450 BM3 [10-12]. A P411-CIS variant of P450 BM3 in which the cysteine ligand 
(C400) was replaced with a serine significantly increased cyclopropanation and N-H insertion 
yields [10]. Specifically, these seminal works showed that reactions between ethyl diazoacetate 
and styrene or aniline formed exclusively the cyclopropanation and N-H insertion products re-
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spectively, in the presence of excess nucleophile (at least 2 eq. with respect to diazoacetate). Alt-
hough it was not reported by others, in our hands, when an equimolar concentration of aniline 
and diazoacetate were combined with heme proteins, diethyl maleate formation was observed.  
 
As a result of this discovery, we started studying the metal-catalyzed decomposition of diazo 
compounds to form cis- and trans- enediones using heme proteins, as well as free porphyrins of 
iron and ruthenium. The decomposition of diazoacetates and diazoketones to form enediones has 
long been considered an undesired by-product of the metal-catalyzed insertion of carbenoids into 
alkenes, alkyl chains and amines (usually formed in yields of 10-20%). As a result, this reaction 
has been largely considered synthetically unavailing (Figure 5.3A), although cis-enediones are 
precursors for the synthesis of heterocyclic compounds, flavoring agents for foods and insecti-
cides. In the absence or in the presence of limiting concentration of a nucleophile for example, a 
carbenoid formed by diazo decomposition with an electrophilic metal center can be subsequently 
attacked by a carbene to form an alkene.  
 
Initially, transition metal complexes used to decompose diazo compounds were heterogeneous 
Cu complexes, followed later by homogeneous Cu, Rh, Pd and Ru complexes.  Table 5.1 shows 
the results of ethyl diazoacetate decomposition catalyzed by several heme proteins, iron and ru-
thenium catalysts. While hemin was found to catalyze the formation of DEM to 12% (entry 1), 
several P450 heme mutants gave very low yields (less than 5%, entries 2 to 5). We tested two 
other heme proteins, chloroperoxidase and myoglobin. Both of these proteins were found to cata-
lyze N-H insertion reactions by us and others. Only chloroperoxidase was able to yield any DEM 
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(12%, entry 6). P450 heme variant T268A, which decreases O-O bond scission activity in oxida-
tion while conversely enhancing cyclopropanation activity, gave a yield of 17% (entry 8). It is 
important to note that none of the P450 variants in entries 2-5 contained the T268A mutation.  
 
P411-CIS produced DEM in 23% yield (entry 9), making it our highest yielding variant. Since 
P411-CIS contains over 15 mutations which differs it from WT BM3 heme, including F87V, 
C400S, and T268A, we wondered whether the yield increase was based solely on the C400S mu-
tation or if the other 14 mutations were beneficial. P450-CIS (P411-CIS-S400C) gave a yield of 
6.1% (entry 10), significantly lower than P450-T268A, indicating that indeed having serine as 
the axial ligand plays an important general role in increased TTN in carbene mediated activities. 
In addition, we believe that F87 may also play a role in increasing the yield, since F87A was a 
poor catalyst. Generation of the variants P411-CIS-V87F and P450-F87V-T268A should be in-
vestigated. We were unable to produce the P450-C400S variant, as this variant was poorly ex-
pressed in E. coli, suggesting it to be highly unstable. The addition of the amphiphile PTS (poly-
oxyethanyl α-tocopheryl sebacate), known to increase yields of cross metathesis and other cou-
pling reactions in water [13-19], increased the yields to 35% (entry 11). It is not yet clear through 
what mechanism PTS interacts with the P450, whether it is by 1) stabilizing the protein, 2) bind-
ing inside the pocket of the enzyme to bring the substrates closer to the active Fe porphyrin, 3) or 
producing a conformational change which is more active for catalysis. To test the second hy-
pothesis, we invetigated the effect of several perfluorocarboxylic acids (PF) that have been 
shown to increase the oxidation activity of wild-type P450 BM3 towards small chain alkanes 
(C1-C6) by binding inside the enzyme similar to long chain carboxylic acids, the most active 
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substrates for oxidation by wild type P450 BM3. Unfortunately, with P411-CIS in the presence 
of PF9, PF10, and PF11, DEM yields were actually lower than those in the absence of any addi-
tive (entries 12-14). Denatured P411-CIS was no longer active towards diazocoupling (entry 15).  
 
Finally, free metal porphyrins were tested. Yields using RuCOMPIX, a hemin analog in which 
Fe was replaced with Ru, were 27% (entry 16).   Based on reports that used iron corroles as cata-
lysts for cyclopropanation, we investigated the use of the iron-based porphyrins C1 and C2. We 
found that FeTTPCl (C1) produced DEM in 17% yield (entry 17), while C2, an electron-
deficient porphyrin, was able to form DEM in 76.5% yield (entry 18). In fact, C2 need not be 
reduced (with cobaltecene or with sodium dithionite) or be run under anaerobic conditions. In all 
cases, EDA coupling reactions were found to be cis-selective, with Z/E ratios of > 16:1. 
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Table 5.1 EDA coupling catalyzed by various catalysts in buffer 
 
Entry5 Catalyst GC Yields (%) 
1 Hemin 12.3 ± 6.8 
2 P450heme-F87A 1.5 ± 0.3 
3 P450heme-C400E 1.4 ± 1.4 
4 P450heme-RH47[20] 4.6 ± 1.7 
5 P450heme-SH44[20] 2.2 ± 0.5 
6 CPO 12.7 ± 0.8 
7 Myoglobin NR   
8 P450heme-T268A 17.4 ± 2.1 
9 P411heme-CIS 23.6 ± 1.2 
10 P411heme-CIS-S400C 6.1 ± 1.0 
11 P411heme-CIS w/ 1% PTS
4 35.0 ± 2.5 
12 P411heme-CIS w/ 1% PF9
3 6.2 ± 0.5 
13 P411heme-CIS w/ 1% PF10
3 11.9 ± 1.3 
14 P411heme-CIS w/ 1% PF11
3 12.3 ± 0.6 
15 P411heme-CIS denatured
1 NR   
16 RuMCOPIX 27.5 ± 0.5 
17 FeTTPCl 17.3 ± 1.7 
18 FePFPCl
2 76.5 ± 5 
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5.2.2 Diazocoupling between EDA and diazoacetophenone 
While we were very excited that EDA coupling occurred with heme proteins and iron porphy-
rins, we were more curious to find whether cross-coupling between diazoacetates and diazo-
ketones could occur. As a result, we tested the cross-coupling reaction between EDA and diazo-
acetophenone (DPE) with a panel of P450 heme variants, P411-CIS, myoglobin and chlo-
roperoxidase. Unfortunately, we found that neither the enzymes nor hemin were able to afford 
the formation of the unsymmetrical alkene. In some cases, with the more active enzymes (P411-
CIS for example), DEM formation was observed, although in lower yields than when EDA was 
used as the sole substrate. This lack of reactivity of the enzymes is not due to steric hindrance, 
since the cross-coupling reaction between EDA and benzyldiazoacetate (BDA) affords the un-
symmetrical alkene in a distribution similar to hemin and FePFPCl (not shown), although in 
lower yields. Catalysts C1 and C2 catalyzed the formation of the unsymmetrical alkene as the 
major product, with C2 forming 3 in higher yields than the 1:1:2 statistical distribution expected 
for 4:5:3 (Table 5.2 entry 4). This is due to the difference in reactivity between the diazoacetate 
and the diazoketone. Since the diazoacetate decomposes faster than the diazoketone, the latter 
will most likely attack the carbenoid of EDA to form the unsymmetrical product, resulting in 
higher yields for the unsymmetrical product 3. On the contrary, when EDA and t-
butyldiazoacetate are reacted with C1 or C2, the expected statistical distribution is observed (not 
shown).      
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Table 5.2 EDA coupling and EDA-DPE cross-coupling catalyzed by C2 
 
    Yields [%](NMR, GC, isolated): [Z/E]
a
 
Entry R1  R2 Solvent 3 4 5 
1 -OCH3CH3 = R1 CDCl3 - 45, 42, 32
b
: [16:1]  - 
2 -OCH3CH3 = R1 KPi Buffer
d
 - 66-80
d
 - 
3 -OCH3CH3 -C6H5 CH2Cl2 55, 31
c
 [8:1] 25[17:1] ND 
4 -OCH3CH3 -C6H5 Buffer 65 [8:1] 18 [17:1] ND 
a
Determined by GC. 
b
Isolated by flash chromatography, but calibration curve was set up with authentic 
DEM.   
c
Isolated by HPLC fraction collection. 
d
100 mM phosphate buffer, pH 7.5 
 
Since C2 catalyzes diazo coupling under air and in the absence of a reductant, we further ex-
plored its catalytic activity. Table 5.2 shows the results of the catalytic decomposition of diazo-
acetate and diazoketone by C2 in different solvents. To determine the NMR yields, we used the 
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proton signals for the methylene groups (=CH) that result from the coupling reaction and spiked 
the reaction mixture with a known concentration of tetramethylsilane, allowing us to calculate 
the selectivity and yield of the unsymmetrical alkene (Figure 5.4). Isolation of the unsymmetrical 
alkene from entry 3 was performed either by HPLC fraction collection followed by lyophiliza-
tion. To corroborate the GC yields obtained using a calibration curve, we compared them with 
NMR yields for EDA coupling, showing that yields were very similar (Table 5.2 entry 1).  Inter-
estingly, selectivity for the formation of the unsymmetrical enediones is higher in phosphate 
buffer compared with solvents such as dichloromethane or chloroform (Table 5.2 entries 2 and 
4). We do not know the reason why.  
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Figure 5.4 Portion of 
1
H NMR of crude reaction between EDA and DPE (entry 3) in CH2Cl2. According to NMR, 
the ratio between 3 and 4 is 1:2. A known concentration of TMS (not shown at 0 ppm) was added to quantify the 
amount of 3 and 4 formed. 5 was not quantified in this manner because the protons are difficult to quantify in the 
aromatic region. It was also difficult to calculate the cis- to trans- ratio using this method; therefore, it was estimated 
by GC. 
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5.2.3 Enoate reductases for the bioreduction of enediones 
Having found that heme porphyrins and enzymes can catalyze diazocoupling reactions, we 
sought to find whether a cascade reaction involving an enzymatic reduction of the formed alkene 
could be devised. First, we sought to find an enoate reductase which showed activity towards cis-
enediones. According to literature reports, enoate reductases have a very wide substrate scope, 
but the nature of the EWG has a big impact on enzyme activity. For example, for most enoate 
reductases, substrates with ketones and aldehydes as EWG are preferred, while esters and car-
boxylic acids are less preferred. In fact, the reduction of most carboxylic acids and esters has 
mostly been achieved using whole cells, with only limited examples using purified reductases. 
Several enoate reductases showed activity towards cis- and trans-enediones such as maleic and 
fumaric acids, as well as their methyl ester analogues (Table 5.3). More importantly, these en-
zymes also recognized analogues with methyl substituents at the α or β carbons and reduced 
them with >99% enantiomeric excess (ee). Substrates with substitutions at both carbons are typi-
cally not recognized, except for one report in which enoate reductases isolated from soybean 
meal were found to be active.  
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Table 5.3 Enoate reductases with activity on enediones (Adapted from [21]) 
Substrate 
Kluyveromyces lactis-ER 
(Yield, ee %) 
Yersinia berciovieri-ER 
(Yield, ee %) 
 
74, (R) 97 87, (R)>99 
 
89, (S) 94 79, (R) 77 
 
From the enzymes listed in Table 5.3, we chose the enoate reductase from Yersinia bercovieri 
(YERS-ER). We hypothesized that since the (R)-enatiomer is formed regardless of the geometry 
of the starting substrate (Z or E), there would be less of a demand for a cross-coupling reaction to 
be highly selective. This gene was codon optimized for E. coli expression and synthesized using 
two gBlocks and subsequently cloned in pET28a
+
 via Gibson Isothermal Assembly [22]. The 
purified enzyme showed a specific activity of 2.16 U/mg and 2.05 U/mg towards diethyl maleate 
and C6H5COCH=CHCOOCH2CH3 (unsymmetrical product between EDA and diazoacetophe-
none), respectively. 
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5.2.4 Tandem diazocoupling/alkene reduction  
As a proof of concept, we sought to combine the EDA coupling reaction catalyzed by FePFPCl 
with the alkene reduction catalyzed by YERS-ER. Kinetic studies were performed for the reduc-
tion of diethyl maleate by YERS-ER in 200 mM KPi buffer. Namely, we performed time courses 
of enzymatic reductions of 40 mM diethyl maleate in which the substrate to enzyme ratios of 
1:10000, 1:2500, 1:1000 and 1:500. To regenerate NADPH, we used the previously described 
glucose dehydrogenase from Bacillus megaterium (GDH), and kept a YERS-ER to GDH molar 
ratio at 1:2. From this work, we chose a ratio of at least 1:1000 for our further studies.  
 
We combined the EDA coupling with the enzymatic reduction of the formed diethyl maleate in 
one-pot, and found that the reaction was able to form diethyl succinate in about 70% yield, with 
complete conversion of the diethyl maleate formed (Figure 5.5A and entries 1 and 3). When the 
one pot reaction was run sequentially; the same yields were observed as in the concurrent system 
(Table 5.4, entry 2), which suggests that catalyst compatibility is not an issue.  In the tandem re-
action, cross-coupling between diazoacetophenone (DPE) and EDA afforded the reduced alkenes 
6, 7 and 8 in 58, 13 and 11% yields, respectively, which corresponds to a 100% reduction of all 
formed alkenes by the diazocoupling (entries 4 and 5 and Figure 5.5B). Similar results were ob-
tained when p-fluorodiazoacetophenone and EDA (4FDPE) were used as substrates for the tan-
dem reaction (entries 6 and 7 and Figure 5.5C).  At 10 mM final concentration in buffer, 4FDPE 
was found to be only slightly soluble, therefore 1% PTS was added to the diazocoupling and tan-
dem reaction.  In the presence of PTS, the total diazocoupling yield was increased by 29%, with 
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a drop in the yield of 3 of about 40%, accompanied by an increase in the yields of 4 and 5 of 
about 45% (Figure 5.6A). Conversely in the tandem reaction, the total yield was increased by 
36% in the presence of PTS. While the yield of 7 remained unchanged, yields of 6 and 8 were 
increased by 30% and 60% respectively (Figure 5.6B). This increase in yield for the less soluble 
products 4, 5, 7 and 8, can be attributed directly to their increased solubility effected by PTS.  
 
The diazocoupling between DPE and (trimethylsylil)diazomethane (TMS) did not yield a high 
amount of the unsymmetrical alkene, therefore in the tandem reaction involving DPE and TMS, 
the reduced dimer of DPE was formed as the major product. It is important to note that the trace 
amounts of unsymmetrical alkene formed in this case was also reduced completely. It was re-
ported that the electron donating properties of the Si(Me)3 decreases the reactivity of this diazo 
compound, which results in slow dimerization and requires higher temperatures (60
o
C) with a Ru 
catalyst [23]. 
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Table 5.4 One pot tandem reaction alkene formation/reduction catalyzed by FePFPCl and YERS-ER 
 
    GC Yields (%)  
Entry Reaction R1 R2 3 4 5 6 7 8 
1 Diazocoupling  OCH2CH3 =R1 - 73.0 - - 0 - 
2 One-pot sequential OCH2CH3 =R1 - 0 - - 75.0 - 
3 One-pot concurrent OCH2CH3 =R1 - 0 - - 77.5 - 
4 Diazocoupling OCH2CH3 C6H5 61 15 10 0 0 0 
5 One-pot concurrent OCH2CH3 C6H5 0 0 0 58 13 11 
6 Diazocoupling OCH2CH3 p-F-C6H5 Major Minor ND 0 0 0 
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Table 5.4 (Continued)         
7 One-pot concurrent OCH2CH3 p-F-C6H5 0 0 0 Major Minor ND 
8 Diazocoupling + 1% PTS   OCH2CH3 p-F-C6H5 Major 8.8 Minor Major 8.8 Minor 
9 One pot concurrent + 1% PTS OCH2CH3 p-F-C6H5 Major 11.4 Minor Major 11.4 Minor 
10 Diazocoupling Si(Me)3 C6H5 0 Traces Major 0 0 0 
11 One-pot concurrent Si(Me)3 C6H5 0 0 0 0 Traces Major 
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Figure 5.5 GC traces of results in Table 5.4 A) entries 1 and 3 B) entries 4 and 5 C) entries 6 and 7.  IS = internal 
standard 
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                        A                                                       B       
    
Figure 5.6 The addition of 1% PTS increases the overall yield of both the diazocoupling A) and tandem B) reac-
tions.  
 
5.2.5 Towards an enantioselective tandem alkene formation/reduction reaction 
Although the previously described tandem reaction is very efficient, the alkane products formed 
are not chiral. To circumvent this limitation, we sought to investigate if FePFPCl could catalyze 
diazocoupling between EDA and α-substituted diazoacetates to form the unsymmetrical alkene 
selectively. We synthesized several α-substituted diazoacetates (Cl, methyl, phenyl). Unfortu-
nately, FePFPCl was unable to catalyze cross-coupling between EDA and α-substituted diazo-
acetates. In the cases where either α-methyl or α-chloro diazoacetate was used as the only sub-
strate, a low yield of the homocoupling product was observed. However, YERS-ER, as well as 
with many other enoate reductases, cannot reduce alkenes with substitutions at both Cα and Cβ.  
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As a result of this conundrum, we sought to find a catalyst which could catalyze cross-coupling 
to form prochiral substrates for the enoate reductase. Recently, Huw Davies and coworkers de-
scribed Rhodium catalysts which catalyze highly selective cross-coupling between ethyl diazo-
acetate and α-phenyl-diazoacetate [24]. Using rhodium acetate, we investigated the cross-
coupling between EDA and α-methyl diazoacetate in various solvents and at different tempera-
tures (Table 5.5). Rhodium acetate yielded both the homocoupling of EDA (10) and the cross-
coupling product (9), but the di-substituted homocoupling product was never observed [24]. In 
CH2Cl2 and hexane, the reaction was selective for 9, regardless of temperature (75:25 selectivity 
in favor of 9 over 10). In toluene and buffer, however, the selectivity sharply decreased. In both 
of these solvents, an unknown product was observed, which only occurred in the presence of the 
Rh(OAc)2 catalyst. Interestingly, rhodium acetate showed no Z/E selectivity.  
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Table 5.5 Diazocoupling catalyzed by Rh(OAc)2 in different solvents and at different temperatures 
 
Entry Solvent T(
o
C) Z/E 10 % 9 in total product Z/E 9 % 9 in total product 
1 CH2Cl2 RT 0.96 22.2 0.76 77.7 
2 CH2Cl2 -80 0.94 37.4 0.77 62.5 
3 hexane RT 0.91 21.2 0.67 78.7 
4 hexane -80 0.97 19.4 0.66 80.5 
5 toluene RT 0.94 16.5 0.89 44.9 
6 toluene -80 0.95 23.0 0.68 41.4 
7 100 mM PKi RT 1.10 47.8 0.67 36.2 
8 50 mM Tris-HCl RT 1.13 33.0 0.71 49.9 
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As a proof of concept, we performed the sequential diazocoupling/reduction in one pot. First, the 
rhodium-catalyzed diazocoupling between EDA and α-methyl diazoacetate in CH2Cl2 produced 
9 and 10. Subsequently, the solvent was dried under nitrogen followed by the addition of 200 
mM KPi buffer, pH 7.5 containing 0.1 mol % YERS-ER, 0.2 mol % GDH, 100 mM glucose and 
0.2 mM NADP
+
.  This preliminary result is promising, since we observed the formation of 11, 
although at a markedly lower yield than 12. The enzyme shows higher activity for 10 over 11, as 
expected. Finally, the reaction did not reach full conversion under the conditions tested (Figure 
5.7).  
 
 
Figure 5.7 One-pot sequential Rhodium catalyzed diazocoupling/enzymatic reduction 
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5.3 Conclusion and future prospects 
In this chapter, we described two efforts. First, we investigated the catalytic activity of P450s, 
metal porphyrins and other heme proteins for the formation of alkenes by diazo decomposition. 
We analyzed several heme proteins and metal porphyrins in their capacity to catalyze diazocou-
pling. P450heme-T268A and P411-CISheme gave modest yields in the diazocoupling of ethyldiazo-
acetate, but like all the other heme proteins tested, were unable to catalyze cross-coupling of di-
azoesters with diazoketones.  The electron deficient porphyrin FePFPCl is an efficient catalyst 
for the decomposition of both diazoacetates and diazoketones. Our preliminary efforts at engi-
neering a tandem reaction that combines the diazocoupling reaction catalyzed by FePFPCl with 
an enoate reductase-catalyzed trans-hydrogenation resulted in moderate to high yields and selec-
tivity for the formation of decorated unsymmetrical diones. Although the combination of enoate 
reductase with a Wittig reaction in one-pot has been described [25], we are the first to show that 
metal complexes of iron and rhodium can be compatible with enoate reductases coupled with a 
GDH regeneration system.  It is noteworthy that compatilibty issues between the iron catalyst 
and the enoate reductase did not exist. We are now working on a preparative scale preparation of 
this tandem reaction.  
 
More optimization of the rhodium catalyzed coupling in the context of the tandem reaction is 
needed. It will be intriguing to study the chirality of product 11, to see whether the (R) enantiose-
lectivity reported by Bommarius and coworkers is conserved [26]. Looking forward, it will be 
interesting to further study the tandem reaction involving Rh as the cross-coupling catalyst to 
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form chiral dicarboxylic acid esters. Parameters such as selectivity for the unsymmetrical alkene 
and Z/E selectivity are important to analyze and improve. Having an immobilized version of the 
Rh catalyst [27] will likely further improve the stability of this reaction. We further envision the 
possibility of using this tandem strategy for many other useful chemical transformations, some of 
which are listed in Figure 5.3. There already exists a large number of characterized enoate reduc-
tases, which could be used for more reactions to achieve highly chiral dicarboxylic acids esters. 
 
5.4 Materials and methods 
5.4.1 Materials 
All chemicals, reagents and catalysts were purchased from Sigma-Aldrich, unless noted other-
wise. Diazoacetophone and 4-fluorodiazoacetophenone were synthesized by Dr. Mark J. Bartlett 
from the John F. Hartwig laboratory at the University of California-Berkeley. E. coli DH5α cells 
were purchased from the Cell Media Facility at the University of Illinois at Urbana-Champaign 
(Urbana, IL).  Oligonucleotides for cloning were purchased from Integrated DNA Technologies 
(IDT DNA) (Coralville, IO.).  Restriction enzymes were purchased from New England Biolabs 
(Ipswich, MA).  NADPH was purchased from Enzo Life Sciences (Farmingdale, NY).  NADP
+
 
was purchased from Roche Diagnostics (Indianapolis, IN).  5-Aminolevulinic acid hydrochloride 
was purchased from Sigma-Aldrich (St. Louis, MO).  Isopropyl-β-D-thiogalactoside (IPTG) was 
purchased from GoldBio (St. Louis, MO).  Gibson Isothermal Assembly Mix was purchased 
from New England Biolabs (Ipswich, MA).  
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5.4.2 Cloning, expression and purification of the enoate reductase from Yersinia 
bercovieri (YERS-ER) 
The gene encoding YERS-ER (Genbank accession number ZP 00823209), codon optimized for 
E. coli expression, was synthesized using two gBlocks purchased from IDT DNA. The gBlocks 
also contains a 20-25 bp overlap which allows the gene to be assembled directly using Gibson 
Isothermal Assembly [22] in pET28a
+
 linearized with the restriction enzymes NdeI and HindIII.  
Following digestion of plasmid pET28a
+
 with NdeI and HindIII, the plasmid pET28a-YERS-ER 
was created via Gibson Assembly following the manufacturer’s protocol, and subsequently trans-
formed into DH5α. After confirmation of the right clone by restriction digestion analysis, the 
correct plasmid was transformed in E. coli BL21.  For expression of YERS-ER, a BL21 colony 
harboring pET28a-YERS-ER was inoculated in 5 ml LB containing 50 µg/mL kanamycin and 
grown overnight at 37ºC. This overnight culture was used to inoculate 500 mL of TB containing 
50 µg/ml kanamycin, which was grown at 37ºC until an OD of ~0.7 had been reached, and sub-
sequently induced with the addition of 0.3 mM IPTG. The induced culture was placed at 25ºC 
for 16 h for protein production.  
 
Following expression, BL21 cells were recovered by centrifugation (6000 x g for 15 min), lysed 
by sonication and clarified by sonication (18 000 x g for 30 min). The protein was subsequently 
purified by affinity chromatography using a HisTrap column fitted to an AKTA FPLC system. 
The protein was subsequently buffer exchanged against 100 mM Kpi buffer, pH 8.1 using an 
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Amicon Ultra concentration tube (10 kDa cut-off) before being stored in 15% glycerol and stored 
in 100 µL aliquots at -80ºC. Yields close to 100 mg/L were obtained.   
 
5.4.3 P450 heme mutagenesis 
P450 heme variants were constructed via Gibson Isothermal Assembly. Primers were generated 
to introduce mutations in the P450heme at the desired locations. The gene-specific primers con-
tained 20-25 bp overlap with the pCWori+ plasmid digested with the restriction enzymes BamHI 
and EcoRI. The reverse primer, named hom-pC-heme-rev, also contained a 6x-His tag sequence 
right after the last codon of the gene to enable affinity purification of the heme proteins. To cre-
ate the desired plasmid, gene fragments were amplified using their respective primers introduc-
ing mutations at desired sites. Subsequently, the gene fragments were PCR purified, mixed in 
equimolar amounts with the vector pCWori+ linearized by digestion (BamHI/EcoRI) and incu-
bated with the Gibson Assembly mix according to the manufacturer’s protocol.   The in vitro 
formed plasmid was transformed in E. coli DH5α and plated on LB + Amp plates. The correct 
plasmids were confirmed by digestion and sequencing. 
 
5.4.4 Cloning of P411-CIS 
The two gBlocks ordered from IDT DNA contained a 30 bp homology at the 5’-end of gBlock 1 
and 3’-end of gBlock 2, respectively. The two gBlocks were spliced by overlap extension PCR 
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using the gene specific primers hom-pC-heme-for and hom-pC-heme-rev. The resultant full gene 
was cloned into pCWori+ digestion with BamHI and EcoRI by Gibson Isothermal Assembly. 
P411-CIS gBlock sequences  
gBlock 1 
ATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGAGCTTAAAAATTTACC
GTTATTAAACACAGATAAACCGGTTCAAGCTTTGATGAAAATTGCGGATGAATTAGG
AGAAATCTTTAAATTCGAGGCGCCTGGTCGTGTAACGCGCTACTTATCAAGTCAGCG
TCTAATTAAAGAAGCATGCGATGAATCACGCTTTGATAAAAACTTAAGTCAAGCGCT
TAAATTTGCGCGTGATTTTGCAGGAGACGGGTTAGTGACAAGCTGGACGCATGAAA
AAAATTGGAAAAAAGCGCATAATATCTTACTTCCAAGCTTCAGTCAGCAGGCAATG
AAAGGCTATCATGCGATGATGGTCGATATCGCCGTGCAGCTTGTTCAAAAGTGGGA
GCGTCTAAATGCAGATGAGCATATTGAAGTATCTGAAGACATGACACGTTTAACGCT
TGATACAATTGGTCTTTGCGGCTTTAACTATCGCTTTAACAGCTTTTACCGAGATCAG
CCTCATCCATTTATTATTAGTATGGTCCGTGCACTGGATGAAGTGATGAACAAGCTG
CAGCGAGCAAATCCAGACGACCCAGCTTATGATGAAAACAAGCGCCAGTTTCAAGA
AGATATCAAGGTGATGAACGACCTAGTAGATAAAATTATTGCAGATCGCAAAGCAC
GTGGTGAACAAAGCGATGATTTATTAACGCAGATGCTAAACGGAAAAGATC 
 
gBlock 2 
ACGCAGATGCTAAACGGAAAAGATCCAGAAACGGGTGAGCCGCTTGATGACGGCAA
CATTCGCTATCAAATTATTACATTCTTAATTGCGGGACACGAAGCGACAAGTGGTCT
TTTATCATTTGCGCTGTATTTCTTAGTGAAAAATCCACATGTATTACAAAAAGTGGC
AGAAGAAGCAGCACGAGTTCTAGTAGATCCTGTTCCAAGCTACAAACAAGTCAAAC
AGCTTAAATATGTCGGCATGGTCTTAAACGAAGCGCTGCGCTTATGGCCAACTGCTC
CTGCGTTTTCCCTATATGCAAAAGAAGATACGGTGCTTGGAGGAGAATATCCTTTAG
AAAAAGGCGACGAAGTGATGGTTCTGATTCCTCAGCTTCACCGTGATAAAACAGTTT
GGGGAGACGATGTGGAAGAGTTCCGTCCAGAGCGTTTTGAAAATCCAAGTGCGATT
CCGCAGCATGCGTTTAAACCGTTTGGAAACGGTCAGCGTGCGAGCATCGGTCAGCA
GTTCGCTCTTCATGAAGCAACGCTGGTACTTGGTATGATGCTAAAACACTTTGACTTT
GAAGATCATACAAACTACGAGCTCGATATTAAAGAAACTTTATCTTTAAAACCTAAA
GGCTTTGTGGTAAAAGCAAAATCGAAAAAAATTCCGCTTGGCGGTATTCCTTCACCT
AGCACT 
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5.4.5 Expression and purification of P450 heme variants 
Expression and purification of P450 BM3 was done as follows.  Briefly, 500 mL Terrific Broth 
(TB) medium supplemented with 100 mg/mL ampicillin, was inoculated with an overnight cul-
ture (5 mL) in a 2.8 L flask and incubated at 30
o
C and 250 rpm shaking.  After 12 h of incuba-
tion, 5-aminolevulinic acid hydrochloride (ALA; 0.5 mM) was added, expression was induced 
by addition of 1 mM IPTG; and the shaking speed was reduced to 180 rpm.  Cells were harvest-
ed by centrifugation for 24 h after induction.  The cell pellets were resuspended in 30 mL 100 
mM potassium phosphate buffer, pH 8.1 and lysed by sonication. Purification was performed by 
affinity chromatography on an AKTA pure HPLC. The enzymes were buffer exchanged against 
100 mM KPi buffer, pH 8.1, stored in 15% glycerol and stored in 100 µL aliquots at -80ºC.  
 
5.4.6 Synthesis of α-methyl diazoacetate 
α-Methyl diazoacetate was synthesized following a published procedure [28]. Briefly, a mixture 
of sodium azide (6.5 g, 100 mmol), 2 M sodium hydroxide solution (200 mL, 40 mmol), tetrabu-
tylammonium bromide (TBAB) (80 mg, 0.25 mmol) in 100 mL hexanes (100 mL) was stirred 
vigorously at 0ºC in an ice bath in an open 1000-mL round-bottom flask. To the stirred solution 
was added Tf2O (8.2 mL, 50 mmol) dropwise through a syringe. After 10 min, a solution of ethyl 
2-methylacetoacetate (3.53 mL, 25 mmol) in 100 mL acetonitrile was added into the reaction 
flask through a funnel, followed by additional 10 mL acetonitrile to complete the transfer. The 
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initially colorless reaction mixture immediately turned yellow. After stirring at 0ºC for 30 min, 
the mixture was diluted successively with ice-water (100 mL) and chilled Et2O (100 mL) and 
transferred to a separation funnel. The organic layer was separated the aqueous layer was further 
extracted with cold Et2O (100 mL, 2 times). The organic fractions were combined, dried over 
anhydrous sodium sulfate, and concentrated to afford the titled compound as a bright yellow oil 
(0.46 g, 13% yield).  
 
5.4.7 Anaerobic diazocoupling reactions  
Reactions were set up in an anaerobic glove bag. Diazo compounds were prepared in DMSO as 2 
M stock solutions immediately before the reactions and prepared freshly every time. Under con-
stant stirring, 1 eq. of Na2S2O4 diazo compounds were added to 100 mM KPi pH 8.1 buffer, fol-
lowed by the addition, in order, of 1% PTS (when necessary), substrates. The catalysts were add-
ed last to start the reactions. After 2 h of reaction, reactions were extracted with 400 µL ethyl 
acetate containing 0.1 mM eicosane, dried with sodium sulfate prior to injection on GC. A GC 
calibration for diethyl maleate (1 mM, 2 mM, 4 mM, and 6 mM) was set up using authentic 
DEM. A response factor of 0.28 of DEM/eicosane was calculated. Extraction efficiencies were 
also calculated to be close to 95%.  
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5.4.8 Diazocoupling reactions and one-pot sequential reactions between EDA 
and α-methyl-EDA 
Reactions were set up in air. Reactions contained 40 mM of each diazoacetate in a solvent of 
choice (buffer, hexane, dichloromethane, and toluene) at the desired temperature. The reactions 
were started with the addition of 1 mol % of Rh(OAc)2, from a stock solution of 64 mM in di-
chloromethane. After 2 h stirring, the reaction in buffer was extracted with 400 µL ethyl acetate, 
while the ones in organic solvent were diluted 2-fold in ethyl acetate prior to analysis on GC-
MS.   
 
For the tandem reaction, after 2 h incubation of the diazocoupling reaction at room temperature, 
dichloromethane was evaporated under nitrogen, followed by the addition of 2.5 mL 200 mM 
KPi buffer, pH 7.5 containing 0.1 mol % YERS-ER, 0.2 mol % GDH, 100 mM glucose and 0.2 
mM NADP
+
.  The reaction was incubated at room temperature with stirring for an additional 3 h. 
 
5.4.9 General protocol for the one-pot diazocoupling/alkene reduction 
To a clean 4 mL vial fitted with a stir bar were added in succession 175 µL 200 mM KPi buffer, 
pH 7.5, 0.1 mol % YERS-ER, 0.2 mol % GDH, 100 mM glucose, 0.2 mM NADP
+
, and 2 nmol 
substrate(s). When 4FDPE was used as a substrate and 1% PTS (from 15% stock) was added to 
the reaction, the substrate 4FDPE was dissolved in the PTS containing buffer by vortexing prior 
to addition of the enzyme components. Reactions were started by the addition of 0.1 mol % FeP-
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FPCl (from 1 mM stock in DMSO). Reactions were incubated at room temperature for 3 h with 
mild stirring (180 rpm). Reactions were extracted with 4 µL of ethyl acetate containing 0.1 mM 
eicosane as internal standard and injected on GC-MS for analysis (ZB5-MS column [0.32 µm, 
0.25 µm, 60 m]: 80ºC for 5 min, 30ºC/min to 315ºC, hold for 5 min). Calibration curves for di-
ethyl maleate, diethyl succinate, and CH3CH2OCOCH=CHCOC6H5 were constructed using the 
same extraction strategy.  
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